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 ABSTRACT
 
Abnormal formation of a blood clot in veins, also called venous thromboembolism 
(VTE), is a major health problem in Western societies that affects 1 in every 1,000 indi-
viduals per year. Susceptibility to VTE is governed by both genetic and environmental 
factors, with approximately 60% of the risk attributed to genetic influences. The most 
prevalent genetic risk factor among VTE patients is a variant in coagulation factor V, 
called Factor V Leiden (FVL). While 20-25% of VTE patients carry the FVL variant, only 
~10% of FVL carriers develop a VTE in their lifetime, indicating that interactions be-
tween FVL and other genetic and/or environmental factors influence the incidence and 
severity of thrombosis. The goal of this thesis was to identify modifier genes that help 
understand the differences in VTE phenotype among FVL carriers and more generally 
the complex genetic factors regulating hemostasis balance. 
The work described here took advantage of the synthetic lethal thrombosis phe-
notype observed in mice carrying two copies of the orthologous FVL (F5L/L) mutation to-
gether with haploinsufficiency for tissue factor pathway inhibitor (Tfpi+/-). F8 deficiency 
was found to ‘rescue’ F5L/L Tfpi+/- lethality, and an initial ENU mutagenesis screen for 
dominant thrombosis modifier genes additionally identified F3 and Actr2 as suppressors 
for this lethal phenotype (Chapter II). 
During the genetic analysis of the ENU-induced mutations, we additionally identi-
fied a de novo deletion in Nbeal2 which originated from a non-ENU treated parent, high-
lighting the potentially confounding effect of spontaneous mutation events in well-
characterized mouse strains. Though initially considered a plausible thrombosis modifi-
er, this mutation failed to rescue the synthetic lethal thrombosis (Chapter III).  
A complementary burden test that highlights genes enriched for mutations ap-
plied to >100 independent F5L/L Tfpi+/- rescues identified 12 novel candidate thrombosis 
modifiers. Preliminary validation data using independent null alleles suggest successful 
rescue for mice haploinsufficient for Sntg1 (Chapter IV). 
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 CHAPTER I: Introduction
 
Venous thromboembolism 
 
Incidence and acquired risk factors 
Venous thromboembolism (VTE) is a condition in which the blood clots 
inappropriately. It includes deep vein thrombosis (DVT) and its major life threatening 
complication, pulmonary embolism (PE). 
VTE is a major health problem affecting approximately 1 in every 1,000 
individuals of European descent [1]. The incidence of VTE is about 30% higher among 
African-Americans but lower among Asians, Hispanics, and Native-Americans [2, 3]. In 
the United States alone, the annual number of VTE events (incident and recurrent) is 
estimated at 600,000, with 10-30% of these events proving fatal within 30 days [4]. 
VTE is a complex disease determined by various environmental factors, genetic 
factors, and the interactions of both [5]. The two most prevalent independent risk factors 
for a first lifetime VTE event are hospitalization or residence in a nursing home (60%) 
and active cancer (20%) [6]. VTE incidence increases markedly with age in both 
genders, with incidence rates generally higher in males compared to females after age 
45 [1, 7]. Independent risk factors for VTE also include surgery, trauma, smoking, 
central vein catheterization, and transvenous pacemakers [8, 9]. Additional risk factors 
among females include oral contraceptive use and hormone replacement therapy (2 to 
6 fold increased relative risk for each) [10] as well as pregnancy and the postpartum 
period [11]. 
 
Genetic risk factors for VTE 
VTE is highly heritable, with a study of 21 extended Spanish families (398 
individuals) resulting in an overall heritability estimate of 61% [12]. A family based 
approach in the US population of European descent reported a heritability of 52% for 
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the best fitting inheritance model (unrestricted non-Mendelian) [13]. A high genetic 
proportion contributing to VTE variance was also seen in males in a Danish twin study 
(55%). However, no contribution was observed in females, suggesting a possible 
difference in VTE heritability between sexes [14]. 
While VTE is a defined clinical manifestation, the acquired or inherited tendency 
to develop VTE is referred to as thrombophilia. Known causes for inherited 
thrombophilia can be divided into two main mechanisms: reduced levels of endogenous 
anticoagulants or increased levels of procoagulant factors. The first report of inherited 
thrombophilia was published in 1965 by Egeberg and colleagues who described a 
Norwegian family suffering from VTE due to a deficiency in levels of the anticoagulant 
antithrombin [15]. Antithrombin III deficiency is inherited in an autosomal-dominant 
fashion and is caused by ~50% reduction in either protein function and/or level in 
plasma [16]. More than a decade later, deficiency in other anticoagulants such as 
protein C [17] and protein S [18] were shown to cause inherited thrombophilia in a 
similar autosomal-dominant manner. While loss-of-function mutations in these natural 
anticoagulants are associated with increased risk for VTE, they are rare in the general 
population (19-77 per 10,000) and their total prevalence in VTE patients is 
approximately 6% [8]. 
Thrombophilia has also been associated with elevated plasma levels of several 
procoagulant proteins. Increased levels of factor I (fibrinogen) [19], II (prothrombin) [20], 
VIII [21], IX [22], X [23] and XI [24] have been associated with VTE [8]. Differences in 
factor VIII plasma levels are strongly associated with an individual’s ABO blood type. 
Factor VIII circulates in plasma in a noncovalent complex with its carrier glycoprotein, 
von Willebrand factor (VWF). Plasma levels of the FVIII-VWF complex are ~25% higher 
in non-O blood group individuals, likely due to glycosylation differences for the VWF 
protein driven by the ABO alleles that encode different alleles of a glycosyltransferase 
[25]. The most prevalent genetic risk factor for VTE [26] is a missense substitution 
Factor V Leiden (FVL, Arg506Gln) that blocks the inactivation of procoagulant factor V 
by activated protein C [27, 28]. FVL is present in 4-5% of Europeans [8, 29] and in 20-
25% of VTE patients [30, 31]. Another relatively common variant (2% in European 
population), a substitution in the prothrombin 3' untranslated region (G20210A), is 
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associated with 30% higher plasma levels of prothrombin [20] and is present in ~4.5% 
of VTE patients [32]. Recent genome wide association studies (GWAS) confirmed the 
known common loci contributing to the genetic risk for VTE such as the ABO blood 
group, FVL, FI, FII and FXI, though few new candidates were identified [26, 33-36]. 
Most of the above investigations have been limited to subjects of European 
descent with the identified risk factors of limited relevance to individuals from other parts 
of the world. For example, two of the common risk variants, FVL and G20210A, arose 
approximately 20,000-35,000 years ago in European populations after the evolutionary 
divergence from Africans and Asians and are therefore very rare or absent in most non-
European populations [37, 38]. Relatively higher factor VIII levels are found in the 
African American population that cannot be explained by ABO blood groups alone [39, 
40], but the underlying genetic determinants are unknown. In Asian populations, loss-of-
function mutations in protein S, protein C, and antithrombin are slightly more prevalent 
but do not explain the majority of VTE cases [41]. Population-specific GWAS studies 
could identify common risk variants in these understudied populations while new whole 
exome/genome sequencing approaches can additionally discover rare variants 
contributing to VTE risk. At present, <50% of VTE heritability can be explained by 
currently known genetic risk factors. 
 
FVL 
FVL is the most prevalent genetic risk factor for VTE, found in 20-25% of all VTE 
patients [30, 31] and in 40-60% of patients with familial thrombophilia [42]. While FVL 
heterozygosity is common among VTE patients, only 10% of individuals heterozygous 
for the FVL variant experience a VTE in their lifetime (Figure 1-1). The risk is much 
higher (80% lifetime risk) for people homozygous for FVL [42] but homozygotes are 
relatively rare in the population (6-7 in 10,000) and thus account for a small proportion 
of VTE patients. The genetic and environmental modifying factors that determine the 
clinical expression of FVL are poorly understood. Patients that carry two known 
thrombotic risk factors such as FVL and deficiency in protein S or protein C have a 
higher risk of VTE than those with either risk factor alone [43], as do patients with FVL 
and an acquired risk factor [44]. Though elevated VTE risks are observed in individuals 
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with FVL mutation (odds ratio, OR=4.9) or the prothrombin G20210A variant (OR=3.8), 
a notably higher risk for VTE is observed in doubly heterozygous individuals (OR=20) 
than the sum of the individual estimated risks for these variants [45], a phenomenon 
referred to as epistasis. In addition to unknown genetic factors that elevate an 
individual’s risk for VTE, there are also likely protective genetic modifiers in the 90% of 
asymptomatic FVL carriers. 
 
FVL in a mouse model 
Our lab previously reported a knock-in mouse with the orthologous FVL mutation 
introduced into the endogenous murine F5 gene (F5L, Arg504Gln). FVL mice have a 
very similar phenotype to humans, with occasional sporadic thrombosis in heterozygous 
mice and more severe manifestations in homozygous animals [46]. Crossbreeding 
experiments showed that co-inheritance of Factor V Leiden homozygosity (F5L/L) 
together with haploinsufficiency for tissue factor pathway inhibitor (Tfpi+/-) results in a 
nearly uniform perinatal lethal thrombosis (Figure 1-2) [47]. A similar interaction between 
F5 and TFPI was previously described in a synthetic in vitro assay for thrombin 
generation, where thrombin generation was markedly increased by a combination of 
50% reduced TFPI and FVL mutant compared to reduced TFPI and wildtype F5 [48]. 
These data indicate that reductions in Tfpi result in a significant worsening of the 
FVL thrombotic phenotype in mice and suggest that there may be other gene mutations 
that will act similarly to modulate thrombosis severity. This synthetic lethality in F5L/L 
Tfpi+/- mice serves as a baseline phenotype for the genetic screens performed in this 
thesis. 
 
Mutagenesis screens 
 
De novo mutations 
De novo mutations are the source of natural variation in DNA and the drivers of 
natural selection. The majority of mutations arise due to mistakes made during DNA 
replication, repair, and recombination processes with different mechanisms involved in 
different types of mutations [49]. Germline de novo mutations in humans are relatively 
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rare. On average, each individual is expected to harbor approximately 75 single 
nucleotide variants (SNVs) [50, 51] and an additional 3-5 small insertions/deletions 
(INDELs) not present in either parent [52]. The frequency of de novo medium size 
structural variants (>20bp) is estimated to be 0.16 per person [53], while de novo large 
copy number variants (>100kb) can be found in one out of 50 individuals [54]. While an 
important cause of disease in humans, spontaneous mutations in model organisms 
have long been considered an invaluable source for studying phenotype-genotype 
correlations. 
In model organisms such as E. coli or S. cerevisiae identifying causative genes 
can be achieved by selection for spontaneous mutants under appropriate conditions, 
facilitated by haploid genomes and easy access to millions of individual organisms. For 
example, resistance to streptomycin can be mapped to a few positions in the rpsL gene 
in E. coli by sequencing the rare mutants able to grow in that antibiotic environment 
[55]. In higher eukaryotes, such as mice, where mutation rates are comparable to 
humans [56], systematic genetic screening dependent on these rare mutation events 
would require an unfeasible number of subjects. Nonetheless, large mouse repositories 
such as the Jackson Laboratory and MRC Harwell have collected such rare mutants, 
many serving as useful models for phenotypic studies [57-60]. Chapter III addresses 
one such unexpected variant and its phenotype. 
 
N-ethyl-N-nitrosourea as mutagen 
In order to expedite the occurrence of de novo mutations in mice, various DNA 
damaging agents and their effect on germ cells have been investigated in the past. 
William Russell and colleagues at Oak Ridge National Laboratory demonstrated 
successful germline mutagenesis using radiation [61] as well as the chemical agents 
chlorambucil [62] and N-ethyl-N-nitrosourea (ENU) [63]. Additionally, biological agents 
such as the transposable elements Sleeping Beauty and PiggyBac have been shown to 
randomly disrupt gene function in the mouse germline [64, 65]. 
Among these approaches, ENU has become the most commonly used agent for 
forward genetic screens. ENU is relatively easy to apply by intraperitoneal injection, has 
a high mutation rate, induces point mutations affecting single loci, and targets 
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spermatogonial stem cells [66]. ENU acts as a mutagen by transferring the ethyl group 
of ENU to oxygen in the DNA molecule [67], causing mis-pairing and subsequent base 
pair substitutions during replication if not corrected by the cell’s mismatch repair 
machinery. The largest publicly available ENU database, Mutagenetix [68], catalogs 
298,819 ENU-induced mutations (January 23rd, 2016). The statistics from this database 
supports the previous reports of ENU preference in base pair modification [69, 70]: 
42.4% of induced SNVs are A/T → G/C transition and 26.5% A/T → T/A transversions, 
while <1% of the mutations are C/G → G/C transitions (Figure 1-3A). Due to the nature 
of ENU, most protein sequence altering mutations are nonsynonymous SNVs (80.2%), 
followed by variants at splice acceptor or donor sites (10.4%) and nonsense mutations 
(4.0%) (Figure 1-3B). 
The standard ENU dosage (3 weekly injections at 90 mg/kg) results in 
approximately 60-65 coding variants per sperm, correlating to about 1.42-1.54 
mutations per megabase (Mb) [71, 72]. As expected, not all ENU-induced SNVs are 
damaging. PolyPhen software [73] predicts no effect on protein function for more than a 
third of ENU-induced SNVs in the Mutagenetix database; 10% of variants are predicted 
to be harmful with another 36% predicted to be probably harmful and 17% possibly 
harmful (Figure 1-3D). As expected, while the majority of phenotype-causing mutations 
in the Mutagenetix database are still missense variants (66.1%), the proportion of 
nonsense SNVs is significantly higher (13.6%) than among the total ENU variants 
(Figure 1-3C). 
Russell et al. at Oak Ridge estimated the incidence of gene altering ENU 
mutations using specific-locus tests [74]. The specific-locus test strain T is a mouse 
strain with seven easily identifiable recessive phenotypic features, including pink eyes 
and short ears (Table 1-1). ENU treated wildtype males were crossed to homozygous T 
strain females. All progeny from this cross should be at least heterozygous for all seven 
loci and would appeared wildtype unless an ENU variant happened to damage the 
paternal allele for one of the seven loci. After screening 6939 progeny, a total of 64 
mutant offspring was identified. Fifty-one of the mutants were independent events, with 
the rest sharing the ENU parent and therefore the independent occurrence of the 
mutation could not be tested [75]. While at the time Russell and colleagues did not know 
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the underlying genes in the specific-locus test and their coding sequence length, we can 
now calculate the incidence of damaging mutations from their work based on those 
seven loci. The total number of base pairs (bp) tested for mutants was ~99.57 Mb 
(14,349 bp (length of the seven genes) * 6939 mice) and the number of independent 
mutants found was 51. Assuming that all the underlying phenotype-altering SNVs were 
in coding sequences, we would expect 0.51 damaging mutations per 1 Mb. This 
suggests that ~35% of all coding ENU variants are phenotype altering. These ENU 
statistics correlate well with our own data (discussed in Chapters II and IV). 
 
Forward genetic screens 
Forward genetics is defined as a strategy that aims to characterize the structural 
alterations at the genome level that are associated or responsible for a specific 
phenotype. It is the opposite of reverse genetics approaches which aim to assess the 
consequences of specific DNA alterations at the phenotypic level [76]. Generation 1 
(G1) offspring from an ENU treated male (G0) are heterozygous for a subset of the 
ENU-induced mutations and can be directly screened for a dominant or semi-dominant 
phenotype of interest. For most genes, the deleterious effect of a mutation is 
compensated by the functional wildtype allele. In order to discover the phenotypes 
caused by such recessive mutations, additional breeding steps are required. The G1 
fathers are typically mated with their G2 daughters to homozygose a subset of the 
mutations in their G3 progeny, which can then be screened for recessive phenotypes 
(Figure 1-4). 
The first genome-wide ENU screens mostly focused on a particular phenotype of 
interest. Early examples include the Takahashi lab that set out to identify the mouse 
clock gene. They tested 304 G1 offspring from ENU treated males on a wheel-running 
activity, a robust behavioral assay for circadian rhythms, and identified one semi-
dominant mutant with an abnormal circadian behavior [77]. Bode and colleagues were 
phenotyping for hyperphenylalaninemia using a Guthrie test that estimates blood levels 
of phenylalanine by bacterial growth inhibition. Initially, they focused on mapping 
dominant mutations but failed to find even a single mutant with a positive phenotype in 
the Guthrie test among >7000 tested G1 offspring. They next screened for recessive 
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mutants among the G3 generation obtained from intercrossing 105 G1 males to their G2 
daughters and successfully identified one recessive mutation [78]. The Dove lab initially 
followed a circling behavior phenotype of a G1 progeny. While testing for the heritability 
for the circling phenotype, they noted an adult-onset anemia in some of the mice within 
the pedigree. This led to discovery of an independently segregating dominant mutation 
that predisposes mice to multiple intestinal neoplasia due to mutations in the mouse 
APC gene [79, 80]. 
In order to maximize discoveries from a genome-wide mutagenesis experiment, a 
collaborative group of scientists proceeded to screen multiple phenotypes in parallel. 
The first two large-scale ENU screens were launched in 1997 in Germany [81] and in 
the UK [82], followed by many others [83]. The first two screens focused on dominant 
mutations while screening for dozens of different phenotypes including skeletal and 
coat-color defects, neurological and behavioral abnormalities, atypical results in clinical 
chemistry tests, and many others. More recent large-scale recessive screens have 
expanded the list of screened phenotypes to hundreds, turning into “mouse clinics” and 
have uncovered many interesting induced mutations that would have likely been missed 
by other laboratories [84]. Still, the “mouse clinics” address only a limited number of 
assays and a large number of specific phenotypes remain to be explored. In addition to 
genome-wide approaches, many specialized regional screens including non-
complementation, deletion, and balancer screens have proved to be very insightful 
(reviewed in [66]). 
 
Sensitized suppressor/enhancer screens 
Instead of starting the ENU screen with a wildtype animal, a sensitized screen is 
based on a preexisting phenotype and allows screening for mutations that suppress or 
enhance that particular phenotype. Such contextual screens have been very successful 
in yeast and invertebrate model organisms [85-87], and several published examples in 
mice also proved the feasibility and relevance of sensitized screens in mammalian 
systems [88-91]. 
While Matera and colleagues looked for enhancement of pigmentation 
deficiencies present in Sox10 haploinsufficient mice in order to identify additional genes 
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in this pathway [89], other groups searched for genes that suppress the phenotype of 
interest. For example, Buchovecky et al. screened for mutations that suppress 
symptoms in Mecp2-null mice in order to identify potential novel therapeutic targets for 
patients with Rett syndrome (with mutations in the MECP2 gene) [90]. Sensitized 
screens could point investigators to novel pathways involved in disease pathology and 
highlight molecules interacting both directly and indirectly with the sensitizing genetic 
variant. As many modifier genes do not exhibit a visible phenotype outside of the 
context of the sensitized background, these genes would be undetected in a typical 
dominant or recessive screen. For example, mice haploinsufficient for Tfpi are 
phenotypically normal and viable [92] and would not be identified in a dominant screen 
for thrombosis. Nevertheless, Tfpi haploinsufficiency in mice markedly increases 
thrombosis in the background of F5L/L [47]. Chapters II and IV describe a sensitized 
screen based on suppression of this F5L/L Tfpi+/- lethal phenotype (Figure 1-5). 
 
Historical mutation mapping strategies 
For many years the most challenging part of a mutagenesis screen was mapping 
the causal mutation. As inbred mice are homozygous throughout the genome, 
outcrossing to a different strain was necessary to introduce differences into the DNA 
sequence as markers for genetic mapping. These mixed strain mice were either back-
crossed (dominant) or inter-crossed (recessive) and their offspring used to define the 
markers that co-segregate with the phenotype. During the pre-reference sequence era, 
the first mapping attempts had only a handful of known polymorphic loci available. As a 
result, the mapped region was usually very large [77, 78]. After the identification of 
denser marker maps such as microsatellites and, later, single nucleotide polymorphisms 
(SNPs), the limitations for mapping were dictated by the recombination events. A 
candidate region was often 1-3 Mb in length and could contain anywhere from dozens 
to hundreds of candidate genes, poorly, if at all, annotated before the completion of a 
comprehensive reference sequence. Even with the correct annotation, some of these 
gene-rich regions required thousands of meioses to narrow the candidate interval. All 
candidate genes would have to be individually Sanger sequenced in the search for ENU 
mutations [93]. 
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While this mapping strategy is straightforward and has proven successful in 
many cases [94-96], it is also very laborious, with multiple potential pitfalls. First, 
crossing to a different mouse strain introduces multiple strain-specific modifier effects 
[97]. Second, generating large pedigrees necessary for mapping from the ENU mutant 
founders could be complicated due to the biological nature of the phenotype of interest 
and the effect of all the other random ENU mutations on survival and fertility. Third, 
while mapping the phenotype to a large chromosomal segment by linkage analysis is 
straightforward, identifying the underlying mutation within this region can be challenging. 
Mutation identification is especially complicated if the region harbors many genes with 
no clear candidate, harbors multiple ENU mutations, or if the causal mutation is non-
coding. 
 
Mutation mapping in the next generation sequencing (NGS) era 
The emergence of NGS techniques greatly enabled the identification of mutations 
within the entire genome [98]. In many examples, combining previously identified 
linkage peaks with whole exome sequencing (WES) data successfully uncovered the 
underlying ENU mutations [99-101]. 
Direct identification of ENU variants removes the necessity for outcrossing to 
another strain and therefore eliminates the potential complication of phenocopies due to 
strain modifiers. However, the challenge remains of identifying the causal mutation 
amongst the ~4000 mutations across the mouse genome. Even with the assumption 
that the underlying mutation has to introduce a change in protein sequence, dozens of 
mutations typically meet this criterion. Without linkage data, extensive validation is 
necessary to prove one of the variants responsible for the phenotype [102]. Arnold and 
colleagues reported that even a coarse linkage to a large chromosomal region may be 
sufficient to eliminate most of the candidate mutations within the coding region [103]. 
While they outcrossed their mice into a different strain for mapping, such coarse 
mapping can also be achieved using the ENU variants themselves as markers for 
mapping. The latter approach is applied in Chapters II and IV and has also been used 
by other investigators [104]. While successful in many cases, coupling linkage analysis 
with NGS still requires production of large pedigrees for the mapping step. 
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Burden testing in ENU screens 
In bacteria where the number of subjects screened can be many orders of 
magnitude higher than in a mouse experiment, saturating for any nucleotide change at 
every position of the genome is possible, even without a mutagenizing agent [55]. 
Extremely rare de novo gain-of-function mutations in the human population (such as 
alpha-1-antitrypsin-Pittsburgh (M358A) [105, 106]) highlight the vast number of 
individuals needed to find even 2 individuals with the same, specific amino acid change 
in the human population. In contrast, de novo loss-of-function mutations, such as those 
resulting in Marfan syndrome, are more commonly characterized in a population 
because loss-of-function of a particular gene can be achieved by many different 
mutations [107]. WES has proven very successful in finding such loss-of-function 
variants in patients with diseases caused by de novo mutations within a single gene 
[108, 109] as well as in multiple genes [110, 111]. The causal genes are identified by 
searching for genes that harbored de novo mutations in all or in a subset of unrelated 
patients. Usually two or three probands with the same disease is enough to highlight the 
single causal gene, while more patients are required when de novo mutations in 
multiple genes (locus heterogeneity) can result in the same phenotype. 
Similar concepts can be applied to map causal variants from an ENU screen. 
This approach relies on screening enough mice to cover the gene space with multiple 
disruptive mutations resulting in two or more mice with the same phenotype. The 
minimum number of mice to be screened will depend on the size of the gene causing 
the phenotype. Disruption of every average sized gene (~ 1,500 nucleotides of coding 
sequence) requires screening ~1,000 mice [75], but could range from 100-10,000 mice 
depending on the size of the gene (Figure 1-6). If there are multiple genes that cause 
the same phenotype, the proportion of mice identified by the screen is expected to be 
much higher. Due to differences in gene size and penetrance of each mutation, it is 
difficult to estimate how many genes underlie the same phenotype without mapping the 
variants using an NGS approach. 
After identifying all of the protein altering ENU-induced SNVs in mice carrying the 
phenotype of interest, an accumulation of mutations is expected at the causal gene(s). If 
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only two mice are identified from a screen with the same phenotype and both have a 
unique mutation within the same gene, it may likely be the causal gene [88]. For 
phenotypes caused by mutations in multiple genes, examining more mice with the same 
phenotype is necessary to identify the underlying causal genes [112, 113]. In Chapter II, 
8 mice with the same phenotype were whole exome sequenced yet no genes harboring 
ENU variants were shared between them. In contrast, sequencing 107 mice with the 
same phenotype in Chapter IV identified 12 genes with more ENU-induced mutations 
than expected by chance. 
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Figure 1-1: Prevalence of FVL mutation 
FVL mutation is present in ~5% of people in European populations. While 20-25% of 
VTE patients carry the FVL mutation, only 10% of FVL carriers experience VTE in their 
lifetime.  
 
 
14 
 
Figure 1-2: Perinatal lethal thrombosis model 
Most mice carrying the genotype F5L/L Tfpi+/- die by the age of weaning due to severe 
thrombosis. Figure adopted from Eitzman et al, 2002 [47]. 
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Figure 1-3: Mutagenetix database 
A) All observed ENU-induced single nucleotide changes B) ENU-induced mutation 
types within gene coding regions C) ENU-induced mutation types that have been 
validated to cause a phenotype D) Altered protein function estimated by PolyPhen 
software. Panels A-D are screenshot from the Mutagenetix website [68] on January 
23rd, 2016.  
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Figure 1-4: Screening strategies 
G0 male is treated with mutagen (red arrow). The progeny (G1) of treated males and 
untreated females will each carry different heterozygous ENU-induced mutations (red 
stars) that can be screened for dominant phenotypes. To assess recessive mutations, 
G1 males are mated to their daughters (G2). Each offspring (G3) will be homozygous 
for a different subset of the original ENU mutations. 
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Figure 1-5: Sensitized screen for thrombosis modifiers 
ENU treated F5L/L males are mated to doubly heterozygous females and the G1 
offspring are screened for survivors carrying the lethal F5L/L Tfpi+/- genotype. The G1 
rescue mice are progeny tested by mating to F5L/L mice. While ENU-induced mutations 
are expected to segregate randomly (black stars) to the progeny, the causal ‘rescue’ 
mutation (red star) is expected be present in all the rescue mice. 
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Figure 1-6: ENU gene space saturation 
This plot shows on x-axis the expected number of screened progeny of ENU-induced 
mice necessary to introduce a mutation into every gene with a corresponding coding 
DNA sequence (CDS) length shown on y-axis in log10 scale assuming published ENU 
mutation rate of 1.5 mutations per 1,000,000 base pairs. Inducing a mutation to every 
average sized gene (~1,500 bp) in the genome requires screening ~400 mice, while 
inducing a disruptive change (~1/3 of all mutations) requires ~1000 mice. 
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Table 1-1: Overview of genes used in the specific-locus test 
Loci Phenotype Gene Location (mm10) 
CDS 
(bp) 
Independent 
mutants 
All 
mutants 
a nonagouti a 
chr2:155,013,570-
155,051,012 
393 0 0 
b brown Tyrp1 
chr4:80,846,571-
80,850,904 
1611 7 8 
c 
chinchilla at 
albino 
Tyr 
chr7:87,427,405-
87,493,411 
1599 10 10 
d dilute Myo5a 
chr9:75,071,206-
75,223,687 
5559 10 14 
p Pink-eyed Oca2 
chr7:56,239,771-
56,536,517 
2499 16 24 
s 
Piebald-
spotting 
Ednrb 
chr14:103814625-
103844173 
1326 4 4 
se Short-ear Bmp5 
chr9:75,775,365-
75,899,017 
1362 3 3 
b/p intermediate - - - 1 1 
   sum: 14349 51 64 
Compiled based on data from Russell et al [75] and sequence information from UCSC 
genome browser (genome.ucsc.edu). mm10 = mouse genome alignment number; CDS 
= coding DNA sequence; bp = base  pair 
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 CHAPTER II: A sensitized mutagenesis screen in Factor V Leiden mice identifies 
novel thrombosis suppressor loci
 
Abstract 
 
Factor V Leiden (FVL) is a common genetic risk factor for venous 
thromboembolism (VTE), though only 10% of individuals carrying this variant develop 
VTE in their lifetime. We conducted a sensitized ENU mutagenesis screen for dominant 
thrombosis modifier genes based on the previously reported synthetic perinatal lethal 
thrombosis phenotype in mice homozygous for FVL (F5L/L) and haploinsufficient for 
tissue factor pathway inhibitor (Tfpi+/-). The observation that both hemizygous and 
heterozygous F8 deficiency enhanced survival of F5L/L Tfpi+/- mice demonstrated that 
genetic mutations in coagulation factor genes, and potentially at other loci, could 
suppress F5L/L Tfpi+/- lethality. G1 progeny of crosses between G0 ENU-mutagenized 
F5L/L males and F5L/+ Tfpi+/- females were genotyped at weaning, with 98 surviving F5L/L 
Tfpi+/- mice (‘rescues’) identified. Sixteen of these G1 rescues exhibited transmission of 
a putative ENU suppressor mutation to subsequent generations. The lines established 
from each of these G1 founders, and the corresponding modifier genes are referred to 
as MF5L (Modifier of Factor 5 Leiden) 1-16. Linkage analysis in the MF5L6 pedigree 
mapped the corresponding modifier locus to a region of chromosome 3 containing the 
tissue factor gene (F3). Though no ENU-induced mutation was identified in the MF5L6 
F3 gene, a genetic cross with F3 gene-targeted mice demonstrated that heterozygous 
tissue factor deficiency (F3+/-) could modify F5L/L Tfpi+/- with incomplete penetrance. 
Thus, like F8 deficiency, reduced F3 activity is a major modifier for F5L/L Tfpi+/- 
thrombosis. Whole exome sequencing of an MF5L12 rescue mouse identified a point 
mutation in a highly conserved domain of the Actr2 gene (R258G) as the sole 
candidate. However, when an independent Actr2 hemizygosity mutation (Actr2+/-) was 
tested for its ability to suppress F5L/L Tfpi+/- lethality, no significant rescue was observed. 
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These data suggest that either Actr2R258G results in gain-of-function or that another, 
closely linked variant is responsible for the rescue in this line. Taken together, these 
findings identify F8 and the Tfpi/F3 axis as key regulators of thrombosis balance in the 
setting of FVL and demonstrates the utility of this sensitized ENU mutagenesis 
approach for the identification of dominant thrombosis suppressor loci. 
 
Introduction 
 
Venous thromboembolism (VTE) is a common disease that affects 1 to 3 per 
1000 individuals per year [1]. VTE susceptibility exhibits a complex etiology involving 
contributions of both genes and environment. Genetic risk factors explain approximately 
60% of the overall risk for VTE [114]. The Factor V Leiden mutation (FVL) is a common 
inherited risk factor for VTE with an allele frequency of 2-10% in most European-derived 
populations [28, 115-117]. FVL is estimated to account for up to 25 percent of the 
genetically-attributable thrombosis risk in humans [115]. However, penetrance is 
incomplete, with only ten percent of FVL heterozygotes developing thrombosis in their 
lifetimes. The severity of thrombosis also varies widely among affected individuals [118]. 
This incomplete penetrance and variable expressivity limits the clinical utility of FVL 
genotyping in the management of VTE [119]. 
The incomplete penetrance and variable expressivity of thrombosis among FVL 
patients can at least partially be explained by genetic interactions between FVL and 
other known thrombotic risk factors such as hemizygosity for antithrombin III or proteins 
C or S, as well as the common prothrombin 20210 polymorphism [119-121]. However, 
<2 percent of FVL heterozygotes would be expected to co-inherit one or more of these 
risk factors, suggesting that a large number of additional genetic factors for VTE and/or 
modifiers of FVL remain to be identified [122]. Although family studies of thrombosis 
susceptibility display ~60% heritability [114], recent large-scale genome wide 
association studies (GWAS) have only confirmed ABO, F5, FGG and F2 as thrombosis 
susceptibility genes, with few additional novel loci identified [26, 33-36], leaving the 
major component of VTE genetic risk still unexplained. 
Mice carrying the orthologous FVL mutation exhibit a mild to moderate 
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prothrombotic phenotype [46], closely mimicking the human disorder, with a similarly 
more severe thrombosis in homozygotes. We previously reported a synthetic lethal 
interaction between FVL homozygosity (F5L/L) and hemizygosity for tissue factor 
pathway inhibitor (Tfpi+/-). Nearly all mice with this lethal genotype combination (F5L/L 
Tfpi+/-) succumb to widespread, systemic thrombosis in the immediate perinatal period 
[47]. 
ENU mutagenesis in mice has been used effectively to identify novel genes 
involved in a number of biological processes [123, 124]. The ENU-induced germline 
mutations transmitted from a mutagenized male mouse (G0) occur at 1.5 mutations per 
megabase, at least 50 fold higher than the endogenous background mutation rate [93, 
125]. Several previous reports have successfully applied an existing phenotype as a 
sensitizer to identify modifier genes. This method has been used effectively to screen 
for suppressor mutants of diabetic nephropathy in mice [91], as well as for modifiers of 
neurochristopathy [89], platelet number [88] and Rett syndrome [90]. 
We now report the results of a dominant sensitized ENU mutagenesis screen for 
thrombosis modifier genes based on the synthetic lethal F5L/L Tfpi+/- interaction, 
identifying mutations at or near the F3, F8 and Actr2 loci as suppressors of F5L/L Tfpi+/- 
dependent lethal thrombosis. 
 
Materials and methods 
 
Mice 
C57BL/6J (B6, stock number 000664), 129S1/SvImJ mice (129, stock number 
002448), and DBA/2J (DBA, stock number 000671), A/J (stock number 000646) and 
BALB/cJ (BALB, stock number 000651) were purchased from the Jackson Laboratory. 
F5L/L (F5tm2Dgi/J, stock number 004080) mice were previously generated [46]. F3 and 
Tfpi deficient mice were a generous gift of Dr. George Broze [92, 126]. F8 deficient mice 
were a generous gift of Dr. Haig Kazazian [127]. All mice designated to be on the B6 
background were backcrossed greater than 8 generations to B6. F5L/L breeding stock 
for genetic mapping were generated from F5L mice serially backcrossed greater than 12 
generations to the 129 strain to create F5L congenic mice. B6 F5L/+ Tfpi+/- mice were 
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crossed to the BALB strain to create F5L/+ Tfpi+/- and F5L/+ Tfpi+/+ G1 (generation 1) 
mice. These mice were intercrossed to create B6BALB mixed background G2 mice. B6 
F5L/+ Tfpi+/- mice were crossed to F5L/+ mice on the A/J or DBA strain background (for 6 
generations) to generate G1 F5L/+ Tfpi+/- mice, which were backgrossed to B6 F5L/+ to 
generate mixed background G2 mice. All mice were maintained on normal chow in a 
specific pathogen-free facility. All animal care and experimental procedures complied 
with the principles of Laboratory and Animal Care established by the National Society for 
Medical Research and were approved by the University of Michigan Committee on Use 
and Care of Animals. 
 
Genotyping  
DNA was isolated from tail biopsies and mice genotyped for Tfpi+/- and F5L as 
previously described [47]. Mice were genotyped for F3 deficiency using custom primers 
listed in Appendix 2-1. All primers were purchased from IDT, Coralville, IA.  
 
ENU mutagenesis and breeding 
ENU was purchased (Sigma Aldrich, St. Louis MO) in ISOPAC vials, and 
prepared according to the following protocol: http://pga.jax.org/enu_protocol.html. A 
single ENU dose of 150 mg/kg was administered intraperitoneally into 159 F5L/L B6 
male mice (referred to as generation 0 or G0 mice). For a second cohort of 900 male 
F5L/L G0 mice, the protocol was changed to three weekly intraperitoneal injections of 
ENU (90 mg/kg). After a 10-week recovery period, each G0 mouse was bred to F5L/+ 
Tfpi+/- mice (Figure 2-1B) on the B6 genetic background to produce G1 offspring, which 
were genotyped at two weeks of age. G1 mice of the F5L/L Tfpi+/- genotype surviving to 
greater than three weeks of age (referred to as ‘rescues’) were considered to carry a 
‘rescue’ mutation. 
 
Modifier gene transmission 
G1 rescue founders were crossed to F5L/L mice on the B6 genetic background to 
produce G2 offspring. G2 mice were outcrossed to F5L/L mice on the 129 genetic 
background. Progeny testing was considered positive with the identification of one or 
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more rescue offspring, regardless of the total number of progeny. 
 
Genetic mapping  
Genetic markers distinguishing the B6 and 129 strains distributed across the 
genome were genotyped using the Illumina GoldenGate Genotyping Universal-32 
platform (Illumina, San Diego CA) at the University of Michigan DNA Sequencing Core. 
Linkage Analysis was performed on the Mendel platform version 14.0 [128] using 806 
informative markers from the total of 1449 genotyped markers. LOD scores ≥3.3 were 
considered significant [129]. The number of mice, the number of SNP markers, and the 
LOD scores for each of the mapped pedigrees are listed in Table 2-1.  
 
Sanger sequencing of the F3 gene 
Genomic DNA was extracted from mouse tail biopsies using the Gentra 
Puregene Tissue Kit (Qiagen, Germantown, MD). A total of 48 overlapping amplicons 
(primers: F3gene_1-F3gene_35; upstreamF3_1-upstreamF3_13, Appendix 2-1) were 
used to Sanger sequence the entire F3 gene (~11kb) and an additional ~5kb of 
upstream sequence on both strands. Sanger sequencing was performed at the 
University of Michigan Sequencing Core. 
 
Estimation of F3 allelic expression 
F5L/L Tfpi+/- mice with one B6 allele (in cis with ENU induced variants) and one 
129 allele at the Chr3 candidate region were outcrossed to DBA wildtype females 
introducing exonic B6-129/DBA SNPs. Five progeny from this cross (2 B6/DBA and 3 
129/DBA allele carriers, identified by DNA genotyping) were tested for differential F3 
allelic expression. From each mouse three tissue samples (lung, liver, whole brain) were 
obtained as previously described [46]. Total RNA was extracted from the tissue samples 
using RNeasy Plus Mini Kit (Qiagen) according to manufacturer's recommendations and 
reverse transcribed using SuperScript II (Invitrogen, Carlsbad, CA). cDNA 
corresponding to exon3-exon5 of F3 was amplified with primers F3-exon-F 
(5'TGCTTCTCGACCACAGACAC) and F3-exon-R (5'CTGCTTCCTGGGCTATTTTG), 
using Gotaq Green Master Mix (Promega, Madison, WI). Primers F3-exon-F and F3-
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exon-R were also used to Sanger sequence the F3 exonic region. The F3 exonic region 
harbors 3 known B6-129/DBA SNPs (rs30268372, rs30269285, rs30269288, 
http://www.ncbi.nlm.nih.gov/SNP/). Relative expression was estimated at SNP sites by 
dividing the area under the Sanger sequencing peak of one allele to another [130]. 
Next, the relative expression of each SNP was compared between the B6 and 129 
allele carrying progeny. 
 
Whole exome sequencing  
Libraries were prepared using Agilent (Agilent Technologies, Santa Clara, CA) or 
NimbleGen (Roche NimbleGen, Madison, WI) mouse whole exome capture kits. 100 bp 
paired-end sequencing was performed on the Illumina Hiseq 2000 platform at the 
University of Michigan DNA Sequencing Core. A detailed overview of the whole exome 
sequencing (WES) pipeline is available at GitHub (github.com/tombergk/FVL_SUP). 
Briefly, sequence reads were aligned using Burrows-Wheeler Alignment software [131] 
to the mouse reference genome (genome assembly GRCm38, Ensembl release 73). 
Reads were sorted and duplications removed using Picard tools 
(http://picard.sourceforge.net). Coverage statistics were estimated using QualiMap 
software [132]. Variants were called across 8 samples using GATK HaplotypeCaller 
software [133]. Standard hard filters recommended by the Broad Institute were applied 
using GATK VariantFiltration [133] followed by an in-house developed pipeline to 
remove variants between the B6 and 129 strains, shared variants within our mouse 
cohort and variants in closer proximity than 200 base pairs from each other. Variants 
were annotated using Annovar software [134] with Refseq annotation (release 61). 
Heterozygous variants within exonic regions with ≥6X coverage unique for only one 
mouse in the cohort were regarded as potential ENU-induced variants. The candidate 
ENU-induced variants were validated by Sanger sequencing. 
 
Generation of an independent Actr2 null allele 
Embryonic stem (ES) cells containing the targeted Actr2tm1a(KOMP)Wtsi “Knockout 
First” allele (ES cell clone EPD0727_2_H12, generated by the Wellcome Trust Sanger 
Institute, Hinxton, UK) were karyotyped by the UC Davis KOMP Repository, Davis, CA 
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and found to contain 71-80% euploid cells. This ES cell line was then injection into B6 
blastocysts by the University of Michigan Transgenic Animal Model Core. Analysis of 
founders identified 6 chimeras, which were mated yielding germline transmission by a 
single 20% chimera. 
 
Statistical data analysis  
Statistical differences among the potential progeny of mouse crosses were 
determined using the Χ2 test. A paired t-test was used for estimating statistical 
differences between the weights of rescue mice and their littermates. Relative 
expression differences for F3 alleles were estimated using the Wilcoxon rank-sum test. 
Kaplan Meier analysis was used to assess significance for putative suppressors 
identified by exome sequencing. 
 
Results 
 
F8 deficiency suppresses F5L/L Tfpi+/- lethality 
To test whether the F5L/L Tfpi+/- lethal phenotype is genetically suppressible by F8 
deficiency (classic hemophilia A), triple heterozygous F5L/+ Tfpi+/- F8 X+X- female mice 
were generated and crossed to F5L/L male mice (Figure 2-1A). One quarter of 
conceptuses were expected to carry the F5L/L Tfpi+/- genotype, with half of all female 
offspring expected to be also F8 X+X- and half of the male mice completely F8 deficient 
(hemizygous). A total of 167 progeny from this cross were genotyped at weaning, with 8 
F5L/L Tfpi+/- F8 X-Y male and 2 F5L/L Tfpi+/- F8 X+X- female mice observed (67% of 
expected for males and 16.7% for females; Table 2-2). 
 
The F5L/L Tfpi+/- phenotype is suppressed by dominant ENU induced mutations 
A sensitized whole genome ENU mutagenesis screen for dominant thrombosis 
suppressor genes was implemented as depicted in Figure 2-1B. ENU mutagenized G0 
F5L/L males were crossed to F5L/+ Tfpi+/- females to generate G1 mice, which were 
screened by genotyping at weaning for F5L and Tfpi+/-. A number of previously described 
visible dominant mutants [82] were observed among the G1 offspring, ranging from 
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belly spotting to skeletal abnormalities in approximately 5.9% of G1 mice, similar to the 
~4.2% rate of observable mutants in previous studies [82], and consistent with the 
estimated ~20-30 functionally significant mutations per G1 mouse expected with this 
ENU mutagenesis protocol [135]. One quarter of G1 embryos would be expected to 
carry the synthetic lethal F5L/L Tfpi+/- genotype. A total of 6,739 G1 mice were screened 
at weaning, identifying 98 live mice (45 females, 53 males) with the F5L/L Tfpi+/- 
genotype, representing 4.43% of the expected 2,214 mice predicted by Mendelian 
genetics (Table 2-3). 
The heritability of each of the 98 G1 putative rescue mutants was evaluated by 
progeny testing through backcrosses to B6 F5L/L mice. The observation of one or more 
rescue mice among the progeny provided evidence that a particular MF5L line carries a 
transmissible rescue mutation. 72 of the 98 G1 rescues produced no offspring, either 
due to early lethality or infertility, with ~50 percent of these mice (34/72) exhibiting a 
grossly runted appearance. Approximately ~45% (44/98) of rescues died by 10 weeks of 
age, with slightly poorer survival for females (Figure 2-1C). 
Twelve male and 4 female G1 rescues produced one or more F5L/L Tfpi+/- progeny 
when bred to B6 F5L/L mice (Table 2-3). These putative mutant mice were subjected to 
further breeding to create lines of genetically informative progeny. The distribution and 
penetrance for each ENU line are listed in Table 2-4. Within the ENU lines, mice with 
the F5L/L Tfpi+/- genotype were ~30% smaller than their F5L/L littermates at the time of 
weaning (p<2.2x10-16; Figure 2-1D), and the size difference was maintained after 
outcrossing to the 129 strain (Figure 2-1E). 
 
Identification of a mapping strain preserving the F5L/L Tfpi+/- lethal phenotype  
Four inbred mouse strains were tested by crosses introducing the F5L and Tfpi- 
alleles, with only 129 retaining the F5L/L Tfpi+/- synthetic lethal phenotype (Table 2-5). 
Analysis of the crosses of F5L/L x F5L/+ Tfpi+/- and F5L/+ x F5L/+ Tfpi+/- on the 129 strain 
background revealed not only an absence of F5L/+ Tfpi+/- mice, but also a 50% reduction 
of F5L/L Tfpi+/+ mice at weaning (Table 2-5). 
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The MF5L6 suppressor mutation maps to a chromosome 3 interval containing F3 
The MF5L1, 6, 8 and 16 lines were crossed to the 129 genetic background and 
generated significant numbers of F5L/L Tfpi+/- on the mixed 129-B6 genetic background 
suggesting potentially mappable mutants. MF5L6 was maintained for 12 generations 
and had 214 genetically informative F5L/L Tfpi+/- mice out of 336 total progeny. Genome-
wide SNP genotyping of the 214 MF5L6 rescues followed by multipoint linkage analysis 
identified 2 loci with maximum LOD scores >3.3 (Figure 2-2A). The signal on Chr 2 
(maximum LOD score=9.81), spanning the Tfpi gene, was expected, since after 
backcrossing to 129 F5L/L mice, the Tfpi+/- allele is always of B6 origin as it is derived 
from the B6 F5L/+ Tfpi+/- female crossed to the original G0 F5L/L male. This region was 
therefore excluded from further analysis. The Chr 3 peak exhibited the next highest 
LOD score (maximum LOD=4.49), with the 1 LOD interval (117.3-124.8 Mb) containing 
38 refseq annotated genes (Figure 2-2C). Additional linkage analysis for the MF5L1, 
MF5L8, and MF5L16 ENU lines failed to identify any peaks with LOD >2.5, other than 
the Chr 2 Tfpi locus (Table 2-1). 
The F3 gene located at Chr3:121.7 Mb within the MF5L6 Chr 3 candidate interval 
(Figure 2-2C) encodes tissue factor (TF), a procoagulant component of the hemostatic 
pathway that is regulated in part by Tfpi, and thus a highly plausible candidate for a 
loss-of-function mutation suppressing the F5L/L  Tfpi+/- phenotype. However, sequence 
analysis of the full set of F3 exons and introns as well as 5 kilobase upstream of exon 1 
failed to identify an ENU-induced mutation. Analysis of F3 mRNA levels in liver, lung, 
and brain tissues of adult mice failed to identify any differences in the level of 
expression from the ENU-mutant and wildtype alleles (Figure 2-3). However, this 
analysis cannot exclude the possibility of a regulatory mutation affecting expression in 
another tissue or other developmental stage. 
 
F3 haploinsufficiency suppresses the F5L/L Tfpi+/- lethal phenotype 
To test F3 as a candidate suppressor of the F5L/L Tfpi+/- phenotype, an 
independent F3 null allele was introduced and triply heterozygous F5L/+ Tfpi+/- F3+/- mice 
were crossed to F5L/L B6 mice (Figure 2-2B). Of 272 progeny genotypes at weaning 
(Table 2-6), 13 F5L/L Tfpi+/- F3+/- were observed, compared to 1 F5L/L Tfpi+/- F3+/+ (p < 
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0.0001), though with significantly fewer male than female F5L/L Tfpi+/- F3+/- mice (2 vs. 11 
p<0.05). Thus, haploinsufficiency for F3+/- rescues the synthetic lethality of F5L/L Tfpi+/-, 
though with incomplete penetrance that also differs by gender. These data strongly 
support the idea of a F3 regulatory mutation responsible for thrombosuppression in 
MF5L6. Further analysis of WES in mice from this line identified two validated ENU 
variants for MF5L6 (Table 2-7) neither of which were located on Chr 3. This likely 
excludes an ENU-induced coding variant responsible for the rescue phenotype in that 
line and is consistent with the hypothesis of a F3 regulatory mutation outside of the 
gene and 5kb upstream region. 
 
WES identifies candidate ENU-induced variants for 8 MF5L lines 
WES was performed on genomic DNA from one rescue mouse from each of 8 
MF5L lines with the largest pedigrees (MF5L1, MF5L5, MF5L6, MF5L8, MF5L9, 
MF5L11, MF5L12, MF5L16). The mean coverage of sequenced exomes was more than 
90X, with >97% of the captured region covered with at least 6 independent reads (Table 
2-8). A total of 125 heterozygous variants were identified as candidate suppressor 
mutations using an in-house filtering pipeline. 79 variants affected the protein sequence 
(Table 2-7). 54.5% were nonsynonymous single nucleotide variants (SNVs), followed by 
UTR (17.6%), synonymous (14.4%) and stopgain SNVs (7.2%). The most common 
mutation events were A/T→G/C transition (35.2%), while C/G→G/C transitions were the 
least represented (2.5%). This spectrum of mutations is consistent with previously 
published ENU reports [70]. Validation was performed on 52 variants using Sanger 
sequencing. These variants were then checked for parent of origin (either the G1 
mutagenized progeny or its nonmutagenized mate). 42 of the variants were identified in 
the G1 rescue and neither parent, suggesting that they were ENU-induced mutations. 
 
Actr2+/G, but not Actr2+/- is associated with rescue of the F5L/L Tfpi+/- phenotype 
Of the 7 ENU-induced nonsynonymous SNVs identified from WES analysis for 
the MF5L12 line, 6 were validated by Sanger sequencing to have arisen in the G1 
rescue (Table 2-7). For each of these 6 SNVs, co-segregation with the survival 
phenotype was tested by Kaplan-Meier analysis of 31 total rescue mice from the 
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MF5L12 line. Only one variant, a nonsynonymous SNV in the Actr2 gene (Actr2+/G) 
demonstrated a significant survival advantage when co-inherited with the F5L/L Tfpi+/- 
genotype (p=1.7x10-6; Figure 2-4A). The Actr2+/G mutation results in an R258G 
substitution in exon 7 of Actr2 at a highly conserved amino acid position, with arginine 
present at this position for all 60 available vertebrate sequences 
(https://genome.ucsc.edu) as well as in plants and fungi (Figure 2-4B). In addition, no 
variants at this position have been identified to date in over 120,000 human alleles 
(ExAC, http://exac.broadinstitute.org accessed 01/2016). 
To test Actr2 haploinsufficiency as a suppressor of the F5L/+Tfpi+/- phenotype, an 
independent Actr2 null allele was generated and F5L/+Tfpi+/- Actr2+/- triple heterozygote 
mice crossed to F5L/L mice. Out of 154 progeny from this cross, only one F5L/L Tfpi+/- 
Actr2+/- mouse survived to weaning (Figure 2-4C), consistent with the expected 
background survival rate. These data suggest that the thrombosis suppression 
observed in MF5L12 is either due to a unique gain-of-function resulting from the Actr2+/G 
mutation or due to another ENU mutation tightly linked to Actr2. 
Semi-quantitative western blots (Figure 2-5A) demonstrate a significant decrease 
in total ARP2 protein in Actr2+/G platelets compared to Actr2+/- and wildtype. Mouse 
embryonic fibroblasts (MEFs) derived from Actr2+/G mice grow poorly in culture 
compared to control MEFs, are less efficient at forming cell-to-cell contacts and display 
F-actin aggregates at the root of cellular protrusions on phalloidin staining (Figure 2-5B). 
Actr2+/G MEFs also exhibit a spreading defect on a fibronectin matrix, decreased cell-
cell contacts, an abnormal F-actin aggregates, and latency in cell spreading on 
fibronectin-coated coverslips (Figure 2-5C). Analysis of peripheral blood from Actr2+/G 
mice demonstrates subtle but significant reductions in mean platelet volume and mean 
platelet mass, compared to littermate controls (p<0.0001; Figure 2-5E), as well as 
reduced platelet aggregation (P < 0.05; Figure 2-5D). 
 
Discussion 
 
We conducted a sensitized ENU mutagenesis screen for dominant suppressors 
of the F5L/L Tfpi+/- lethal genotype. F8 deficiency suppressed F5L/L Tfpi+/-, indicating that 
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the F5L/L Tfpi+/- lethality is suppressible. This is also consistent with human studies 
demonstrating elevated F8 levels as a VTE risk factor. Analysis of offspring from the 
Leiden screen identified 98 F5L/L Tfpi+/- mice that survived to weaning, with 16 of these 
rescues exhibiting the transmission of an ENU suppressor mutation. Genetic mapping 
studies proved to be very difficult due to the presence of mouse strain specific genes 
capable of interacting with the F5L/L Tfpi+/- phenotype. Nonetheless, mapping of MF5L6 
localized it to a region of chromosome 3 containing the tissue factor gene. Using an 
independent F3 knockout allele, F3 haploinsufficiency was demonstrated to rescue with 
incomplete penetrance. WES for MF5L12 revealed a point mutation in a highly 
conserved domain in the Actr2 gene (R258G) as the sole candidate. However, when 
Actr2 hemizygosity (Actr2+/-) was tested for its ability to suppress F5L/L Tfpi+/- lethality, 
only a background level of F5L/L Tfpi+/- survivors was observed. This suggests that either 
the Actr2R258G mutation functions by a mechanism other than haploinsufficiency or a 
closely linked variant is responsible for the rescue in this ENU line. 
A fundamental aspect of our screening strategy is that only dominant and not 
recessive mutations will be identified. However, it is assumed that most common human 
modifier genes are dominant in inheritance rather than recessive, as a recessive 
mutation would be much less likely to reach high population prevalence. The validity of 
this assumption is supported by the observation that all of the common human 
thrombophilia mutations already known, including FVL and the prothrombin G20210A 
mutation, are autosomal dominant. 
Our screening strategy will only detect mutations that alter the hemostatic 
balance in an antithrombotic direction by compensating for F5L/L Tfpi+/- lethality. ENU-
induced mutations are most likely to result in partial or complete loss of function. Thus, 
most of the mutations identified by our dominant screen can be expected to be due to 
haploinsufficiency. All or most of these mutations are likely to be silent on a wild-type 
background and would thus be missed in a conventional, unsensitized mutagenesis 
screen. Similarly, the corresponding human mutations may also be completely silent by 
themselves, but may function as important modifier genes when co-inherited with 
another thrombophilia mutation such as FVL. 
At first glance, the 98 independent F5L/L Tfpi+/- putative suppressor mice 
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comprised an abundant source of candidates for novel thrombosis suppressor gene 
identification. However, in our initial report of the F5L/L Tfpi+/- phenotype, we observed a 
low level of survival for F5L/L Tfpi+/- mice (3.75% of expected conceptuses) [47]. The 
overall observed number of rescues in this screen was 4.43% of expected conceptuses, 
which is a little higher than the background survival rate. Of note, the survival is close to 
three fold higher in the mice that received three weekly doses of ENU (5.7%) compared 
to mice with one dose of ENU (2%) suggesting that at least a subset of the rescues 
reflect the effect of authentic ENU-induced suppressor mutations. In addition, 
considering that the increased mutation burden could contribute to overall poorer health 
in G1 mice produced from a mutagenized parent, this could actually reduce the 
background survival rate within the screen. 
As our initial strategy for suppressor mutant identification was based on 
traditional genetic mapping/candidate gene analysis, it was necessary to outcross 
surviving F5L/L Tfpi+/- to F5L/L mice on another genetic background and then perform an 
incross to generate genetically informative data. To avoid deleterious modifier genes 
from the 129 genetic background [46], we first chose to test the DBA, A/J and BALB. In 
each instance, a mixed background cross of F5L/+ Tfpi+/- x F5L/+ Tfpi+/+ resulted in 
completely penetrant non-lethality of the F5L/L Tfpi+/-, demonstrating the existence of 
powerful thrombosis suppressor genes associated with these strains. Thus, we were 
forced to resort to the prothrombotic 129 strain as an outcross strain for genetic 
mapping. As a result, 4 of our lines contained significant numbers of F5L/L Tfpi+/- on the 
mixed 129-B6 genetic background. We attempted to genetically map the suppressor 
mutants in these lines and were successful in mapping MF5L6 to a region containing 
the F3 gene. Although we failed to identify an ENU-induced mutation in or near F3 gene 
in MF5L6, F3 represented such a compelling candidate suppressor that we tested the 
ability of F3 haploinsufficiency to suppress F5L/L Tfpi+/-. Initiation of coagulation by F3 is 
directly opposed by Tfpi. Our data demonstrate that reduction of F3 levels by ~50% 
restored viability to F5L/L Tfpi+/- mice, presumably by compensating for the similar 
reduction in Tfpi. Since the surviving F5L/L Tfpi+/- F3+/- mice had a grossly normal 
appearance and lifespan, the reason for the reduced penetrance is unknown, but could 
be largely explained by the significant reduction of male F5L/L Tfpi+/- F3+/- compared to 
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females among surviving progeny. Gender-specific differences in venous thrombosis 
recurrence have been previously documented [136, 137]. These data are consistent 
with a critical role of extrinsic pathway control through F3/Tfpi balance, particularly in the 
setting of FVL. Thus, modest variations in expression of either F3 or Tfpi could be 
important for modifying VTE in humans. Indeed, Tfpi variants have been associated with 
both venous thromboembolism and myocardial infarction in human studies [138, 139]. 
The failure to identify significant linkage in the remaining mappable lines could be 
due to complex strain modifier gene interactions between the 129 and B6 mouse strains 
[140]. Since we failed to identify significant linkage peaks in lines other than MF5L6, we 
used a WES approach to identify suppressors in the other lines. This work resulted in 
the identification of a single heterozygous Actr2+/G mutation that co-segregated with the 
F5L/L Tfpi+/- survival phenotype in the MF5L12 line. The Actr2 gene encodes the ARP2 
protein, which is an essential component of the ARP2/3 complex. This mutation occurs 
at an amino acid position in the ARP2 protein that is conserved from humans to plants 
and fungi. The ARP2/3 complex is essential for actin branching and polymerization and 
complete ARP3 deficiency is incompatible with life [141]. The other members of the 
complex include ARPC 1-5. Disruption of any one of the members of the ARP2/3 
complex has been demonstrated to reduce the activity of the complex [141]. 
Relative to blood coagulation and thrombosis, ARP2 deficiency was 
demonstrated to influence platelet shape change, a process that is critical for normal 
platelet function and thus for hemostasis [142]. Given the Actr2+/G mutation changed 
such a highly conserved amino acid, we surmised that this change would result in loss 
of function. However, Actr2 haploinsufficiency via an independent Actr2 knockout allele 
(Actr2+/-) failed to suppress the F5L/L Tfpi+/- lethal genotype. 
In conclusion, through the design and execution of the Leiden sensitized ENU 
mutagenesis screen, we have identified F3, F8, and Actr2 as potential suppressor 
genes for F5L/L Tfpi+/- lethality. Given the observation of potent strain specific modifiers 
in the Leiden screen as well as the utility of NGS in mouse genetic studies [71], 
performing the entire Leiden mutagenesis screen in a single mouse genetic background 
may enable the rapid identification of additional suppressor genes. 
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Figure 2-1: F8 deficient thrombosuppression and design of the Leiden ENU 
mutagenesis screen 
A. The mating scheme and observed distributions of the F5L/+ Tfpi+/- F8 deficiency 
rescue experiments. F8 X- results in incompletely penetrant suppression of the F5L/+ 
Tfpi+/- phenotype. B. The mating scheme and observed distribution of the Leiden 
screen. F5L/+ Tfpi+/- male mice were mutagenized with either 1 x 150mg/kg or 3 x 90 
mg/kg ENU and bred with non-mutagenized F5L/L females. Sixteen and 83 F5L/L Tfpi+/- 
progeny, respectively were observed in each of the dosing regimens, with over twice the 
rate of F5L/L Tfpi+/- survivors in the progeny of the 3 x 90 mg/kg treated mice. C. On the 
whole, there were insignificant survival differences among the different genders of F5L/L 
Tfpi+/- putative suppressor mice. D and E. F5L/L Tfpi+/- putative suppressor mice were 
distinctly smaller than their non-F5L/L Tfpi+/- littermates in both the pure B6 and mixed 
B6-129 genetic backgrounds. 
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Figure 2-2: Discovery and validation of the chromosome 3 thrombosuppressor 
locus 
A. Linkage analysis for the MF5L6 line. The Chr 2 locus (LOD score=9.81) includes the 
Tfpi gene. The Chr 3 peak had the highest LOD score in the Chr3 subregion:117.3-
124.8Mb (LOD score=4.49, 1 LOD interval). B. The mating scheme and observed 
distribution of the F5L/+ Tfpi+/- F3 deficiency rescue experiment. F3+/- results in 
incompletely penetrant suppression of the F5L/+ Tfpi+/- phenotype. C. The Chr 3 
candidate interval (chr3:117.3-124.8 Mb) contains 38 refseq annotated genes, including 
F3. 
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Figure 2-3: Allele specific RNA expression of F3 
Relative RNA expression of B6 (ENU mutagenized) and 129 alleles from F3 measured 
at three DBA-B6/129 SNP sites (SNP1=rs30268372, SNP2=rs30269285, 
SNP3=rs30269288) in adult lung (red), liver (blue) and whole brain (green) tissues. 
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Figure 2-4: Discovery and validation of Actr2 as a candidate thrombosuppressor 
gene by NGS 
A. Kaplan-Meier survival plot for F5L/L Tfpi+/- mice with and without the Actr2+/G mutation. 
F5L/L Tfpi+/- Actr2+/G have significantly better survival than F5L/L Tfpi+/- Actr2+/+ (n = 35 
mice). Probability of survival was calculated and plotted using Medcalc. B. ARP2 amino 
acid R258 is highly conserved in animals, plants and fungi. C. The mating scheme and 
observed distribution of the F5L/+ Tfpi+/- Actr2+/- rescue experiments. Actr2 
haploinsufficiency failed to suppress the F5L/+ Tfpi+/- phenotype. 
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Figure 2-5: Functional analysis of the Actr2 mutant mice 
A. Platelets were analyzed for ARP2 protein in Actr2+/G, Actr2+/- and Actr2+/+ mice. For 
the statistical analysis, platelet protein extracts from three independent experiments 
were analyzed by Western blotting as described in Materials and Methods. The relative 
intensities of ARP2 as compared to control are displayed as the mean ± SEM (n = 3). 
The asterisk indicates significant difference when compared to control at q < 0.05 
(Mann-Whitney, FDR). Platelet alpha tubulin serves as a loading control. B. Mouse 
embryonic fibroblasts derived from Actr2+/G, Actr2G/G, and wildtype mice and stained 
with phalloidin revealed a tendency to display F-actin aggregates at the root of cellular 
protrusions. C. A significant spreading defect of Actr2+/G murine embryonic fibroblasts 
on a fibronectin matrix was observed (p<0.05). D and E. Whole blood platelet 
aggregation in Actr2+/G heterozygous mice was significantly reduced compared to 
wildtype littermate control mice (p<0.05). Complete blood counts revealed defects in 
Mean Platelet Volume and Mean Platelet Mass in the Actr2+/G mice compared to their 
littermates (n=45, p<0.0001). 
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Table 2-1: Overview of linkage analysis 
ENU 
Lines 
Number of 
mice 
Number of 
markers 
Best LOD 
score 
Tfpi LOD 
score 
Overlapping 
SNVs 
MF5L1 27 862 1.15 3.47234 no 
MF5L6 98 806 4.49 9.80518 no 
MF5L9 84 721 2.5 12.81776 no 
MF5L16 14 822 1.61 1.61088 no 
LOD stands for logarithm of the odds (to the base 10) 
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Table 2-2: Distribution of genotypes from a cross of F5L/+ Tfpi+/- F8X+/X- to F5L/L 
F5 
genotype 
Tfpi 
genotype 
F8 
genotype 
Expected % Observed % 
L/+ +/- X+/Y 13.9 8.3% 12 7.2% 
L/+ +/- X-/Y 13.9 8.3% 15 9.0% 
L/+ +/- X+/X+ 13.9 8.3% 15 9.0% 
L/+ +/- X+/X- 13.9 8.3% 17 10.2% 
L/+ +/+ X+/Y 13.9 8.3% 12 7.2% 
L/+ +/+ X-/Y 13.9 8.3% 17 10.2% 
L/+ +/+ X+/X+ 13.9 8.3% 11 6.6% 
L/+ +/+ X+/X- 13.9 8.3% 9 5.4% 
L/L +/- X+/Y 0 0.0% 0 0.0% 
L/L +/- X-/Y 0 0.0% 8 4.8% 
L/L +/- X+/X+ 0 0.0% 1 0.6% 
L/L +/- X+/X- 0 0.0% 2 1.2% 
L/L +/+ X+/Y 13.9 8.3% 9 5.4% 
L/L +/+ X-/Y 13.9 8.3% 16 9.6% 
L/L +/+ X+/X+ 13.9 8.3% 10 6.0% 
L/L +/+ X+/X- 13.9 8.3% 9 5.4% 
   167 100.0% 167 100.0% 
Parental genotypes: F5L/L Tfpi+/+ F8X+/Y and F5L/+ Tfpi+/- F8X+/X- 
 
  
41 
Table 2-3: Overview of all identified G1 F5L/L Tfpi+/- mice 
ENU 
lines 
MouseID Sex 
Age 
(days) 
# Litters # Progeny # Rescues ENU dosage 
MF5L1 45201 M NA 8 30 2 1x150 mg/kg 
MF5L2 53882 F 626 4 14 1 1x150 mg/kg 
MF5L3 57372 F 263 3 6 1 1x150 mg/kg 
MF5L4 57258 M NA 1 3 1 1x150 mg/kg 
MF5L5 80689 M 694 9 36 7 3x90 mg/kg 
MF5L6 96560 M 882 3 11 3 3x90 mg/kg 
MF5L7 98420 F 681 12 42 1 3x90 mg/kg 
MF5L8 14268 M 210 4 19 5 3x90 mg/kg 
MF5L9 14411 M 687 17 55 8 3x90 mg/kg 
MF5L10 14414 M 835 21 67 6 3x90 mg/kg 
MF5L11 24813 M 834 17 40 10 3x90 mg/kg 
MF5L12 24582 M 525 5 10 4 3x90 mg/kg 
MF5L13 25356 M 843 19 35 4 3x90 mg/kg 
MF5L14 25609 M 662 5 22 2 3x90 mg/kg 
MF5L15 25605 F 511 3 13 2 3x90 mg/kg 
MF5L16 33193 M 178 4 15 6 3x90 mg/kg 
NA 2105 M NA 0 0 0 3x90 mg/kg 
NA 2164 M 770 0 0 0 3x90 mg/kg 
NA 2216 F NA 0 0 0 3x90 mg/kg 
NA 2383 M NA 0 0 0 3x90 mg/kg 
NA 2730 M NA 0 0 0 3x90 mg/kg 
NA 3000 M NA 0 0 0 3x90 mg/kg 
NA 5260 F 308 0 0 0 3x90 mg/kg 
NA 5396 M NA 0 0 0 3x90 mg/kg 
NA 5401 F NA 0 0 0 3x90 mg/kg 
NA 6654 M NA 0 0 0 3x90 mg/kg 
NA 6927 M 24 0 0 0 3x90 mg/kg 
NA 7372 M 25 0 0 0 3x90 mg/kg 
NA 13019 F 66 0 0 0 3x90 mg/kg 
NA 13785 F 58 0 0 0 3x90 mg/kg 
NA 13901 F 17 0 0 0 3x90 mg/kg 
NA 14126 M 22 0 0 0 3x90 mg/kg 
NA 14418 F 42 0 0 0 3x90 mg/kg 
NA 14805 F 252 0 0 0 3x90 mg/kg 
NA 18589 F 27 0 0 0 3x90 mg/kg 
NA 18591 F 663 0 0 0 3x90 mg/kg 
NA 22721 M NA 0 0 0 3x90 mg/kg 
NA 23617 F 553 1 0 0 3x90 mg/kg 
NA 23899 M 33 0 0 0 3x90 mg/kg 
NA 24259 F 33 0 0 0 3x90 mg/kg 
NA 24355 F 18 0 0 0 3x90 mg/kg 
NA 24511 F 18 0 0 0 3x90 mg/kg 
NA 24744 F 294 0 0 0 3x90 mg/kg 
NA 24914 F 22 0 0 0 3x90 mg/kg 
NA 25293 F 444 2 0 0 3x90 mg/kg 
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NA 25681 F 255 1 0 0 3x90 mg/kg 
NA 25876 F 23 0 0 0 3x90 mg/kg 
NA 25948 M 32 0 0 0 3x90 mg/kg 
NA 29035 F 56 0 0 0 3x90 mg/kg 
NA 31710 F 140 0 0 0 3x90 mg/kg 
NA 31881 F 161 1 0 0 3x90 mg/kg 
NA 33095 M 46 0 0 0 3x90 mg/kg 
NA 33434 M 34 0 0 0 3x90 mg/kg 
NA 42058 F 306 0 0 0 1x150 mg/kg 
NA 42127 M 320 5 14 0 1x150 mg/kg 
NA 42885 F NA 0 0 0 1x150 mg/kg 
NA 45755 M 136 0 0 0 1x150 mg/kg 
NA 51255 F NA 3 8 0 1x150 mg/kg 
NA 51283 F NA 0 0 0 1x150 mg/kg 
NA 51665 F 203 1 1 0 1x150 mg/kg 
NA 51735 F NA 5 11 0 1x150 mg/kg 
NA 53087 M NA 0 0 0 1x150 mg/kg 
NA 57931 M 34 0 0 0 1x150 mg/kg 
NA 60776 F NA 3 11 0 1x150 mg/kg 
NA 74064 F NA 0 0 0 3x90 mg/kg 
NA 74637 M 26 0 0 0 3x90 mg/kg 
NA 76278 F 147 1 3 0 3x90 mg/kg 
NA 76387 F NA 0 0 0 3x90 mg/kg 
NA 76526 F 24 0 0 0 3x90 mg/kg 
NA 76582 F NA 0 0 0 3x90 mg/kg 
NA 76824 M NA 0 0 0 3x90 mg/kg 
NA 76947 M NA 0 0 0 3x90 mg/kg 
NA 76989 M NA 0 0 0 3x90 mg/kg 
NA 80493 M NA 0 0 0 3x90 mg/kg 
NA 80821 F NA 0 0 0 3x90 mg/kg 
NA 80840 F NA 0 0 0 3x90 mg/kg 
NA 89215 M 831 0 0 0 3x90 mg/kg 
NA 89285 F NA 0 0 0 3x90 mg/kg 
NA 89957 M NA 0 0 0 3x90 mg/kg 
NA 89965 M NA 0 0 0 3x90 mg/kg 
NA 90152 M NA 0 0 0 3x90 mg/kg 
NA 90488 M NA 0 0 0 3x90 mg/kg 
NA 90832 M NA 0 0 0 3x90 mg/kg 
NA 91310 M NA 0 0 0 3x90 mg/kg 
NA 91570 M NA 0 0 0 3x90 mg/kg 
NA 96245 F 386 0 0 0 3x90 mg/kg 
NA 96247 F NA 0 0 0 3x90 mg/kg 
NA 96440 M NA 0 0 0 3x90 mg/kg 
NA 96684 M 15 0 0 0 3x90 mg/kg 
NA 96685 M 15 0 0 0 3x90 mg/kg 
NA 96839 F NA 0 0 0 3x90 mg/kg 
NA 96868 M 659 3 6 0 3x90 mg/kg 
NA 98148 M NA 0 0 0 3x90 mg/kg 
NA 98172 F 860 0 0 0 3x90 mg/kg 
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NA 98313 M NA 0 0 0 3x90 mg/kg 
NA 98441 M NA 0 0 0 3x90 mg/kg 
NA 98491 M NA 0 0 0 3x90 mg/kg 
NA 98759 M 350 0 0 0 3x90 mg/kg 
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Table 2-4: Overview of the ENU pedigrees 
ENU Lines Total Mice Littermates 
Total F5L/L Tfpi+/- 
mice 
Penetrance 
MF5L1 654 470 184 78.3% 
MF5L2 14 13 1 15.4% 
MF5L3 50 47 3 12.8% 
MF5L4 3 2 1 100% 
MF5L5 255 205 50 48.8% 
MF5L6 1393 1057 336 63.6% 
MF5L7 42 41 1 4.9% 
MF5L8 543 411 132 64.2% 
MF5L9 1127 863 264 61.2% 
MF5L10 111 96 15 31.3% 
MF5L11 459 338 121 71.6% 
MF5L12 200 154 46 59.7% 
MF5L13 115 102 13 25.5% 
MF5L14 47 44 3 13.6% 
MF5L15 40 37 3 16.2% 
MF5L16 442 323 119 73.7% 
Penetrance is calculated as follows: Total # F5L/L Tfpi+/- mice / (Littermates / 2) 
 
  
45 
Table 2-5: Synthetic lethal phenotype on 129 genetic background 
F5 
genotype 
Tfpi 
genotype 
Expected % Observed % 
L/+ +/+ 44.25 25.0% 76 42.9% 
L/+ +/- 44.25 25.0% 74 41.8% 
L/L +/+ 44.25 25.0% 27 15.3% 
L/L +/- 44.25 25.0% 0 0.0% 
  177 100.0% 177 100.0% 
Parental genotypes: F5L/L and F5L/+ Tfpi+/- 
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Table 2-6: Distribution of genotypes from a cross of F5L/+ Tfpi+/- F3+/- to F5L/L 
F5 
genotype 
Tfpi 
genotype 
F3 
genotype 
Expected % Observed % 
L/+ +/- +/- 38.9 14.3% 39 14.3% 
L/+ +/- +/+ 38.9 14.3% 58 21.3% 
L/+ +/+ +/- 38.9 14.3% 38 14.0% 
L/+ +/+ +/+ 38.9 14.3% 53 19.5% 
L/L +/- +/- 38.9 14.3% 13 4.8% 
L/L +/+ +/- 38.9 14.3% 27 9.9% 
L/L +/+ +/+ 38.9 14.3% 44 16.2% 
L/L +/- +/+ 0 0.0% 1 0.4% 
   272 100.0% 273 100.0% 
Parental genotypes: F5L/L Tfpi+/+ F3+/+ and F5L/+ Tfpi+/- F3+/-  
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Table 2-7: Candidate ENU-induced mutations 
Chr Pos R A Type 
ENU 
lines 
Gene Exon 
AA 
change 
Validation 
17 25722876 T A NS MF5L1 Chtf18 13 N541Y ENU 
7 79822260 A C NS MF5L6 Anpep 20 D955E ENU 
7 101990583 A T SG MF5L6 Numa1 4 K47X ENU 
1 33746762 T G NS MF5L8 Bag2 3 I160L ENU 
1 36163249 T C NS MF5L8 Uggt1 29 Y1089C ENU 
1 40125203 A G NS MF5L8 Il1r2 9 N410S ENU 
9 123712602 T G NS MF5L8 Lztfl1 3 I51L ENU 
10 128290865 C T SG MF5L8 Stat2 23 Q820X ENU 
14 8169757 A G NS MF5L8 Pdhb 7 S218P ENU 
15 89456795 G T SG MF5L8 Mapk8ip2 3 G148X ENU 
17 12271353 T A NS MF5L8 Map3k4 3 N397I ENU 
17 45416968 T A SG MF5L8 Cdc5l 7 K294X ENU 
19 39563826 C T NS MF5L8 Cyp2c39 7 A321V ENU 
19 46065668 C G NS MF5L8 Pprc1 6 I1150M ENU 
7 82868974 G A NS MF5L9 Mex3b 2 G166R ENU 
9 21634876 T C NS MF5L9 Smarca4 3 S117P ENU 
10 67538372 T C NS MF5L9 Egr2 1 M51T ENU 
19 56810315 G T SG MF5L9 
A630007B0
6Rik 
2 S247X ENU 
4 141581029 A G NS MF5L11 Fblim1 8 I323T ENU 
5 123760656 T A SG MF5L11 Kntc1 8 C204X ENU 
5 136373331 T C NS MF5L11 Cux1 5 K144E ENU 
9 123963447 G T NS MF5L11 Ccr1 2 H349N ENU 
10 84958016 A G NS MF5L11 Ric8b 4 S248G ENU 
11 57221033 A T NS MF5L11 Gria1 7 T224S ENU 
11 101740781 T G NS MF5L11 Dhx8 8 V400G ENU 
13 112368238 G A SG MF5L11 Ankrd55 9 W506X ENU 
14 32966414 A G NS MF5L11 Wdfy4 56 W2921R ENU 
16 92605854 T C NS MF5L11 Runx1 8 Y400C ENU 
5 86719746 T A NS MF5L12 Tmprss11e 5 D155V ENU 
6 129517379 A G NS MF5L12 Tmem52b 5 E182G ENU 
6 148237808 G A NS MF5L12 Tmtc1 20 R939W ENU 
7 141620530 G A NS MF5L12 Ap2a2 12 G504E ENU 
11 20077297 G C NS MF5L12 Actr2 7 R258G ENU 
11 67921730 C T NS MF5L12 Usp43 1 G107S ENU 
6 36523684 A G NS MF5L16 Chrm2 3 I159V ENU 
8 70259804 G A NS MF5L16 Sugp2 9 R1023Q ENU 
10 77260815 T C NS MF5L16 Pofut2 2 F125L ENU 
10 114800967 T C NS MF5L16 Trhde 1 S112G ENU 
13 61568333 A T NS MF5L16 Cts3 3 H71Q ENU 
13 90898831 G A NS MF5L16 Atp6ap1l 4 P76S ENU 
13 94443934 G A NS MF5L16 Ap3b1 9 A321T ENU 
15 6786636 C T SG MF5L16 Rictor 31 R1130X ENU 
2 70509665 G C NS MF5L1 Erich2 2 C158S chr2 
7 14225894 T C NS MF5L1 Sult2a6 5 Q238R NA 
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7 15940142 T C NS MF5L1 Gltscr2 6 H254R NA 
7 85754889 A T NS MF5L1 Vmn2r72 1 D31E NA 
8 108949251 A G NS MF5L1 Zfhx3 9 Q2311R NA 
12 110977486 G A NS MF5L1 Ankrd9 3 T5I seq error 
3 99352190 A G NS MF5L5 Tbx15 8 N459S NA 
3 135228816 T A NS MF5L5 Cenpe 13 D381E NA 
6 35080128 G A NS MF5L5 Cnot4 2 R3C NA 
8 70913530 A T NS MF5L5 Map1s 5 I360F NA 
17 70657633 T G SP MF5L5 Dlgap1 4 
c.1368+2
T 
NA 
1 82741945 C A NS MF5L6 Mff 6 Q190K de novo 
2 67516594 A G NS MF5L6 Xirp2 7 R3060G chr2 
2 76724952 G A NS MF5L6 Ttn 167 R22243C chr2 
2 76939280 T A NS MF5L6 Ttn 34 N2675I chr2 
2 88423385 A T NS MF5L6 Olfr1181 1 F213L chr2 
2 111537791 A T NS MF5L6 Olfr1294 1 L166Q chr2 
2 140120707 T C NS MF5L6 Esf1 14 K815E chr2 
5 108650355 C T NS MF5L6 Dgkq 18 R679H not ENU 
2 76549471 A C NS MF5L8 Osbpl6 7 D135A chr2 
2 112407616 G A NS MF5L8 Katnbl1 5 V152I chr2 
2 112630022 A G NS MF5L8 Aven 4 T162A chr2 
2 153136757 G A NS MF5L8 Hck 9 V276M chr2 
2 153225070 T A NS MF5L8 Tspyl3 1 T83S chr2 
11 52145503 T C NS MF5L8 Olfr1373 1 E9G not ENU 
11 69129597 A G NS MF5L8 Aloxe3 4 M156V not ENU 
16 59554543 C T NS MF5L8 Crybg3 1 R402H not ENU 
2 101696795 C T NS MF5L9 Traf6 8 R297C chr2 
18 71327504 C T NS MF5L9 Dcc 24 D1172N de novo 
2 30086662 A G NS MF5L11 Pkn3 15 K572E chr2 
2 40874986 G T NS MF5L11 Lrp1b 55 Q2943K chr2 
2 61804747 T C NS MF5L11 Tbr1 1 S14P chr2 
2 144572561 G A NS MF5L11 Sec23b 10 G398R chr2 
13 100285719 C T NS MF5L12 Naip7 14 A1269T seq error 
10 117278121 T C SL MF5L16 Lyz2 4 X149W NA 
11 60710357 G A NS MF5L16 Llgl1 16 R707H not ENU 
13 34896062 T A SG MF5L16 Prpf4b 11 L803X Not ENU 
Chr=chromosome; Pos=nucleotide position; R=reference allele; A=alternate allele; 
NS=nonsynonymous; SP=splicing; SG=stopgain; SL=stoploss; AA change= amino acid 
change; 
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Table 2-8: Overview of the WES data 
 WHOLE GENOME AGILENT CAPTURE REGION 
ENU 
Lines  
# Reads 
Mapped 
% 
# Reads 
Mapped 
% 
Mean 
coverage 
% bp 
covered 
at ≥6X 
Mapping 
quality 
(max 60) 
MF5L1 97388058 91.06% 43177469 44.34% 73.88 >97% 34.42 
MF5L5 110246719 93.07% 52837528 47.93% 89.9 >97% 34.36 
MF5L6 133205717 86.03% 56688221 42.56% 93.93 >97% 33.89 
MF5L8 128521513 96.48% 61950221 48.20% 105.88 >98% 34.69 
MF5L9 109882856 94.18% 55469742 50.48% 95.56 >97% 34.67 
MF5L11 110448223 96.38% 54907249 49.71% 93.22 >97% 35.08 
MF5L12 105612822 94.27% 50684794 47.99% 87.28 >97% 34.68 
MF5L16 115987369 90.33% 63608463 49.54% 110.83 >98% 34.26 
Average 113911660 92.73% 54915461 47.59% 93.81 >97% 34.51 
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Notes 
 
This chapter is in preparation for submission to the journal PNAS under the title “A 
sensitized mutagenesis screen in Factor V Leiden mice identifies novel thrombosis 
suppressor loci” by Randal J. Westrick*, Kärt Tomberg*, Guojing Zhu, Amy E. Siebert, 
Mary E. Winn, Sarah L. Dobies, Sara L. Manning, Marisa A. Brake, Audrey Cleuren, 
David R. Siemieniak, Jishu Xu, Jun Z. Li, and David Ginsburg. (* contributed equally) 
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 CHAPTER III: Spontaneous 8bp deletion in Nbeal2 recapitulates the gray platelet 
syndrome in mice
 
Abstract 
 
During the analysis of a whole genome ENU mutagenesis screen for thrombosis 
modifiers, a spontaneous 8 base pair (bp) deletion causing a frameshift in exon 27 of 
the Nbeal2 gene was identified. Though initially considered as a plausible thrombosis 
modifier, this Nbeal2 mutation failed to suppress the synthetic lethal thrombosis on 
which the original ENU screen was based. Mutations in NBEAL2 cause Gray Platelet 
Syndrome (GPS), an autosomal recessive bleeding disorder characterized by macro-
thrombocytopenia and gray-appearing platelets due to lack of platelet alpha granules. 
Mice homozygous for the Nbeal2 8 bp deletion (Nbeal2gps/gps) exhibit a phenotype simi-
lar to human GPS, with significantly reduced platelet counts compared to littermate con-
trols (p=1.63 x 10-7). Nbeal2gps/gps mice also have markedly reduced numbers of platelet 
alpha granules and an increased level of emperipolesis, consistent with previously 
characterized mice carrying targeted Nbeal2 null alleles. These findings confirm previ-
ous reports, provide an additional mouse model for GPS, and highlight the potentially 
confounding effect of background spontaneous mutation events in well-characterized 
mouse strains. 
 
Introduction 
 
The laboratory mouse has been used extensively as a model organism, with 
multiple inbred mouse strains routinely available from a number of suppliers. These 
inbred strains have been extensively characterized and the genome of more than 20 
have been sequenced [143, 144]. Whole genome sequencing in humans has 
demonstrated that in addition to approximately 75 de novo single nucleotide variants 
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(SNVs) [145], each human genome carries on average 6-12 new insertions and 
deletions or 'INDELs' (1-50 bp) and occasional copy number and complex structural 
variants [52, 146]. Mice have been shown to exhibit comparable mutation rates [56] and 
therefore elaborate breeding schemes are necessary in large mouse facilities to 
maintain genetically stable mouse strains [147]. However, identification of the 
occasional de novo deleterious variants in mice has resulted in useful models for 
phenotypic studies [57-60]. Forward genetic screens can be performed taking 
advantage of such spontaneous mutations, but given the low de novo mutation rate, N-
ethyl-N-nitrosourea (ENU) is typically applied to markedly increase the density of 
random mutations [63, 74]. ENU induces on average 1 mutation per every 700,000 bp, 
which results in >50 fold increase compared to spontaneous mutation rates seen in 
mice [93, 125]. 
NBEAL2 encodes neurobeachin-like-2, a BEACH domain containing protein, with 
a proposed role in vesicular trafficking and granule development [148]. Mutations in 
NBEAL2 were recently shown to be the cause of the autosomal recessive form of Gray 
Platelet Syndrome (GPS) [149-151]. GPS is a rare bleeding disorder characterized by 
macrothrombocytopenia and gray-appearing platelets due to lack of platelet alpha 
granules [152]. Mice with targeted deletion of Nbeal2 [153-155] exhibit 
thrombocytopenia, deficiency in platelet alpha granules, a higher than normal mean 
platelet volume, splenomegaly, impaired platelet aggregation and adhesion, and a mild 
bleeding tendency, all consistent with the human phenotype [152, 156]. 
During the analysis of a whole genome ENU mutagenesis screen for thrombosis 
modifiers, we identified a spontaneous 8 bp deletion causing a frameshift in exon 27 of 
the Nbeal2 gene. Analysis of the associated mouse pedigree demonstrated that this 
mutation arose within the Jackson Laboratory 129S1/SvImJ mouse colony and not from 
the ENU screen. 
 
Materials and methods 
 
Animal procedures 
Animal husbandry in this study was carried out according to the Principles of 
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Laboratory and Animal Care established by the National Society for Medical Research. 
The University of Michigan’s University Committee on Use and Care of Animals 
(UCUCA) has approved the protocol number 05191 and the University of Colorado 
Institutional Animal Care and Use Committee approved the protocol 96114. The care 
and maintenance of animals was closely supervised by University of Michigan ULAM 
personnel or University of Colorado Institutional Animal Care and Use Committee 
(IACUC) and animals were housed in their facilities. ULAM/IACUC also provided expert 
veterinary advice and assistance when necessary and cages were monitored closely by 
our laboratory personnel as well as university veterinary staff. To minimize discomfort 
and unnecessary suffering of experimental mice, analgesics were administered for all 
procedures involving significant discomfort. Blood samples were obtained from the 
retro-orbital plexus of anesthetized animals achieved with isoflurane inhalation. Mice 
were euthanized for collection of tissues for histologic, biochemical, and genetic 
analysis. The UCUCA Endstage Illness and Humane Endpoint Guidelines were also 
closely followed and animals euthanized accordingly by carbon dioxide overdose or 
exsanguination under anesthesia.  
F5L/L (F5tm2Dgi/J, Jackson Laboratory stock number 004080) mice were previously 
generated [46], Tfpi deficient mice (Tfpitm1Gjb) were a generous gift of Dr. George Broze 
[92], and Nbeal2tm1Lex/tm1Lex mice with targeted deletion of the Nbeal2 gene were 
previously generated from cryopreserved spermatozoa obtained from the Mutant Mouse 
Regional Resource Center at the University of California, Davis [154]. Nbeal2 allele 
carrying the spontaneous 8bp deletion described in Results will be referred throughout 
the text as Nbeal2gps. Two cohorts of Nbeal2gps mice were analyzed. Set 1 refers to 
Nbeal2gps mice intercrossed after 2 backcrosses to C57BL/6J mice (stock number 
000664), while set 2 mice were intercrossed after 7 backcrosses to C57BL/6J. 
 
Whole exome sequencing of thrombosis suppressor line 
Genomic DNA (gDNA) was extracted from mouse tail biopsies using the Gentra 
Puregene Tissue Kit (Qiagen) according to manufacturer’s instructions. Exonic DNA 
was captured with either SureSelect Mouse All Exon (Agilent) or SeqCap EZ Mouse 
Exome Design (NimbleGen) kits and 100 bp paired-end sequencing was performed on 
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the Illumina HiSeq 2000 platform at the University of Michigan's DNA Sequencing Core. 
All generated fastq files have been deposited to the NCBI Sequence Read Archive 
(Project accession number #SRP063933). Detailed overview of the variant calling 
pipeline and filtration is available online as a GitHub repository [157]. In short, reads 
were aligned with the Burrows-Wheeler Aligner [131] to the Mus Musculus GRCm38 
reference genome, duplicates were removed using Picard [158], and variants across all 
samples were simultaneously called and filtered with GATK [133]. Variants were 
annotated using Annovar software [134] with Refseq annotation. Variants between 
C57BL/6J and 129S1/SvImJ, as well as unannotated variants within our mouse cohort 
present in more than one independent line, were removed from the ENU candidate list. 
All unique heterozygous variants present in multiple mice within the suppressor line 
MF5L6 (Chapter II) with a minimum of 6X coverage were considered as potential 
candidates and further validated using Sanger sequencing. 
 
129S1/SvImJ de novo mutation analysis 
Exome analysis was performed for the parents (F63pF64) and a female sibling 
(F63pF65) of the 129S1/SvImJ individual sequenced for the Sanger Mouse Genomes 
Sequencing project [143]. Exome sequencing and variant calling was performed as 
previously described [159]. Approximately 95% of all variants (SNV and INDELs) in 
each of the 3 samples were also found in dbSNP, and an additional ~5600 variants that 
were common between the three exomes were also found in whole genome variant 
data from the Sanger Mouse Genomes project. There were 92 variants unique to the 
129S1/SvImJ female sibling sample, in that they were not found in variant calls from 
either parental exome. Out of the 92 “unique” called variants, manual analysis of the 
alignment files in all samples and Sanger sequencing of PCR products revealed that 91 
were true variants with false negative calls in one of the parent samples and one variant 
was a false positive call. 
 
Genotyping Nbeal2gps allele 
The Nbeal2gps allele was detected using two three-primer PCR assays (Figure 3-
1) with common forward (5'AAGGCAGGAAGACGTCAGAA, primer F) and reverse 
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(5'GACCTCAGTGTCCGCCTAGA, primer R) primers. In the first PCR based genotyping 
design, the third primer (5'AC|GTCTGGCT|GTCCGTAGAT, primer WT) is located over 
the undeleted 8 bp to detect the presence of the wildtype allele. This PCR reaction 
results in two products (413 bp, 235 bp). In the second PCR design the third primer 
(5'AACGAC|GTCCGTAGATGAGG, primer DEL) spans the 8 bp deletion to detect the 
presence of the deletion allele. This reaction also produces two products (405 bp, 227 
bp). PCR was performed using GoTaq Green Master Mix (Promega) and the products 
visualized on a 2% agarose gel. Selected genotyping results were further confirmed by 
Sanger sequencing. 
 
Estimation of differential allelic expression 
Liver, lung, and bone marrow tissue samples were collected in RNAlater 
(Ambion) from a Nbeal2gps/+ mouse. Total RNA was extracted using an RNeasy Mini Kit 
(Qiagen) and converted to coding DNA (cDNA) using SuperScript III One-Step RT-PCR 
(Invitrogen) following the manufacturer’s instructions. gDNA was prepared from a tail 
biopsy. Forward and reverse genotyping primers (primer F and primer R) were used to 
amplify the Nbeal2 deletion region from gDNA and the cDNAs from liver and lung. PCR 
products were extracted from agarose gels using a QIAquick Gel Purification Kit 
(Qiagen) and submitted for Sanger sequencing. The differential allelic expression was 
estimated from the ratio between the wildtype and Nbeal2gps sequence peak areas in 
cDNA samples compared to gDNA using Phred software [160]. This ratio was calculated 
for multiple positions within the PCR product where the wildtype and Nbeal2gps alleles 
contain a different nucleotide. 
 
Western blot 
Murine whole blood was collected via the inferior vena cava into 
acid/citrate/dextrose. Platelet-rich plasma (PRP) was obtained by centrifugation at 200 g 
for 5 min. Washed platelets were pelleted from PRP by centrifugation at 1,000 g for 2 
min in the presence of prostacyclin PGI1 (0.1 μM) and resuspended in modified 
Tyrode’s buffer (137 mM NaCl, 0.3 mM Na2HPO4, 2 mM KCl, 12 mM NaHCO3, 5 mM 
HEPES, 5 mM glucose) [161]. Total protein was harvested from washed platelets using 
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cell lysis buffer containing 1% Triton X-100 and protease inhibitors (mini complete 
tablets, Roche). Protein concentration was measured with Protein Dye Reagent 
(BioRad), and 30 μg of total protein was separated in duplicate lanes of a 4-15% Mini-
Protean TGX gel (BioRad). Protein was transferred to nitrocellulose and probed with a 
rabbit monoclonal antibody against NBEAL2 (ab187162, Abcam) or a rabbit polyclonal 
antibody against beta actin (ab8227, Abcam), followed by an HRP-linked goat anti-
rabbit secondary antibody (Pierce). Detection was performed with ECL Lightning Plus 
(Perkin Elmer). 
 
Complete blood counts 
Twenty-five microliters of blood were collected from the retro-orbital sinus of 5-6 
week old mice from set 1. Blood was anticoagulated with 4% sodium citrate (Sigma-
Aldrich) and diluted 10x in PBS (phosphate-buffered saline, Gibco) supplemented with 
5% bovine serum albumin (Sigma-Aldrich). Complete blood counts (CBC) were 
performed on the ADVIA 2120 Hematology System (Siemens) according to 
manufacturer’s instructions while being blinded to the genotype of the mouse from 
which the sample was obtained. Additional blood was collected from >20 week old 
females from set 2 using heparinized capillary tubes and anticoagulated using EDTA 
containing tubes (BD microtainer). CBC were performed on the Hemavet 950FS 
system. All data were analyzed and visualized using the ‘stats’ and ‘beeswarm’ 
packages in R software [162]. 
 
Flow cytometry 
Absolute neutrophil counts (ANC) were measured by flow cytometry as 
previously described [163]. Briefly, 50 μl of anticoagulated whole blood was added to 
Trucount tubes (BD Biosciences) and processed according to the manufacturer’s 
protocol. Samples were incubated at room temperature in the dark for 15 minutes with 
rat anti-mouse FITC-conjugated Ly-6G clone 1A8 (Molecular Probes) and rat anti-
mouse CD45 PE/Cy7 antibodies. This incubation was followed by the addition of 450 μl 
of red blood cell lysis buffer (eBioscience). Samples were incubated for 30 minutes in 
the dark at room temperature prior to data acquision using a Gallios 561 flow cytometer 
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(Beckman Coulter). Data were acquired at medium flow rate for 2 minutes. The 
neutrophil population was defined as CD45/Ly-6G positive events. The bead population 
was clearly visualized as different from the neutrophil population. The ANC was 
calculated according to the formula provided by the manufacturer: ANC (cells/ μl)= 
(CD45 and Ly-6G positive events/ Trucount beads)x(# beads per test/test volume). 
 
Peripheral blood and bone marrow analysis 
Peripheral blood smears were prepared from 9 mice of each genotype and 
Wright-Giemsa stained using the HealthCare PROTOCOL Hema 3 kit according to the 
manufacturer’s instructions (Fisher Scientific). For each sample, the intensity of platelet 
staining and platelet granularity were categorized into three levels (light, intermediate or 
dark) by one of the authors (RK) blinded to the genotype of the mouse from which the 
sample was obtained. Representative images from the blood smears were taken using 
a Leica DMLB microscope at 1000x magnification. Bone marrow sections as well as 
bone marrow cytology slides were prepared by the Unit for Laboratory Animal Medicine 
histology core. Histopathologic evaluation was performed by an investigator blinded to 
the genotypes of the evaluated mice. 
 
Transmission electron microscopy 
Blood from one Nbeal2+/+ and one Nbeal2gps/gps mouse from set 1 was collected 
by retro-orbital puncture and fixed in 4% glutaraldehyde as previously described [164]. 
Fixed samples were further prepared by the University of Michigan's Microscopy and 
Image Analysis Core for platelet transmission electron microscopy. Platelet sections 
were examined on a JEOL JEM-1400Plus transmission electron microscope at two 
different magnifications (5000x, 40000x). Platelet area was measured from images at 
5000x magnification using ImageJ software [165] for 100 platelets from 5 different fields 
for each genotype. The latter analysis was performed with the observer blinded to the 
genotypes of the platelets. 
 
Statistical analysis 
A non-parametric Wilcoxon test was used to estimate significance in the CBC 
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measured values, platelet area, the assigned platelet staining intensity values of the 
Wright-Giemsa stained blood smears, and the difference in the level of emperipolesis in 
bone marrow slides between Nbeal2gps/gps and wildtype mice. A chi-square test was 
applied to estimate deviations from expected Mendelian proportions in Nbeal2 mouse 
crosses. All statistical analyses were performed using the ‘stats’ package in R software 
[162]. 
 
Results 
 
De novo frameshift mutation in Nbeal2 identified by whole exome sequencing 
We performed a sensitized dominant ENU screen designed to identify suppressor 
mutations for a synthetic lethal thrombosis phenotype (F5L/L Tfpi+/-) [47] in C57BL/6J 
mice (Chapter II). In order to map the ENU induced mutations, outcrosses were 
performed between the mutagenized mice and F5L/L mice [46] bred >12 generations to 
the 129S1/SvImJ genetic background. Within a suppressor line, all ENU induced 
mutations should segregate randomly to the next generation except the suppressor 
mutation, which is expected to be present in all F5L/L Tfpi+/- mice. Whole exome 
sequencing was applied to 4 mice from one of the suppressor lines (MF5L6; Figure 3-2) 
and variants shared between the 4 mice were investigated as candidate suppressor 
mutations. A total of 215 unique exonic heterozygous SNVs and 8 heterozygous 
INDELs were identified in the 4 exomes from a total of 76,950 initially called variants. 
Twelve of the SNVs and one of the INDELs were present in more than one sequenced 
mouse (Table 3-1), while no variant was present in all 4 mice with the exception of 
variants closely linked to the Tfpi- locus. The only shared INDEL (between G6-ENU and 
G9-ENU; Figure 3-3A) was an 8 bp deletion (AGCCAGAC) in the 27th exon of Nbeal2, 
confirmed by Sanger sequencing (Figure 3-3B). This allele will be denoted Nbeal2gps. 
Genotyping additional members of the pedigree demonstrated absence of this deletion 
allele in generation 5 (G5) ENU mutagenized progeny exhibiting the suppressor 
phenotype (Figure 3-3A). Instead, the G6-ENU mouse inherited the deletion from its 
non-ENU parent and would have been missed in our mouse cohort if it had not been 
coincidentally shared by the whole exome sequenced G9-ENU mouse. Absence of the 
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Nbeal2gps allele in the first five generations of ENU pedigree excludes Nbeal2gps as the 
original suppressor mutation. Additionally, Nbeal2gps failed to segregate with the 
suppressor phenotype in later generations (Figure 3-2). Further genotyping identified a 
cohort of 129S1/SvImJ mice purchased from the Jackson Laboratory as the likely 
source of the deletion variant (Figure 3-4A). 
 
The Nbeal2gps allele is not segregating in 129S1/SvImJ stock 
To minimize cumulative genetic drift, the 129S1/SvImJ colony at the Jackson 
Laboratory is maintained under a Genetic Stability Program (GSP) [147]. In this 
scheme, foundation breeding colonies are maintained with cryopreserved embryos that 
are descendants of a single, founder breeder pair. To trace the origin of the Nbeal2gps 
allele, six archived samples from the 129S1/SvImJ (# 002448) colony at the Jackson 
Laboratory were genotyped, including the 129S1/SvImJ founder pair, “Adam and Eve” 
(F60) as well as archived samples from before (F56, F59) and after (F61, F63) 
implementation of the GSP program. The Nbeal2 deletion was not found in any of these 
samples (Figure 3-4B). Exome sequencing data from two additional 129S1/SvImJ 
samples (F63pF67) [159], whole genome sequencing data from the Sanger Mouse 
Genomes Project, F63pF65 [143], and exome sequencing data from a female sibling, 
as well as the dam and sire (F63pF64) of the 129S1/SvImJ individual sequenced by the 
Sanger Mouse Genomes project identified only wildtype Nbeal2 (Figure 3-4C). Mice 
with the Nbeal2gps allele were purchased after the implementation of GSP. Since neither 
Adam nor Eve were carriers, the deletion must have arisen later in the colony but is no 
longer segregating in the 129S1/SvImJ stock at the Jackson Laboratory. 
 
An 8 bp deletion results in a frameshift mutation in Nbeal2 
The identified 8bp deletion in Nbeal2 is expected to cause a frameshift that 
introduces an early stop codon 28 amino acids downstream of the deletion site (Figure 
3-3D). The expression level of Nbeal2gps mRNA from bone marrow, liver, and lung 
tissues was assessed by RT-PCR and Sanger sequencing. Although Nbeal2gps mRNA 
could be detected by RT-PCR, the level was ~64% lower in bone marrow, ~73% lower 
in liver, and ~59% lower in lung compared to the wildtype allele (Figure 3-5). These 
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results are consistent with nonsense-mediated decay [166]. In addition, no band was 
detected at the expected size (~305kDa) by western blot analysis of washed platelets 
obtained from Nbeal2gps/gps mice (Figure 3-3C) and no truncated protein was observed 
with an N-terminal antibody (Figure 3-6). 
 
Nbeal2gps/gps mice are viable and fertile 
A mouse carrying the Nbeal2 deletion allele (Figure 3-2) was outbred from the 
ENU suppressor line for two generations to remove the F5L and Tfpi mutant alleles, as 
well as the majority of residual, unlinked ENU induced variants. Mice carrying one 
(Nbeal2gps/+) or two deletion alleles (Nbeal2gps/gps) were viable, fertile and had no 
apparent phenotype by visual inspection. No significant deviation from the expected 
Mendelian distribution was observed in the progeny when crossing the Nbeal2gps/+ mice 
to C57BL/6J wildtype mice or in the progeny from the Nbeal2gps/+ intercross (Table 3-2). 
 
Nbeal2gps/gps mice exhibit thrombocytopenia and neutropenia 
Complete blood counts (CBC) were performed on 24 Nbeal2gps/+, 26 Nbeal2gps/gps 
mice, and 14 wildtype littermate controls from set 1. No significant differences were 
observed between Nbeal2gps/+ and Nbeal2+/+ mice in any of the measured parameters 
(Table 3-3) and those genotypes were subsequently grouped together as controls for 
comparison to Nbeal2gps/gps mice. Platelet counts of Nbeal2gps/gps mice were significantly 
reduced compared to control mice (623 vs 968 x 103 cells/μl, p=1.63 x 10-7) as was the 
absolute neutrophil count (0.27 vs 0.77 x 103 cells/μl, p=2.44 x 10-9) (Figure 3-7; Table 
3-3). All other CBC parameters, including mean platelet volume, were indistinguishable 
between Nbeal2gps/gps and control mice (Table 3-3). In addition, no difference was 
observed in mean platelet area quantitated in electron microscopy images. However, in 
CBCs obtained from a second cohort of 6 Nbeal2gps/+ and 8 Nbeal2gps/gps females, both 
neutrophil counts (p=0.0047) and mean platelet volume (p=0.016) were higher in the 
Nbeal2gps/gps mice compared to littermate controls (Figure 3-7). Additional analysis of 
neutrophil counts for the set 2 mice by flow cytometry showed no significant differences. 
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Nbeal2gps/gps platelets are deficient in alpha granules 
The intensity of platelet staining with Wright-Giemsa dye was indistinguishable 
between Nbeal2gps/+ and wildtype mice (p-value=0.298), but significantly reduced in 
Nbeal2gps/gps mice (p-value=1.9x10-4; Figure 3-8A; Table 3-4) consistent with a reduction 
in platelet alpha granules [152, 156]. Transmission electron microscopy also displayed a 
marked reduction of alpha granules in Nbeal2gps/gps mouse compared to wildtype control 
(Figure 3-8B), consistent with the human GPS phenotype [152, 156]. 
 
Emperipolesis of neutrophils in bone marrow and spleen of Nbeal2gps/gps mice 
Nbeal2gps/gps mice exhibit higher levels of megakaryocytic emperipolesis (the 
presence of an intact cell within the cytoplasm of another cell) in the bone marrow 
compared to wildtype mice, consistent with previously reported human and mouse GPS 
phenotypes [152, 153, 167-169]. Though emperipolesis is occasionally observed in 
megakaryocytes of wildtype mice (~11%), approximately half of the bone marrow 
megakaryocytes in Nbeal2gps/gps mice exhibited some degree of emperipolesis (p=1.9 x 
10-8; Figure 3-9A,B; Table 3-4). Megakaryocytes containing more than one neutrophil 
were observed exclusively in the bone marrow of Nbeal2gps/gps mice. Similarly, increased 
emperipolesis was observed in spleens of Nbeal2gps/gps mice (Figure 3-9C,D). 
Nbeal2gps/gps bone marrows demonstrated no defect in myeloid maturation though there 
appeared to be a mild increase in myeloid and megakaryocytic extramedullary 
hematopoiesis. 
 
Discussion 
 
We report the identification and characterization of a spontaneous Nbeal2 
mutation in 129S1/SvImJ. Homozygosity for this 8 bp frameshift results in loss of 
NBEAL2 expression and phenotypic features characteristic of GPS in humans [152, 
156]. These findings are also consistent with three other previous reports of Nbeal2 
deficient mice generated by gene targeting [153-155]. 
Though an initial cohort of Nbeal2gps/gps mice (set 1) demonstrated differences in 
neutrophil counts and mean platelet volumes (Table 3-3) compared to previously 
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reported mouse and human phenotypes, these features were not confirmed in the 
second cohort (mice backcrossed 5 additional generations into C57BL/6J). These data 
suggest that the differences observed in set 1 mice are due to either strain background 
effects [97] or loosely linked passenger mutations [170] that were removed by 
consecutive backcrossing. Additional confounding factors could include the difference in 
age between the two mouse cohorts. Comparison of the absolute neutrophil count 
(ANC) from the Hemavet analyzer to the ANC obtained by flow cytometry demonstrates 
consistent overestimates on the Hemavet. This discrepancy could be secondary to 
limitations of the Hemavet system in discerning between neutrophils and monocytes. 
Similar results have been previously reported [171]. The quantification of ANC by flow 
cytometry should identify the population corresponding exclusively to neutrophils. In 
addition, the use of Trucount counting tubes has been well validated and offers an 
internal control with respect to sample preparation. The estimated coefficient of variation 
for our flow cytometry ANC assay using the Trucount beads is 3.48%. Thus, we 
consider the results obtained by FACS to more accurately represent the ANC. 
Our data establish that the Nbeal2gps allele is a spontaneous mutation that arose 
in the 129S1/SvImJ stock at the Jackson Laboratory in 2007 at F63. Though, we were 
unable to confirm the presence of the mutation in archival samples, this is likely due to 
the small number of archived samples available. Published rates of spontaneous 
mutations in mice range from 10-5 to 10-6 per locus per gamete on the basis of specific 
locus testing with visible phenotypes [172]. More recently, whole genome sequencing 
and pedigree analyses have estimated a mutation rate of 5.4 x 10-9 per base/ per 
generation in wildtype laboratory mice [125], which is roughly 28 mutations, genome 
wide per generation / diploid genome. New mutations have a 25% chance of becoming 
fixed in an inbred population, assuming random segregation in the absence of selection 
[147]. We performed exome sequencing on a single 129S1/SvImJ trio (F63pF64 and 
F63pF65) and did not find a de novo, coding SNV or small INDEL (see Materials and 
Methods). This is consistent with previously published mutation rates (given a ~50 Mb 
exome, at 10X minimum coverage where the likelihood of detecting a germ line de 
novo, exonic mutation is ~5% in any individual). 
The Nbeal2gps allele was identified via whole exome sequencing of the progeny 
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of an ENU treated mouse. While next generation sequencing approaches have high 
utility for mapping both spontaneous [49] as well as chemically induced de novo 
variants [71], the origin of a single nucleotide variant cannot be established from 
sequencing data alone. While ENU-induced mutations are certainly the most common in 
an ENU colony, spontaneous mutations are also present at predictable frequencies and 
unlike ENU mutations, spontaneous mutations are not limited to SNVs and can include 
structural alterations (copy number variants and rearrangements). Therefore, while 
infrequent, it is not surprising that spontaneous mutations with relevant phenotypes 
have been recovered in ENU screens [173]. 
Ultimately, the origin of causative mutations (ENU or spontaneous) can be 
established through additional genotyping of the ENU pedigree, assuming breeding 
records and samples have been carefully maintained and archived. Generally, strong 
dominant phenotypes due to de novo variants are easily detected in mouse colonies; 
however, mild dominant phenotypes or recessive phenotypes may go unnoticed 
depending on the breeding paradigm. For these reasons, it is important to adhere to 
published guidelines on mouse colony management and genetic quality control 
monitoring [174]. In the case of the Nbeal2gps allele, the platelet defect had no impact on 
survival of F5L/L Tfpi+/- mice and we were able to identify the variant only due to next 
generation sequencing.  
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Figure 3-1. Schematic overview of the Nbeal2 genotyping primers 
Common forward (primer F) and reverse (primer R) primers are used in two three-
primer PCR assays. In the first PCR based genotyping design, the third primer (primer 
WT) is located over the undeleted 8 bp to detect the presence of the wildtype allele. 
This PCR reaction results in two products (413 bp, 235 bp). In the second PCR design 
the third primer (primer DEL) spans the 8 bp deletion (depicted in red) to detect the 
presence of the deletion allele. This reaction also produces two products (405 bp, 227 
bp). 
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Figure 3-2: Pedigree of the MF5L6 suppressor line 
Only progeny mice with the F5L/L Tfpi+/- genotype and 
unaffected parents are shown in the pedigree. Black 
boxes highlight the mice subjected to whole exome 
sequencing. The red box highlights mouse 67339 that 
was used for Nbeal2gps allele outcrossing and line 
establishment. 
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Figure 3-3: De novo 8 bp deletion in the Nbeal2 gene 
The whole exome sequenced G6-ENU mouse inherited the Nbeal2 deletion from a non-
ENU parent 31925 (A). Sanger sequencing validates the heterozygous frameshift 
mutation in the suppressor pedigree (B). Western blot analysis of washed mouse 
platelets show a band at the expected size for NBEAL2 (~305kDa) in wildtype mice. 
This band is missing in Nbeal2tm1Lex/tm1Lex mice as well as mice homozygous for the 
Nbeal2gps allele (C). Schematic overview of the Nbeal2 gene, the location of the deletion 
and the expected frameshift (D). 
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Figure 3-4: Genotyping of 129S1/SvImJ archived samples from the Jackson 
Laboratory 
Two different mice (A91, A92) purchased from the Jackson Laboratory (JAX) had 
Nbeal2gps/+ progeny (red). One of these progeny (asterisk) was the sire of the female 
used to build the ENU suppressor line (A). All genotyped 129S1/SvImJ (# 002448) mice 
were wildtype at the Nbeal2 locus, including the “Adam and Eve” founders of the 
Jackson Laboratory GSP 129S1/SvImJ stock (F60) [147] and two subsequent 
generations of cryopreserved embryo stock (F61, F63) (B). The Nbeal2 deletion was 
also absent in two post-GSP 129S1/SvImJ animals: whole exome sequencing data 
(F63pF67) from the Mouse Mutant Resource [159] and whole genome sequencing data 
(F63pF65) from the Sanger Mouse Genomes Project (C) [143].   
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Figure 3-5: Differential allelic expression of Nbeal2 mRNA in Nbeal2gps/+ bone 
marrow, lung, and liver 
Allelic expression was measured at every position in the Sanger sequenced RT-PCR 
product where the reference and deletion alleles had a different nucleotide. Dotted lines 
fill the gaps. In all tested tissues, the relative expression of Nbeal2gps allele is lower than 
wildtype, set as 100% (A). Boxplot of all data points show on average ~65% reduction in 
expression of the deletion allele (B). 
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Figure 3-6: Western blot analysis for NBEAL2 and beta Actin 
Here we show full blots for the Western blot analysis. Areas surrounded by black boxes 
were displayed in Figure 3-3C. 
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Figure 3-7: Comparison of CBCs 
Platelet counts are lower in Nbeal2gps/gps mice compared to control mice in both set 1 (A) 
and set 2 (B) mice while hemoglobin levels are similar between the two groups (C). 
Nbeal2gps/gps mice from set 1 exhibit significant neutropenia (D), which is not observed in 
set 2 by CBC (E) or flow cytometry (F). Mean platelet volume (G) and area (H) do not 
differ in set 1 mice, but show an increase in size for Nbeal2gps/gps mice in set 2 (I).  
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Figure 3-8: Deficiency in platelet alpha granules 
Nbeal2gps/gps platelets appear pale compared to wildtype (black arrows, A). Transmission 
electron microscopy (TEM) images show dark alpha granules in wildtype platelets 
(black arrows), which are missing in Nbeal2gps/gps platelets. Red arrows indicate 
mitochondria (B).  
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Figure 3-9: Emperipolesis of neutrophils in bone marrow and spleen 
Increased emperipolesis of neutrophils (black arrows) in Nbeal2gps/gps mice compared to 
wildtype was observed in both histologic (A) and cytologic (B) preparations of bone 
marrow as well as spleen (C and D, respectively).  
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Table 3-1: Overview of the exonic variants called from WES in 4 mice from the 
MF5L6 pedigree 
Type All SNVs Unique SNVs In > 1 mouse 
nonsense 87 3 1 
nonsynonymous 11,854 66 6 
synonymous 21,130 27 2 
splice 90 2 0 
exonic 34,288 117 3 
Total: 67,449 215 12 
 
Type All INDELs Unique INDELs In > 1 mouse 
frameshift 344 3 1 (Nbeal2) 
nonframeshift 460 0 0 
splice 71 1 0 
exonic 8626 4 0 
Total: 9501 8 1 
WES=whole exomose sequencing; Details available at github.com/tombergk/NBEAL2 
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Table 3-2: Expected and observed number of progeny in Nbeal2gps/+ crosses 
Cross Nbeal2+/+ Nbeal2gps/+ Nbeal2gps/gps P-value* 
Nbeal2gps/+ x Nbeal2+/+ 46% (37) 54% (44) - 0.4367 
Expected 50% 50% -  
Nbeal2gps/+ x Nbeal2gps/+ 24% (23) 47% (44) 29% (27) 0.6965 
Expected 25% 50% 25%  
*A chi-square test was applied to estimate deviations from expected Mendelian 
proportions. Number of mice genotyped available in parentheses. 
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Table 3-3: CBC mean values and standard deviations by genotype in set 1 mice 
Abbr. 
Nbeal2+/+ 
mean ± sd 
Nbeal2gps/+ 
mean ± sd 
P-value 
Nbeal2+/+, gps/+ 
mean ± sd 
Nbeal2gps/gps 
mean ± sd 
P-value* 
WBC 6.80 ± 1.46 7.23 ± 2.08 0.75 7.07 ± 1.86 7.04 ± 2.34 0.56 
RBC 9.45 ± 0.85 8.96 ± 1.08 0.17 9.14 ± 1.02 8.91 ± 0.68 0.46 
HGB 13.43 ± 1.28 12.58 ± 1.74 0.12 12.89 ± 1.62 12.77 ± 1.11 0.79 
HCT 4.89 ± 0.39 4.66 ± 0.59 0.23 4.74 ± 0.53 4.68 ± 0.34 0.65 
MCV 51.88 ± 2.05 52.06 ± 1.72 0.81 51.99 ± 1.82 52.66 ± 1.63 0.13 
MCH 14.19 ± 0.48 14.16 ± 0.70 0.84 14.17 ± 0.62 14.47 ± 0.72 0.18 
MCHC 27.41 ± 0.95 27.19 ± 1.00 0.62 27.27 ± 0.97 27.48 ± 1.04 0.48 
CHCM 28.28 ± 2.02 28.20 ± 2.08 0.95 28.23 ± 2.03 27.10 ± 1.91 0.11 
CH 14.67 ± 0.88 14.68 ± 0.83 0.84 14.67 ± 0.84 14.27 ± 1.02 0.09 
RDW 15.94 ± 1.93 16.25 ± 1.85 0.40 16.13 ± 1.86 16.16 ± 1.32 0.50 
HDW 1.66 ± 0.21 1.61 ± 0.14 0.73 1.63 ± 0.17 1.52 ± 0.09 4.44x10-3 
PLT 906.4 ± 280.6 1004.6 ± 247.6 0.15 968.4 ± 260.9 622.7 ± 128.6 1.63x10-7 
MPV 6.64 ± 0.51 6.80 ± 0.40 0.36 6.74 ± 0.45 6.72 ± 0.57 0.78 
Neut 0.86 ± 0.36 0.73 ± 0.29 0.27 0.77 ± 0.32 0.27 ± 0.19 2.44x10-9 
Lymph 5.05 ± 1.17 5.57 ± 2.10 0.35 5.38 ± 1.81 5.97 ± 2.46 0.56 
WBC (White Blood Cell count), RBC (Red Blood Cell count), HGB (Hemoglobin 
concentration), HCT (Hematocrit), MCV (Mean Corpuscular Volume), MCH (Mean 
Corpuscular Hemoglobin), MCHC (Mean Corpuscular Hemoglobin Concentration), 
CHCM (Corpuscular Hemoglobin Concentration Mean), CH (Cellular Hemoglobin 
Content), RDW (Red Cell Volume Distribution Width), HDW (Hemoglobin Concentration 
Distribution Width), PLT (Platelet count), MPV (Mean Platelet Volume), Neut (Neutrophil 
cell count), Lymph (Lymphocyte cell count). * Significant p-values after Bonferroni 
correction (p-value ≤ 0.0033) for multiple testing are highlighted in bold font 
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Table 3-4: Intensity of platelet staining and frequency of emperipolesis events in 
bone marrow megakaryocytes 
Intensity of platelet staining (n=9) 
Genotypes Light (1) Medium (2) Dark (3) Average P-value 
Nbeal2+/+ 0 1 8 2.89  
Nbeal2gps/+ 0 3 6 2.67 0.298 
Nbeal2gps/gps 7 2 0 1.22 0.0001898 
 Number of emperipolesis events (n=3)* 
Genotypes 0 1 ≥2 Average P-value 
Nbeal2+/+ 81 (89%) 10 (11%) 0 0.11  
Nbeal2gps/gps 35 (51%) 19 (27%) 15 (22%) 0.71 1.898x10-8 
* 3 slides per genotype, >20 megakaryocytes per slide 
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Notes 
 
This chapter is being revised for publication in the journal PLoS ONE under the title 
“Spontaneous 8bp Deletion in Nbeal2 Recapitulates the Gray Platelet Syndrome in 
Mice” by Kärt Tomberg, Rami Khoriaty, Randal J. Westrick, Heather E. Fairfield, Laura 
G. Reinholdt, Gary L. Brodsky, Pavel Davizon-Castillo, David Ginsburg, and Jorge Di 
Paola 
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 CHAPTER IV: ENU mutagenesis and whole exome sequencing to identify throm-
bosis modifier genes
 
Abstract 
 
Only ~10% of individuals carrying the common venous thrombosis risk factor, 
Factor V Leiden (FVL) will develop venous thrombosis in their lifetime. In order to 
identify potential FVL modifier genes, we performed a sensitized dominant ENU 
mutagenesis screen, based on the perinatal synthetic lethal thrombosis previously 
observed in mice homozygous for FVL (F5L/L) and haploinsufficient for tissue factor 
pathway inhibitor (Tfpi+/-). Out of 2595 G1 (generation 1) offspring of mutagenized F5L/L 
males (G0) and unmutagenized F5L/+ Tfpi+/- females, a total of 70 viable F5L/L Tfpi+/- 
progeny (‘rescues’) were identified, with 13 producing ≥1 G2 rescues. Linkage analysis 
conducted in 3 largest pedigrees using ENU-induced coding variants as genetic 
markers failed to map the corresponding suppressor loci. However, in one of the 
pedigrees, a maternally inherited (not ENU-induced) de novo mutation (Plcb4R335Q) 
exhibited significant co-segregation with the rescue phenotype (p=0.02). Whole exome 
sequencing was next applied to DNA from 107 rescue progeny to identify candidate 
genes that are enriched for ENU mutations. A total of 3481 potentially deleterious 
candidate ENU variants were identified in 2984 genes. After adjusting for coding region 
size, the ENU-induced mutation burden was significantly greater than expected by 
chance for Arl6ip5, C6 and Itgb6 genes (false discovery rate<0.1, based on 106 
permutations) and suggestive for 9 additional genes. Simultaneous introduction of 
CRISPR-Cas9 reagents for the top 6 genes were used to produce >100 null alleles. 
Preliminary validation data shows significant increase in rescue progeny from mice 
carrying a subset of CRISPR-Cas9 induced alleles in 5 of the genes (p=6.7x10-5, 
compared to expected background survival). 
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Introduction 
 
Venous thromboembolism (VTE) affects 1:1000 individuals in the US each year 
and is highly heritable [12, 13]. The most common known genetic risk factor for VTE is a 
single nucleotide variant (SNV) in the F5 gene, referred to as Factor V Leiden (FVL, 
Arg506Gln) [26]. While the FVL variant is present in ~25% of VTE patients [31], only 
10% of individuals heterozygous for FVL develop thrombosis in their lifetime. 
To identify genetic variants potentially modifying FVL, we recently employed a 
dominant ENU screen (Chapter II) in mice sensitized for thrombosis. Mice homozygous 
for the FVL mutation (F5L/L) and haploinsufficient for tissue factor pathway inhibitor 
(Tfpi+/-) die of perinatal thrombosis [47]. After ENU mutagenesis, 98 G1 F5L/L Tfpi+/- 
progeny survived to weaning (‘rescues’) and 16 of them exhibited successful transmis-
sion of the ENU-induced suppressor mutation. However, subsequent efforts to genet-
ically map the corresponding suppressor loci were largely unsuccessful due to the con-
founding effects of complex strain-specific differences introduced by the required genet-
ic outcross (Chapter II). Similar genetic background effects have complicated previous 
mapping efforts [175] and have been noted to significantly alter other phenotypes of in-
terest [97, 176]. Additional challenges of traditional mapping approaches include the re-
quirement for large pedigrees and limited mapping resolution, with candidate intervals 
typically harboring tens to hundreds of genes and multiple closely linked mutations. 
The emergence of high throughput sequencing methods has greatly enabled the 
direct identification of ENU-induced mutations and removed the necessity for outcross-
ing to introduce genetic markers for mapping [72, 104]. Here, we initially employed the 
previously successful approach [113] of mapping causal variants in rescue pedigrees 
using coding ENU-induced mutations as genetic markers. Application of a novel muta-
tion burden test facilitated the identification of 12 candidate thrombosis modifier genes 
from bulk sequencing of 107 F5L/L Tfpi+/- rescue mice without the requirement of genetic 
crosses for mapping. 
 
Materials and methods 
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Mice 
Mice carrying the murine homolog of the FVL mutation (F5L; B6.129S2-F5tm2Dgi/J, 
Jackson Laboratory stock #004080) [46] or the TFPI Kunitz domain deletion (Tfpi-) [92] 
were generated as previously described. Mice were genotyped using PCR assays with 
primers and conditions as previously described [46, 92], and maintained on the 
C57BL/6J background (Jackson Laboratory stock #000664). All animal care and proce-
dures were performed in accordance with the Principles of Laboratory and Animal Care 
established by the National Society for Medical Research. University Committee on Use 
and Care of Animals at University of Michigan has approved the protocol number 05191 
used for current study. The University of Michigan is fully accredited by the Association 
for Assessment and Accreditation of Laboratory Animal Care, International (AAALAC, 
Intl) and the animal care and use program conforms to the standards of “The Guide for 
the Care and Use of Laboratory Animals,” Revised 2011. All animal procedures were 
approved by the University of Michigan IACUC. 
 
ENU screen 
ENU mutagenesis was performed as previously described (Chapter II), with all 
mice on the C57BL/6J genetic background. Briefly, 189 F5L/L male mice (6-8 weeks old) 
were administrated three weekly intraperitoneal injections of 90 mg/kg of ENU (N-ethyl-
N-nitrosourea, Sigma-Aldrich). Eight weeks later, 177 surviving males were mated to 
F5L/+ Tfpi+/- females and their G1 progeny were genotyped at age 2-3 weeks to identify 
viable F5L/L Tfpi+/- offspring. F5L/L Tfpi+/- G1 rescues were crossed to F5L/L mice on the 
C57BL/6J genetic background and transmission was considered positive with the pres-
ence of one or more rescue progeny. Theoretical mapping power in rescue pedigrees 
was estimated by 10,000 simulations using SIMLINK software [177]. 
 
Whole exome sequencing 
Gender, age, whole exome sequencing (WES) details, and other characteristics 
for 108 rescue mice are provided in Appendix 4-1. Genomic DNA (gDNA) extracted 
from tail biopsies of 56 G1 offspring from the current ENU screen and from an additional 
50 F5L/L Tfpi+/- mice on the C57BL/6J background from the previous screen (Chapter II) 
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were subjected to WES at the Northwest Genomics Center, University of Washington. 
Sequencing libraries were prepared using the Roche NimbleGen exome capture sys-
tem. DNA from an additional two rescue offspring were subjected to WES at Beijing 
Genomics Institute or Centrillion Genomics Technologies, respectively (Appendix 4-1). 
These two libraries were prepared using the Agilent SureSelect capture system. 100 bp 
paired-end sequencing was performed for all 108 exome libraries using Illumina HiSeq 
2000 or 4000 sequencing instruments. Two WES mice represented rescue pedigree 1: 
the G1 founder and a G2 rescue offspring. The latter was used for linkage analysis, but 
excluded from the burden analysis (Appendix 4-1). 
 
WES data analysis 
Average sequencing coverage, estimated by QualiMap software [132], was 77X, 
and >96% of the captured area was covered by at least 6 independent reads (Appendix 
4-1). A detailed description of variant calling as well as in-house developed scripts for 
variant filtration are online as a GitHub repository (github.com/tombergk/FVL_mod). In 
short, Burrows-Wheeler Aligner [131] was used to align reads to the Mus Musculus 
GRCm38 reference genome, Picard [158] to remove duplicates, and GATK [133] to call 
and filter the variants. Annovar software [134] was applied to annotate the variants us-
ing the Refseq database. All variants within our mouse cohort present in more than one 
rescue were declared non-ENU induced and therefore removed. Unique heterozygous 
variants with a minimum of 6X coverage were considered as potential ENU-induced mu-
tations. 
 
Mutation frequency estimations 
All ENU-induced variants predicted to be potentially harmful within protein coding 
sequences including missense, nonsense, splice site altering SNVs, and out-of-frame 
insertions-deletions (INDELs), were totaled for every gene. The number of potentially 
damaging variants per gene was compared to a probability distribution of each gene be-
ing targeted by chance. Probability distributions were obtained by running 10 million 
random permutations using probabilities adjusted to the length of the protein coding re-
gion. A detailed pipeline for the permutation analysis is available online 
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(github.com/tombergk/FVL_mod). Genes that harbored more potentially damaging 
ENU-induced variants than expected by chance were considered as candidate modifier 
genes (at false discovery rate (FDR) ≤0.1 and ≤0.25). Statistical correction for multiple 
testing was applied as previously described [178]. 
 
Variant validation by Sanger sequencing 
All primers were designed using Primer3 software [179] and purchased from In-
tegrated DNA Technologies. PCR was performed using GoTaq Green PCR Master Mix 
(Promega), visualized on 2% agarose gel, and purified using QIAquick Gel Extraction 
Kit (Qiagen). Sanger sequencing of purified PCR products was performed by the Uni-
versity of Michigan Sequencing Core. All PCR primers (named: gene name+’_OF/OR’) 
and internal sequencing primers (named: gene name+’_IF/IR’) are listed in Appendix 4-
2. 
 
gRNA design and in vitro transcription 
gRNA target sequences were designed with computational tools [180, 181] 
(http://www.broadinstitute.org/rnai/public/analysis-tools/sgrna-design or http://genome-
engineering.org) and top predictions per each candidate gene were selected for func-
tional testing (Appendix 4-3). sgRNA for C6, Ces3b, Itgb6, and Sntg1 were in vitro syn-
thesized (MAXIscript T7 Kit, Thermo Fisher) from double stranded DNA templates by 
GeneArt gene synthesis service (Thermo Fisher) while sgRNA for Arl6ip5 was in vitro 
synthesized using Guide-it sgRNA In Vitro Transcription Kit (Clontech) (Appendix 4-3). 
The Cpn1 sgRNA target was cloned into plasmid pX330-U6-Chimeric_BB-CBh-
hSpCas9 (Addgene.org Plasmid #42230) [182]. The sgRNAs were purified prior to ac-
tivity testing (MEGAclear Transcription Clean-Up Kit, Thermo Fisher). Both the Wash 
and Elution Solutions of the MEGAclear Kit were pre-filtered with 0.02 μm size exclusion 
membrane filters (Anotop syringe filters, Whatman) to remove particulates from zygote 
microinjection solutions, thus preventing microinjection needle blockages. 
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in vitro Cas9 DNA cleavage assay 
Target DNA for the in vitro cleavage assay was PCR amplified from genomic 
DNA isolated from JM8.A3 C57BL/6N mouse embryonic stem (ES) cells [183] with can-
didate gene specific primers (Appendix 4-3). In vitro digestion of target DNA was carried 
out by complexes of synthetic sgRNA and S. pyogenes Cas9 Nuclease (New England 
BioLabs) according to manufacturer's recommendations. Agarose gel electrophoresis of 
the reaction products was used to identify sgRNA molecules that mediated template 
cleavage by Cas9 protein (Figure 4-1A). Arl6ip5 was assayed separately, with one out 
of four tested sgRNAs successfully cleaving the PCR template (data not shown). 
 
Cell culture DNA cleavage assay 
Synthetic sgRNAs that targeted Cpn1 were not identified by the in vitro Cas9 
DNA cleavage assay (Figure 4-1B). As an alternative assay, sgRNA target sequences 
were subcloned into pX330-U6-Chimeric_BB-CBh-hSpCas9 and co-electroporated into 
JM8.A3 ES cells as previously described [184]. Briefly, 15 μg of a Cas9 plasmid and 5 
μg of a PGK1-puro expression plasmid [185] were co-electroporated into 0.8 X10E7 ES 
cells. On days two and three after electroporation media containing 2 μg/ml puromycin 
were applied to the cells; then selection free media was applied for four days. Surviving 
ES cells were collected and genomic DNA was purified. The Cpn1 region targeted by 
the sgRNA was PCR amplified and tested for the presence of indel formation with a T7 
endonuclease I assay according to the manufacturer’s directions (New England Bi-
olabs). 
 
Generation of CRISPR-Cas9 gene edited mice 
CRISPR-Cas9 gene edited mice were generated in collaboration with the Univer-
sity of Michigan Transgenic Animal Model Core. Arl6ip5 mutant mice: sgRNA targeting 
Arl6ip5 was combined with Cas9 protein and microinjected into the male pronucleus of 
fertilized mouse eggs obtained by the mating of stud males carrying the F5L/+ Tfpi+/- 
genotype on the C57BL/6J background with superovulated (C57BL/6 X SJL) F1 female 
mice (B6SJLF1/J, Jackson Laboratory stock #100012). Multigenic mutant mice: a pre-
mixed solution containing 2.5 ng/μl of each sgRNA for Arl6ip5, C6, Ces3b, Itgb6, Sntg1, 
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and 5 ng/μl of Cas9 mRNA (GeneArt CRISPR Nuclease mRNA, Thermo Fisher) was 
prepared in RNAse free microinjection buffer (10 mM Tris-Hcl, pH 7.4, 0.25 mM EDTA). 
The mixture also include 2.5 ng/μl of pX330-U6-Chimeric_BB-CBh-hSpCas9 plasmid 
containing guide C37G1 targeting Cpn1 and a 2.5 ng/ul of pX330-U6-Chimeric_BB-
CBh-hSpCas9 plasmid containing guide C37G2 targeting Cpn1 (Appendix 4-3). The 
mixture of sgRNAs, Cas9 mRNA, and plasmids was microinjected into the male pronu-
cleus of fertilized mouse eggs obtained from the mating of stud males carrying the F5L/+ 
Tfpi+/- genotype on the C57BL/6J background with superovulated C57BL/6J female 
mice. Microinjected eggs were transferred to pseudopregnant B6DF1 female mice 
(Jackson Laboratory stock #100006). DNA extracted from tail biopsies was genotyped 
for the presence of gene editing. 
 
Genotyping CRISPR alleles 
Initially, gRNA targeted loci were tested using PCR and Sanger sequencing (pri-
mer sequences provided in Appendix 4-3). Small INDELs were deconvoluted from 
Sanger sequencing reads using TIDE software [186]. PCR products carrying small IN-
DELs in 4 F5L/+ Tfpi+/- mice were cloned using the Zero Blunt TOPO PCR Cloning Kit 
(Invitrogen) following the manufacturer’s instructions. A minimum of 10 clones from 
each reaction were selected, expanded in 5 ml of LB broth (Invitrogen), purified using 
the QIAprep Spin Miniprep Kit (Qiagen), and submitted to Sanger sequencing. Large 
(>50 bp) deletions were genotyped using PCR reactions that resulted in two visibly dis-
tinct product sizes for the deletion and wildtype alleles. One large inversion event (134 
bp) was genotyped using inversion specific forward primer. Expected product sizes and 
genotyping primers for each deletion and the inversion are listed in Table 4-1. All geno-
typing strategies were initially validated using Sanger sequencing. 
 
RT-PCR 
Liver tissue samples were collected in RNAlater (Ambion) from Arl6ip5+/+ and 
Arl6ip5+/- mice. Total RNA was extracted using the RNeasy Mini Kit (Qiagen). Comple-
mentary DNA (cDNA) synthesis was performed using the SuperScript III One-Step RT-
PCR (Invitrogen). An intron 1 spanning cDNA specific PCR product (RT-PCR primers 
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5’-3’: CAGAGGAACATGGACGTGA, CACCAGCACCACAATGACTC) amplified from 
the liver mRNA of Arl6ip5+/- mice resulted in two expected product sizes (237 bp for the 
wildtype and 214 bp for the deletion allele). The intensities of the wildtype and deletion 
allele PCR bands from three Arl6ip5+/- mice were quantified and compared to each other 
using ImageJ software [165]. 
 
Statistical analysis 
Kaplan-Meier survival curves and log-rank test to estimate significant differences 
in mouse survival were performed using the ‘survival’ package in R [187]. A paired two-
tailed Student’s t-test was applied to estimate differences in weights between rescue 
mice and their littermates. Chi-square tests were applied to estimate deviations from 
expected proportions in mouse crosses as well as recombination rates between the Tfpi 
and Plcb4 loci. Benjamini and Hochberg FDR for ENU burden analysis, Student’s t-
tests, and chi-square tests were performed using the ‘stats’ package in R software 
[162]. Linkage Analysis was performed on the Mendel platform version 14.0 [128] and 
LOD scores ≥3.3 were considered genome-wide significant [129]. 
 
Results and discussion 
 
F5L/L Tfpi+/- mice exhibit reduced survival and smaller size 
A previously described (Chapter II) sensitized ENU mutagenesis was extended to 
screen for dominant suppressors of the perinatal lethal F5L/L Tfpi+/- genotype (Figure 4-
2A). 2595 G1 offspring were generated from mutagenized C57BL/6J F5L/L males 
crossed to unmutagenized C57BL/6J F5L/+ Tfpi+/- females, with a total of 70 viable F5L/L 
Tfpi+/- rescue progeny identified at weaning. Approximately 50% of the rescue mice died 
by 6 weeks of age, with slightly worse survival observed in females (p=0.033; Figure 4-
2B). Females were also underrepresented compared to males during the initial genotyp-
ing (26 females compared to 44 males, p=0.031). In addition, F5L/L Tfpi+/- rescues were 
on average 25-30% smaller than their littermates at 2-3 weeks of age (p=7x10-12; Figure 
4-2C,D). The proportion of identified rescues among G1 offspring, their smaller weight 
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compared to littermates, and slightly worse survival for female vs male rescues, were all 
consistent with our previous report (Chapter II). 
 
Rescue pedigrees exhibit reduced fertility and incomplete penetrance 
The 35 G1 F5L/L Tfpi+/- mice alive at 6 weeks of age were mated to F5L/L mice to 
test the heritability of the survival phenotype. Fifteen of these 35 mice generated at least 
one litter and 13 (1 female, 12 males) produced ≥1 offspring with the F5L/L Tfpi+/- geno-
type (Table 4-2). Across all pedigrees, mice beyond G1 (≥G2) continued to exhibit re-
duced survival with more pronounced underrepresentation of females (p=0.001; Figure 
4-2E), and an average ~27% lower body weight compared to littermates at the time of 
genotyping (p=2x10-16; Figure 4-2F). In the previous screen (Chapter II), rescues were 
outcrossed to the 129S1/SvImJ strain to introduce genetic diversity required for subse-
quent mapping experiments. However, complex strain modifier gene interactions con-
founded this analysis and resulted in a large number of “phenocopies” (defined as via-
ble rescues despite lacking the original rescue mutation). To minimize this problem in 
the current screen, rescue pedigrees were maintained exclusively on the C57BL/6J 
background. While half of the pedigrees (8/16) previously generated on the mixed 
129S1/SvImJ-C57BL/6J background generated >45 rescue progeny per pedigree (Ta-
ble 2-4 in Chapter II) all pedigrees on the pure C57BL/6J background in the current 
study yielded <30 rescue mice, with the majority of pedigrees generating ≤3 rescues 
(Table 4-2). Such poor breeding performance in comparison to the previous screen is 
likely explained by a general positive effect of mixing 129S1/SvImJ-C57BL/6J strain 
background either directly on rescue fertility (hybrid vigor) or indirectly by reducing the 
severity of the F5L/L phenotype. C57BL/6J and 129S1/SvImJ strains have been shown 
to exhibit significant differences in a number of hemostasis-related parameters including 
platelet count, TFPI and TF expression levels [188]. Variation in genes underlying such 
strain specific differences may have contributed as modifiers to the rescue pedigrees in 
Chapter II. 
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WES identifies 6771 ENU-induced variants in 107 rescues 
In order to identify all/most exonic ENU mutations, a total of 107 G1 rescues (57 
from the current ENU screen and an additional 50 rescues from the previous screen 
(Chapter II)) were subjected to WES (Appendix 4-1). From ~1.5 million initially called 
variants, 6735 SNVs and 36 INDELs within exonic regions were identified as potential 
ENU-induced mutations, using an in-house filtering pipeline (see Materials and meth-
ods). The most common exonic variants were nonsynonymous SNVs (47%), followed 
by mutations in 3’ and 5’ untranslated regions (31%) and synonymous SNVs (15%). The 
remaining variants (7%) were classified as splice site altering, stoploss, stopgain, or IN-
DELs (Figure 4-3A). T/A -> C/G (47%), and T/A -> A/T (24%) SNVs were overrepre-
sented, while C/G -> G/C (0.8%) changes were greatly underrepresented (Figure 4-3B), 
consistent with previously reported ENU studies [70, 84]. Since ENU is administered to 
the G0 father of G1 rescues, only female progeny are expected to carry induced muta-
tions on the X chromosome, while males inherit their only X chromosome from the un-
mutagenized mother. Among the called variants, all chromosomes harbored a similar 
number of mutations in both sexes, with the exception of the X chromosome where fe-
males had a >35 fold increase in SNVs per mouse (Figure 4-3C). The average number 
of exonic ENU mutations for G1 rescues from the current and previous screens was ~65 
SNV per mouse (Figure 4-3D), consistent with expected ENU mutation rates [72, 84]. 
These data suggest that most called variants are likely to be of ENU origin. 
 
Linkage analysis with coding ENU variants fails to map suppressor loci 
The three largest pedigrees (1, 6, and 13) were still poorly powered (29.6%, 
21.7% and 39.4%, respectively) to identify the rescue variants by linkage analysis 
(Figures 4-4A, 4-5A, 4-6A). A total of 86 candidate ENU variants across the three 
pedigrees were validated by Sanger sequencing (Table 4-3). Sixty-nine variants present 
in G1 rescue but not in their parents (G0) were further genotyped in all other rescue 
progeny in respective pedigrees. As expected from the power estimations, none of the 
19 ENU variants tested in pedigree 1 (Figure 4-4B), showed linkage with a LOD-
score >1.25 (Figure 4-4C). Similarly, 26 and 24 variants analyzed in pedigrees 6 and 13, 
respectively (Figures 4-5B, 4-6B) also failed to demonstrate a LOD-score >1.5 (Figures 
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4-5C, 4-6C). Failure to map the causal loci in any of these pedigrees was likely due to 
the lack of genetic power for mapping. However, we cannot exclude a contribution from 
insufficient marker coverage. While WES has been successfully applied to identify 
causal ENU variants within inbred lines [113] and in mixed background lines [71, 100], 
~3000 ENU variants identified by whole genome sequencing (WGS) provide a much 
denser and more even coverage of the entire genome and expectedly outperforms 
WES in mapping [104]. On the other hand, WGS requires sequencing multiple pedigree 
members [72], or pooled samples at high coverage [104] and may present the challenge 
of interpreting causality from many closely linked non-coding variants. 
 
Six independent G1 rescues derived from the same G0 mating 
142 G0 matings (1 ENU-treated G0 male crossed with 2 untreated females) pro-
duced a total of 70 rescues (Figure 4-2A) from a subset of 42 G0 matings, with a single 
rescue from 27 G0 matings, and 2-3 rescues from 14 G0 matings (Figure 4-7A). How-
ever, one G0 mating produced 6 rescues out of a total of 39 offspring (p=2x10-5 com-
pared to all G0 matings; p=0.02 compared to G0 matings with rescue offspring, Figure 
4-7A). This observation suggests a potential shared ‘rescue’ variant rather than 6 inde-
pendent rescue mutations in the same G0 founder. A similar observation was previously 
reported by Wansleeben and colleagues where 7 independent ENU pedigrees with an 
identical cardiac edema phenotype were mapped to the same genetic locus and hy-
pothesized to share the underlying causal variant [175]. 
 
A Plcb4 mutation co-segregates with the rescue phenotype in 3 G1 siblings and 
their rescue offspring 
Our in-house pipeline for ENU-induced variant analysis (see Methods) filters out 
all variants shared between 2 or more G1 rescue mice based on the assumption that 
ENU-induced variants should be unique in each individual G1. However, rescue siblings 
could theoretically originate from the same mutagenized spermatogonial stem cell and 
share ~50% of their induced mutations [63]. Among 107 whole exome sequenced G1 
mice, 38 were siblings (13 sib-pairs and 4 trios, Appendix 4-1). 190 heterozygous vari-
ants present in 2-3 mice (representing sibpairs or trios) out of 107 rescues were exam-
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ined, with 15 found to be shared by siblings (Table 4-4). Of the 7 sibs/trios sharing an 
otherwise novel variant, none shared >10% of their identified variants – inconsistent 
with the expected 50% for progeny originating from the same ENU-treated stem cell. 
 However, three shared protein-altering variants (Plcb4R335Q, Pyhin1G157T, and 
Fignl2G82S) were identified for the unusual G0 mating with 6 G1 rescues (Table 4-4). 
Plcb4R335Q was detected as a de novo mutation in one of the G0 females (Figure 4-7B) 
and was present in 3 out of 6 G1 rescue siblings. Plcb4 is located approximately 50 
megabases upstream of the Tfpi locus on chromosome 2, with predicted recombination 
rate of ~14.1% (Figure 4-7C) [189, 190]. While non-rescue littermates exhibited the ex-
pected rate of recombination (14.9%) between the Plcb4R335 and Tfpi loci, all 32 rescue 
mice (3 G1s and their ≥G2 progeny) were non-recombinant and carried the Plcb4R335 
variant. This co-segregation between the Plcb4R335 variant and the rescue phenotype is 
statistically significant (p=0.02; Figure 4-7C). Plcb4R335Q lies within a highly conserved 
region of Plcb4 (Figure 4-7D) and is predicted to be deleterious by Polyphen-2 [191]. 
The other identified non-ENU variants (Pyhin1G157T and Fignl2G82S) did not segregate 
with the rescue phenotype. 
Although the estimated de novo mutation rate for inbred mice (~5.4 x 10-9 
bp/generation) is ~100X lower than the ENU mutation rate [125], other de novo variants 
have coincidentally been identified in ENU screens (Chapter III) [173]. Mutations identi-
fied by DNA sequencing of offspring from ENU screen will not distinguish between an 
ENU-induced and de novo origin, though the former is generally assumed, given its 
much higher prevalence in the setting of a mutagenesis screen. De novo mutations orig-
inating in the G0 paternal or maternal lineages will be identified by analysis of parental 
genotypes, as was the case for the Plcb4R355Q variant. However, this variant was origi-
nally removed from the candidate list by a filtering step based on the assumption that 
each ENU-induced mutation should be unique to a single G1 offspring. This filtering al-
gorithm has been very efficient for removing false positive variants in our and previous 
screens [71]. However, our findings illustrate the risk for potential false negative results 
that this approach confers. 
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Mutation burden analysis identifies additional candidate thrombosis suppressor 
genes 
WES data for 107 independent rescue mice were jointly analyzed to identify can-
didate genes that are enriched for potentially deleterious ENU-induced variants includ-
ing missense, nonsense, frameshift, and splice site altering mutations (3481 variants in 
2984 genes, Appendix 4-4). The majority of genes harbored only a single ENU-induced 
variant while in Ttn, the largest gene in the mouse genome, 15 SNVs were identified, 
with the rest of the genes harboring ≤5 ENU variants (Figure 4-3E). After adjusting for 
coding region size, the ENU-induced mutation burden was significantly greater than ex-
pected by chance for 3 genes (FDR<0.1, Arl6ip5, Itgb6, C6) and suggestive for 9 addi-
tional genes (FDR<0.25) (Figure 4-8). Sanger sequencing validated 36 of the 37 vari-
ants within these 12 candidate genes. Two additional, independent ENU-induced muta-
tions were identified in Plcb4. After including the two Plcb4R335Q mutations removed by 
the original variant filtering (see above), this gene was also enriched for mutations 
(FDR<0.25). Similar concepts to the mutation burden analysis have been applied to 
identify genes underlying rare diseases caused by de novo loss-of-function variants in 
humans [108-111]. This approach enables the identification of multiple candidate genes 
in parallel and does not require the maintenance or survival of rescue mice for pedigree 
generation. 
 
Testing candidate thrombosis modifiers by independent CRISPR-Cas9-generated 
alleles 
In order to validate the top candidate thrombosis suppressor genes identified 
above, independent null alleles were generated with CRISPR-Cas9. First, F5L/+ Tfpi+/- 
males and B6SJLF1/J females were mated to generate zygotes for microinjection with 
complexed Arl6ip5 sgRNA and Cas9 protein. Out of 354 injected zygotes, 155 offspring 
were generated, with genotyping identifying one mouse mosaic for a 23 base pair dele-
tion in exon 1 of Arl6ip5 (F5L/+ Tfpi+/+ Arl6ip5-, Figure 4-9). This frameshift mutation is 
expected to result in an early stop codon. RT-PCR from heterozygous mice showed de-
creased levels of mRNA from the deletion allele compared to the wildtype allele, con-
sistent with nonsense-mediated decay (Figure 4-9D). Mice triply heterozygous for the 
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F5L, Tfpi- and Arl6ip5- alleles were generated and crossed to F5L/L mice. Out of 123 
progeny, 5 F5L/L Tfpi+/- mice were identified, 2 of which carried the Arl6ip5 null allele 
(Figure 4-9E). The additional three F5L/L Tfpi+/- Arl6ip5+/+ mice were viable, suggesting 
strain modifiers from the SJL background as the cause of their rescue. Therefore, the 
influence of the Arl6ip5 null allele on F5L/L Tfpi+/- survival phenotype could not be as-
sessed in this system. 
To eliminate the potential confounding influence of the SJL strain, the CRISPR-
Cas9 experiment was repeated using C57BL/6J egg donors, though these are known to 
be less efficient for transgenesis than eggs derived from B6SJLF1/J females [192]. In 
addition to reagents targeting Arl6ip5, we pooled guides against five additional candi-
date genes (C6, Itgb6, Cpn1, Sntg1 and Ces3b; Figure 4-8). From 294 microinjected 
zygotes, we obtained 39 progeny, 70% fewer than on the mixed background (155 with 
B6SJLF1/J, see above). Nevertheless, approximately 190 independent targeting events 
were observed across the 6 genes in 36 mice including small INDELs, single nucleotide 
changes, and several large (>50bp) deletions or inversions. Targeted alleles were either 
homozygous, heterozygous, or mosaic. While the number of editing events varied great-
ly for different sgRNAs (2.5-85%) the strategy to simultaneously target multiple genes 
[182] proved successful and cost-effective. 
 
Preliminary validation data suggest increased number of rescues progeny for 
combined CRISPR-Cas9 alleles 
From the 39 progeny of the CRISPR-Cas9 targeting experiment, 4 males with the 
F5L/+ Tfpi+/- genotype in addition to multiple targeted alleles in Itgb6, Cpn1, Sntg1, 
Ces3b, and/or Arl6ip5 (Figure 4-10) were directly crossed to untreated C57BL/6J F5L/L 
females. Out of 15 progeny, 2 viable F5L/L Tfpi+/- mice were identified at genotyping 
(46.2% of the expected F5L/L Tfpi+/- conceptuses), significantly more than the previously 
observed background survival rate (3.75%, p=0.0002). These 2 rescue mice each car-
ried a different CRISPR-Cas9-induced mutation in the Sntg1 gene (Sntg1-A or Sntg1-C; 
Figure 4-10) but were wildtype at the other 5 targeted loci. 
 
In conclusion, we performed a dominant, sensitized ENU mutagenesis screen for 
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modifiers of thrombosis, identifying 70 viable rescues with the otherwise synthetic lethal 
F5L/L Tfpi+/- genotype. Reduced fertility on a pure C57BL/6J genetic background limited 
the generation of expanded pedigrees, complicating efforts to map the corresponding 
putative suppressor loci. However, application of a novel mutation burden test to WES 
data derived from a total of 107 rescue mice identified 12 novel thrombosis modifier 
candidate genes. Rescue mice carrying CRISPR-Cas9-induced alleles in Sntg1 were 
identified at significantly higher frequency compared to background (p=0.0002) serving 
as preliminary validation for this approach. 
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Figure 4-1: In vitro cleavage assay for sgRNAs 
A) sgRNA+Cas9 targeting created double strand breaks in DNA templates obtained 
from genomic DNA by PCR. Expected sizes after sgRNA+Cas9 endonuclease activity: 
430bp/240bp (Ces3b), 334bp/273bp (Sntg1), 530bp/275bp (Itgb6), and 383bp/296bp 
(C6). B) sgRNA+Cas9 complexes targeting Cpn1 using two different guides (g1, g2) 
failed to created double strand breaks. Positive control (P.C.) was added to ensure 
Cas9 protein activity, with expected sizes after cleavage (390bp/140bp) indicated by 
white stars. 
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Figure 4-2: A sensitized ENU suppressor screen for thrombosis modifiers 
A) The ENU screen strategy is depicted here, along with the total numbers of G1 
offspring by genotype. B) Survival curves for G1 rescue mice. Survival for females is 
slightly reduced compared to males (p=0.033). C-D) Weight at genotyping (at 14-21 
days) for G1 rescues compared to control littermates. E) Survival of rescue mice 
beyond G1 (≥G2) is also reduced, also with worse outcome in females (p=0.001). F) 
≥G2 rescue offspring also exhibit reduced weights compared to their littermates at 
genotyping.  
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Figure 4-3: Distribution of ENU-induced mutations in WES data from 107 G1 
rescues 
A) Overview of mutation types for the 6771 observed ENU-induced exonic variants. B) 
Distribution of missense mutations by nucleotide substitution type. C) Distribution of 
ENU-variants by chromosome. D) The average number of exonic SNVs is ~65 for both 
the current (G1-new) and previous (G1-old) screens. E) Number of genes (x-axis) 
sorted by the number of protein-altering ENU-induced mutations observed per gene (y-
axis). Most genes (2567) carry only 1 mutation. In contrast, the ~0.1 megabase coding 
region of Ttn carries a total of 15 independent ENU variants.  
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Figure 4-4: Genetic mapping of ENU-induced variants in pedigree 1 
A) Overview of pedigree 1 (only rescue mice displayed). B) All coding ENU-induced 
mutations identified by WES were genotyped in all rescues from the pedigree by Sanger 
sequencing. Blue boxes indicate presence and red boxes indicate absence of the 
mutation. P1-P3 refers to 3 parental genotypes (G0 male and 2 untreated females). C) 
Linkage analysis using the ENU-induced variants from (B) as genetic markers. 
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Figure 4-5: Genetic mapping of ENU-induced variants in pedigree 6 
A) Overview of pedigree 6 (only rescue mice displayed). B) All coding ENU-induced 
mutations identified by WES were genotyped in most rescues from the pedigree by 
Sanger sequencing. Blue boxes indicate presence and red boxes indicate absence of 
the mutation. P1-P3 refers to 3 parental genotypes (G0 male and 2 untreated females). 
C) Linkage analysis using the ENU-induced variants from (B) as genetic markers.   
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Figure 4-6: Genetic mapping of ENU-induced variants in pedigree 13 
A) Overview of pedigree 13 (only rescue mice displayed). B) All coding ENU-induced 
mutations identified by WES were genotyped in all rescues from the pedigree if present 
in key mice 3 and 5 by Sanger sequencing. Blue boxes indicate presence and red 
boxes indicate absence of the mutation. P1-P3 refers to 3 parental genotypes (G0 male 
and 2 untreated females). C) Linkage analysis using the ENU-induced variants from (B) 
as genetic markers. 
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Figure 4-7: Segregation of the Plcb4R335Q variant 
A) The number of G1 rescues (x-axis) and the number of all progeny (y-axis) produced 
from each of the 142 G0 ENU matings is depicted here. Nearly all matings generated ≤2 
G1 rescues, with 1 mating producing a significantly higher number of G1 rescue 
progeny (n=6) compared to all other ENU matings (p=2x10-5). B) Partial pedigree of the 
ENU mating with 6 G1 rescues. Three G1 rescues inherited the de novo SNV (R335Q) 
in Plcb4 gene from the G0 mother. Arrows highlight the founder G1 rescues of 
pedigrees 12 and 13. C) Top, relative locations of the Plcb4 and Tfpi genes on 
chromosome 2, with predicted recombination rate is ~14%. Bottom, recombination rates 
observed among 32 rescues carrying the Plcb4R335Q variant and their littermates 
(n=139). D) The Plcb4R335Q mutation lies in a highly conserved region of exon 13. 
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Figure 4-8: Mutation enrichment per gene in WES data from 107 G1 rescues 
All genes with potentially deleterious ENU mutations are sorted by their chromosomal 
position of the x-axis, with the y-axis indicating the statistical significance (negative log 
of the p-value) of each gene’s enrichment based on 10,000,000 permutations and 
normalized to coding region size. Each dot represents a gene and the diameter is 
proportional to the number of mutations observed. Dotted lines represent FDR values of 
0.1 and 0.25. White dot highlighted with star represents the Plcb4 gene after including 
the filtered non-ENU mutations.  
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Figure 4-9: Validation of Arl6ip5 as a thrombosis suppressor using CRISPR-Cas9-
generated independent null allele 
A) Schematic overview of the Arl6ip5 protein sequence and the early stop codon 
introduced by the 23 bp frameshift deletion. Stars highlight the original three ENU-
induced mutations. B) Ar6ip5 genotyping assay and C) the Sanger sequence for the 
wildtype and deletion allele. D) Top, RT-PCR with intron spanning cDNA specific primers 
show two bands for the Arl6ip5+/- mice. The upper band represents the wildtype allele 
and the faint lower band represents the null allele. Bottom, the lower band intensity is 
~20% that of the upper band, consistent with nonsense mediated decay. E) Among 123 
progeny from the validation mating, 5 F5L/L Tfpi+/- mice were genotyped, two of which 
were Arl6ip5+/- and three of which were Arl6ip5+/+. 
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Figure 4-10: CRISPR-Cas9-induced INDELs in F5L/+ Tfpi+/- mice used for rescue 
validation 
The sequence of the gRNAs and the CRISPR-Cas9 induced mutations are shown for A) 
Arl6ip5 B) Itgb6 C) Cpn1 D) Sntg1 and E) Ces3b. All edited positions are highlighted in 
red, with dash referring to a deleted position. The letters A-D on the left of each allele 
refer to the 4 different F5L/+ Tfpi+/- mice. Each mouse carries multiple mutations in 
different genes.  
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Table 4-1: CRISPR-Cas9 alleles 
Gene 
Allele 
name 
Mutation 
type 
Mutation 
length 
Genotyping/Sequencing primers: 
Forward, Reverse (5’-3’) 
Expected 
PCR 
product 
sizes 
Arl6ip5 
del63 
in frame 
deletion 
63 bp 
CAGAGGAACATGGACGTGAA 
GAAAGGGGACCTCAGAGAGC 
371 bp 
308 bp 
del151 
frameshift 
deletion 
151 bp 
TTTAACCGCAGAACCAATCC 
GAAAGGGGACCTCAGAGAGC 
469 bp 
318 bp 
Itgb6 
del163 
splice site 
deletion 
163 bp 
CATTCAACCGCACTGAGAGA 
AAATTAAGCGGCAGGTGTTG 
446 bp 
283 bp 
del11 
frameshift 
deletion 
11 bp 
AATCCGACTTTGGTCCACTG 
GTGTTGTCCGGATAGCCACT 
SS 
C6 
ins1 
frameshift 
insertion 
1 bp 
GGGTTCTCAAGCTCCCTTCAA 
GGAGAAGTCAGTGGGGTTCAG 
SS 
del3 
in frame 
deletion 
3 bp 
GGGTTCTCAAGCTCCCTTCAA 
GGAGAAGTCAGTGGGGTTCAG 
SS 
Cpn1 
del81 
splice site 
deletion 
81 bp 
GTTCATGGAAGGCAGGATGT 
GTGGAATGGGGTGAGACAAG 
296 bp 
215 bp 
inv134 
frameshift 
inversion 
144 bp 
-12 bp (5’) 
+2 bp (3’) 
GTTCATGGAAGGCAGGATGT 
ACATCCTGCCTTCCATGAAC 
GTGGAATGGGGTGAGACAAG 
296 bp 
226 bp 
Sntg1 
del11 
frameshift 
deletion 
11 bp 
TACGACAGCCAGGACTCAGTA 
GGCGTGGAGACCAGATTTTC 
SS 
del2 
Frameshift 
deletion 
2 bp 
TACGACAGCCAGGACTCAGTA 
GGCGTGGAGACCAGATTTTC 
SS 
Ces3b 
del14A 
frameshift 
deletion 
14 bp 
ACAAATAGACGCTGGAGGAGC 
CCCTTGTAGCCCAGGGTATT 
SS 
del14B 
frameshift 
deletion 
14 bp 
ACAAATAGACGCTGGAGGAGC 
CCCTTGTAGCCCAGGGTATT 
SS 
SS=Sample is subjected to Sanger sequencing and analyzed using TIDE software [186] 
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Table 4-2: Overview of rescue pedigrees 
Rescue 
pedigree  
G1 rescue 
ID 
Sex 
Total # 
progeny 
# Rescues Penetrance 
PED1 60654 M 208 23 33.2% 
PED2 82147 M 34 2 17.7% 
PED3 82723 M 91 2 6.6% 
PED4 83071 F 50 2 12% 
PED5 83217 M 4 1 76.9% 
PED6 83457 M 188 22 35.1% 
PED7 83737 M 18 3 50% 
PED8 83796 M 19 3 47.6% 
PED9 83882 M 4 1 76.9% 
PED10 83875 M 39 8 61.5% 
PED11 10382 M 25 3 36.1% 
PED12 11241 M 32 5 46.9% 
PED13 11954 M 107 27 75.8% 
PED=pedigree; Penetrance is calculated as follows: #Rescues / (Total # of progeny - 
#Rescues) / 2 
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Table 4-3: Overview of candidate ENU-induced variants in pedigrees 1, 6, and 13 
PED Chr Position Ref Alt Type Gene Exon 
AA 
change 
Validation 
PED 1 3 28048031 T A SG Pld1 10 C310X ENU 
PED 1 3 92825401 A G NS Kprp 2 V114A ENU 
PED 1 3 125561508 C A NS Ndst4 3 T355K ENU 
PED 1 4 154887641 C T S Mmel1 10 Y264Y ENU 
PED 1 6 126975169 T C NS D6Wsu163e 14 V542A ENU 
PED 1 6 132957264 A T SG Tas2r131 1 L194X ENU 
PED 1 7 80284342 C A NS Vps33b 10 D253E ENU 
PED 1 7 86923065 A T NS Vmn2r78 5 T545S ENU 
PED 1 10 43022236 A C NS Sobp 6 M451R ENU 
PED 1 12 72481551 T A NS Lrrc9 20 W876R ENU 
PED 1 12 85476338 T A NS Fos 4 F341L ENU 
PED 1 13 23034506 A T NS Vmn1r214 1 M57L ENU 
PED 1 15 59341976 T C NS 
E430025E2
1Rik 21 D877G ENU 
PED 1 16 28827933 G T NS Mb21d2 2 R430S ENU 
PED 1 16 38266025 A G NS Nr1i2 2 I26T ENU 
PED 1 16 49896392 T C NS Cd47 7 I262T ENU 
PED 1 17 46576613 G A NS Ptk7 12 R592C ENU 
PED 1 17 80216552 T A S Ttc39d 1 P213P ENU 
PED 1 19 3793072 T C S Suv420h1 5 H56H ENU 
PED 1 14 12376664 C T NS Cadps 28 D1283N not ENU 
PED 1 16 33885002 C T S Itgb5 5 L221L not ENU 
PED 1 2 26439278 A C S Sec16a 2 A908A not in G1 
PED 1 3 133084916 G A NS Gstcd 2 T30M not in G1 
PED 1 7 39474173 C T NS Zfp939 5 T550I not in G1 
PED 1 11 116539241 C T NS Ube2o 18 A1224T not in G1 
PED 1 12 4865787 G T SG Mfsd2b 12 Y408X not in G1 
PED 1 1 26687400 A T NS 
4931408C2
0Rik 1 N9K seq error 
PED 1 1 171356715 G C NS Pfdn2 3 D59H seq error 
PED 1 5 24326433 C T S Kcnh2 6 V493V seq error 
PED 1 6 116042915 C G NS Tmcc1 4 R485S seq error 
PED 1 10 79268510 T A NS Vmn2r81 3 H322Q seq error 
PED 1 11 50603529 T G S Adamts2 2 G143G seq error 
PED 1 14 78513605 G A S Akap11 7 F447F seq error 
PED 6 1 58017826 T C S Sgol2 7 S1056S ENU 
PED 6 1 75243553 A G NS Dnajb2 8 T239A ENU 
PED 6 2 30008245 A G NS Sptan1 30 S1326G ENU 
PED 6 2 30090396 T C S Pkn3 21 V803V ENU 
PED 6 4 42939543 T A NS N28178 10 I345N ENU 
PED 6 4 116599350 T A NS Ccdc17 11 W439R ENU 
PED 6 4 143617300 T C NS Gm13083 3 L390P ENU 
PED 6 6 38195359 A G NS 
D630045J1
2Rik 2 S625P ENU 
PED 6 6 58935706 A G NS Fam13a 18 V654A ENU 
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PED 6 6 87282723 G A S Antxr1 8 N200N ENU 
PED 6 6 113591215 A G S Fancd2 42 E1363E ENU 
PED 6 6 121849860 A G NS Mug1 6 K214R ENU 
PED 6 7 4149610 A G S Leng9 1 C22C ENU 
PED 6 7 29109255 T C NS Ryr1 13 E464G ENU 
PED 6 7 123983815 T C NS Hs3st4 1 V212A ENU 
PED 6 8 86713501 A G NS Lonp2 13 K710E ENU 
PED 6 8 112002558 A G S Kars 5 Y172Y ENU 
PED 6 8 125941760 C A NS BC021891 9 T695K ENU 
PED 6 9 81631894 A G NS Htr1b 1 L220P ENU 
PED 6 10 18516089 T A NS Nhsl1 5 V197E ENU 
PED 6 10 81370704 A G NS Fzr1 5 L127P ENU 
PED 6 11 78212187 C T NS Supt6 31 D1407N ENU 
PED 6 13 55652099 T A NS Ddx46 7 V274E ENU 
PED 6 13 59536282 T C NS Agtpbp1 3 T42A ENU 
PED 6 15 63825049 A T SG Gsdmc2 14 Y424X ENU 
PED 6 18 37720736 A T NS Pcdhgb4 1 L61F ENU 
PED 13 1 11140236 A T NS Prex2 17 I588F ENU 
PED 13 1 149840641 A G NS Pla2g4a 17 F698L ENU 
PED 13 2 25443328 T C NS Abca2 30 V1655A ENU 
PED 13 3 59325883 T A NS Igsf10 6 T1810S ENU 
PED 13 6 30641588 A G NS Cpa1 5 K194E ENU 
PED 13 6 97993317 T A NS Mitf 3 M166K ENU 
PED 13 6 125101969 T A NS Chd4 7 I289N ENU 
PED 13 7 127788499 T G NS Setd1a 12 D997E ENU 
PED 13 
8 13562168 T G NS 
1700029H1
4Rik 1 K61Q ENU 
PED 13 9 38464760 A T NS Olfr904 1 T240S ENU 
PED 13 10 7678676 A G NS Nup43 8 E341G ENU 
PED 13 11 33964797 G A NS Kcnmb1 2 V33I ENU 
PED 13 
12 71154824 C T NS 
2700049A0
3Rik 8 R341C ENU 
PED 13 12 76204304 T C NS Tex21 9 T453A ENU 
PED 13 12 85926893 T C NS Ttll5 24 I805T ENU 
PED 13 12 106042885 T G NS Vrk1 3 V70G ENU 
PED 13 
13 22441416 T C NS 
Vmn1r-
ps103 1 Y49H ENU 
PED 13 13 37931499 A C NS Rreb1 10 K945Q ENU 
PED 13 13 43057177 A T SP Phactr1 6 NA ENU 
PED 13 14 50964318 T C NS Pnp2 6 S254P ENU 
PED 13 15 78888476 C A NS Gga1 9 T269K ENU 
PED 13 16 58824697 T A NS Olfr175-ps1 2 D4V ENU 
PED 13 19 8912851 T C NS Ganab 18 Y715H ENU 
PED 13 
19 23616626 T C SP 
1700028P1
4Rik 3 NA ENU 
PED 13 2 86046847 A T NS Olfr1034 1 M122L seq error 
PED 13 9 44417150 A T NS Ccdc84 3 M115K seq error 
PED 13 14 7549840 G C NS Gm3558 6 L187V seq error 
PED=pedigree; NS=nonsynonymous; S=synonymous; SP=splicing; SG=stopgain 
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Table 4-4: Overview of WES variants present in 2 or 3 G1 rescues 
# G1-1 G1-2 G1-3 Chr Pos Ref Alt Type Gene 
3 118774 118780 NA 13 60800325 G A S Ctsll3 
3 118774 118780 NA 15 99624277 T TTGG NFSI Racgap1 
5 105078 118769 NA 13 67041404 
ATCTT
T 
A FSD Zfp712 
5 105078 118769 NA 13 67041411 G 
GCCG
AGAAA 
FSI Zfp712 
5 105078 118769 NA 13 67041413 T A NS Zfp712 
7 105079 118776 NA 5 108502429 C T UTR Pcgf3 
7 105079 118777 NA 7 75752211 C T UTR Akap13 
7 105079 118777 NA 9 44849652 C T NS Kmt2a 
10 118761 118765 NA 7 62464404 C T UTR Peg12 
13 118789 118790 NA 1 71030121 A C UTR Bard1 
16 118798 118802 FCH 1 173637462 G T NS Pyhin1 
16 118798 FCH NA 2 135950362 G A NS Plcb4 
16 118798 FCH NA 9 65075750 C A S Dpp8 
16 118798 118802 NA 15 101054156 C T NS Fignl2 
17 118831 118832 NA 5 142173682 CA C FSD Sdk1 
 118789 118790 105081 1 173874425 C CT FSI Mndal 
 118761 118821 118766 3 152235750 TTG T UTR Fubp1 
 105079 118833 NA 4 148001086 T A NS Nppa 
 118789 105080 NA 5 33640643 TA T UTR Slbp 
 118831 118832 118836 6 18853853 T G UTR Naa38 
 105078 118782 NA 7 3717638 A T NS Pirb 
 118789 118808 NA 9 64708711 A T UTR Megf11 
 105079 105082 105085 11 93885765 C G UTR Utp18 
 118789 105079 NA 17 55799717 A T NS Emr4 
 118831 FCH NA 19 8707650 C T UTR Slc3a2 
 105079 118806 NA 19 8736205 G T S Wdr74 
 118773 118774 118780 1 36424939 G A NS Lman2l 
 105076 118816 118771 1 42698791 TCGC T UTR Pou3f3 
 105076 105077 118782 1 66175367 C T UTR Map2 
 119158 105087 NA 1 74160515 GACAA G UTR Cxcr2 
 118792 118793 118832 1 89892184 
GCGC
A 
G UTR Agap1 
 118872 118819 NA 1 105813719 T C NS Tnfrsf11a 
 118792 105086 118774 1 106172068 TGGC T NFSD Phlpp1 
 105077 118786 NA 1 134994010 C T NS Lgr6 
 118766 118779 NA 1 139458389 G A S Aspm 
 105069 105073 118836 1 151344527 CGCG C UTR Ivns1abp 
 118805 118804 NA 1 171286664 G 
GGGG
C 
FSI Usp21 
 105083 105088 NA 1 194815569 T C UTR Plxna2 
 118801 118831 NA 2 11690278 A C UTR Il2ra 
 118868 118826 NA 2 22971229 G A SG Abi1 
 119157 FCH NA 2 25271399 C A UTR Ssna1 
108 
 118858 118779 NA 2 28549061 G A NS Ralgds 
 105069 105072 NA 2 29991921 G T NS Sptan1 
 118792 118771 NA 2 59858718 T C NS Wdsub1 
 118803 118804 118807 2 62517699 G A S Fap 
 105070 105071 118803 2 65238415 G C NS Cobll1 
 118799 118800 118801 2 70574141 A G NS Gad1 
 118794 118796 NA 2 91555431 C A NS Ckap5 
 118794 118796 NA 2 91991212 C T NS Creb3l1 
 118858 118845 118851 2 118697652 G A UTR Pak6 
 105070 118805 118807 2 119321322 G C NC Gm14207 
 105070 118805 118807 2 119321324 G C NC Gm14207 
 118872 118816 118823 2 127080607 C CCT UTR Blvra 
 118805 118851 118781 2 130103303 
TATTAT
A 
T UTR AU015228 
 105066 118875 NA 2 130397415 G C NS Cpxm1 
 105068 118875 118829 2 131083323 T C NS Siglec1 
 118805 118821 NA 2 132306308 C T UTR Cds2 
 105088 118812 118831 2 160906675 G A UTR Emilin3 
 118836 118838 NA 2 180058100 A G NS Ss18l1 
 118815 118830 NA 3 96155661 C T NS Otud7b 
 118847 118852 118853 4 41395315 T A NS Kif24 
 118791 118799 NA 4 88722309 T C UTR Klhl9 
 105065 105080 NA 4 109982772 
TTGG
G 
T UTR Dmrta2 
 119160 118847 NA 4 118160162 C T NS Kdm4a 
 105075 118825 NA 4 133338995 C T SP Wdtc1 
 118765 118826 NA 4 141003992 T C S Atp13a2 
 105084 105087 118776 4 146195792 C T S Zfp600 
 118826 118838 NA 4 154281898 C T NS Arhgef16 
 118781 118787 NA 5 5508078 G A S Cldn12 
 118771 118787 NA 5 27851909 C T UTR Htr5a 
 105086 118785 NA 5 36486732 T C UTR Ccdc96 
 118868 118851 NA 5 37336642 C T NS Evc 
 105085 118761 NA 5 53200293 T C NS Sel1l3 
 105082 118812 118826 5 90366149 GGCC G UTR Ankrd17 
 105082 118848 NA 5 93043898 A G NS Sowahb 
 119158 118798 FCH 5 97087608 G A S Bmp2k 
 119157 118831 NA 5 107830346 G A UTR Ube2d2b 
 118808 118813 118774 5 111387757 TTCC T UTR Pitpnb 
 105069 118765 118772 5 111387787 TTCC T UTR Pitpnb 
 105066 118819 NA 5 121853037 A G NS Fam109a 
 118815 118825 NA 5 123961301 C T NS Ccdc62 
 105070 105071 118804 5 135377864 C T UTR Pom121 
 105070 105071 118804 5 135377865 A G UTR Pom121 
 118855 118829 NA 5 138141436 C 
CTTTC
T 
UTR Zfp113 
 118855 118845 NA 5 149624997 T C NS Hsph1 
 105066 118765 118832 6 24664944 AGCG A UTR Wasl 
 118820 118830 118831 6 24800820 G A UTR Spam1 
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 105074 118762 119157 6 30129559 AT A UTR Nrf1 
 119158 118836 NA 6 78428475 G GA UTR Reg1 
 105084 118771 NA 6 82738394 A G S Hk2 
 105072 118765 NA 6 91950692 C T UTR 
4930590J
08Rik 
 118790 105065 NA 6 116634875 GAAC G UTR Rassf4 
 118805 118807 NA 6 124845055 G A S Leprel2 
 118790 105072 NA 6 125339139 A G NS Scnn1a 
 105088 118812 NA 6 136708398 G A S Gucy2c 
 105068 118804 NA 7 5059580 C T NS Ccdc106 
 118875 118836 NA 7 16945553 G A NS Pnmal2 
 105083 FCH NA 7 22691836 G C NS Gm8693 
 118764 118829 NA 7 25439439 C T NC 
4732471J
01Rik 
 118845 118847 NA 7 27529549 A T NS Hipk4 
 118799 118761 NA 7 29705126 A T NS Catsperg2 
 118787 FCH NA 7 30447942 C T UTR Kirrel2 
 118851 118775 118785 7 34133101 CCCG C UTR Wtip 
 118858 118845 NA 7 46245375 G A S Otog 
 105074 FCH NA 7 47112788 T C UTR Ptpn5 
 118791 118825 NA 7 102268218 T C UTR Stim1 
 105076 105079 118780 7 114043054 G GTA UTR Spon1 
 118806 118829 NA 7 128252809 G A S Tgfb1i1 
 105073 118847 NA 8 13396751 C T NS Atp4b 
 118803 119157 NA 8 24950714 AC A UTR Adam9 
 118853 118765 NA 8 70072934 C T UTR Tm6sf2 
 105072 105078 118779 8 70596077 
ATGTG
TT 
A NFSD Isyna1 
 105068 118821 118824 8 70783517 C T NS Mast3 
 118791 118800 NA 8 119446196 T G UTR Osgin1 
 118858 118868 118872 9 22208225 A 
AAAAC
C 
NC 
1810064F
22Rik 
 118847 118852 NA 9 27323340 C T S Igsf9b 
 118769 118833 NA 9 39258290 A G S Olfr945 
 118858 118830 NA 9 54734546 C A UTR Wdr61 
 105075 119157 NA 9 54764815 T A UTR Crabp1 
 105075 118832 NA 9 87221292 T C NS 
4922501C
03Rik 
 118813 118814 118816 9 106880189 C CG UTR Vprbp 
 118813 118814 118816 9 106880191 CA C UTR Vprbp 
 118792 118831 NA 9 108489283 C A S Lamb2 
 118846 118872 NA 9 108961099 G A SP Col7a1 
 118858 118848 118851 10 34152583 ATCT A NFSD Dse 
 105087 118855 NA 10 40251193 C T S Gtf3c6 
 118821 118779 NA 10 76436466 G A S Pcnt 
 118851 118852 NA 10 78612011 G T NS Olfr1357 
 118847 118775 NA 10 80786000 C T S Dot1l 
 118792 118793 118802 10 81400280 C T UTR Nfic 
 118801 118824 NA 10 84725951 GAGC G UTR Polr3b 
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 118792 118803 NA 10 89806205 G A S Uhrf1bp1l 
 105066 105088 118803 10 93527671 G A S Amdhd1 
 105087 118821 NA 10 111473269 CCCG C UTR Nap1l1 
 105088 118786 NA 10 128670959 T C NS Suox 
 118803 118808 NA 10 129754805 TA T FSD Olfr807 
 118803 118808 NA 10 129754808 G T NS Olfr807 
 118872 119157 118779 11 4094482 C A S Mtfp1 
 118847 118852 NA 11 50853988 A G NS Grm6 
 118796 118805 NA 11 59780560 A G UTR Mprip 
 118793 119159 NA 11 77719484 A T NS Cryba1 
 105080 118779 NA 11 78034535 C T NS Dhrs13 
 118796 118855 NA 11 82942399 A G NC Slfn5os 
 118824 118829 NA 11 83188993 C T NS Slfn4 
 118792 119160 NA 11 97700261 T C UTR Pcgf2 
 118790 118832 NA 11 102403687 A T NS Slc25a39 
 118813 118820 NA 11 119144127 TG T UTR Tbc1d16 
 105073 118762 NA 12 57364197 G A NS Mipol1 
 105084 118818 NA 12 84943390 C A UTR Arel1 
 105071 105088 NA 12 87773716 T C S Gm21319 
 105075 105077 118771 13 21722322 A G S Hist1h2bm 
 105077 118771 NA 13 21722331 T G S Hist1h2bm 
 105070 118776 NA 13 25209451 
TAAAA
C 
T UTR Dcdc2a 
 105071 118805 118808 13 30382122 C 
CCCC
CCCG 
UTR Agtr1a 
 118799 118803 NA 13 48967821 A G NS Fam120a 
 105075 118821 NA 13 67365318 A T UTR Zfp456 
 105080 118777 118779 13 72630732 A C S Irx2 
 118847 118775 NA 13 74050127 G T NS Cep72 
 105087 118841 NA 13 100223394 T C NS Naip5 
 105087 118841 NA 13 100223424 T C NS Naip5 
 105087 118841 NA 13 100223443 A G S Naip5 
 105076 118825 NA 14 8225665 G T UTR Acox2 
 118778 118784 NA 14 18204378 G T UTR Nr1d2 
 105075 105083 118766 14 27403249 TCAAA T UTR Arhgef3 
 118799 118764 119157 14 50425002 CCAT C NFSD Olfr739 
 118790 118794 118766 14 55519400 C A UTR Nrl 
 118868 118825 NA 14 117978631 T A UTR Gpc6 
 118810 118762 118779 15 8444175 A AAG UTR Nipbl 
 105085 118780 NA 15 76173066 C T NS Plec 
 105070 118800 NA 15 76304239 G A SG Oplah 
 118805 118804 118820 15 92341925 G A UTR Cntn1 
 118845 118848 NA 16 32142967 A T UTR Nrros 
 118818 118784 NA 17 19811890 A T NS Vmn2r103 
 105071 118771 NA 17 21733940 C T UTR Zfp229 
 118851 FCH NA 17 23359573 G A S Vmn2r115 
 118851 FCH NA 17 23359602 T C NS Vmn2r115 
 119158 118791 119160 17 35172151 G A NS Aif1 
 105080 118764 NA 17 46752154 C A UTR Cnpy3 
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 105077 119157 NA 17 74395668 G A NS Slc30a6 
 118791 118815 118830 18 15063301 TTCC T NFSD Kctd1 
 105072 118769 NA 18 45685164 A G NC 
A330093E
20Rik 
 118846 118833 NA 18 67289316 C T UTR Impa2 
 118819 118766 NA 18 84012957 C A UTR Tshz1 
 105070 118807 NA 19 32820156 T TA UTR Pten 
 118846 118847 NA 19 44550268 T C UTR Ndufb8 
 105072 105078 118762 19 55279482 
GCCT
GTTAC
A 
G NFSD Acsl5 
 119157 118829 NA X 73353972 C A SG Zfp275 
 118794 118816 NA X 73458848 A G NS Haus7 
 118805 118806 NA X 139236314 C T NS Mum1l1 
 119158 118791 NA X 143861625 A AG UTR Dcx 
#=sibpair number (Appendix 4-1); NS=nonsynonymous; S=synonymous,;SP=splicing; 
SG=stopgain; UTR=untraslated region; NC=non-coding RNA exonic; FSD=frameshift 
deletion; FSI=frameshift insertion; NFSD=nonframeshift deletion; NFSI=nonframeshift 
insertion 
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Notes 
 
This chapter is in preparation for submission under the title “ENU mutagenesis and 
whole exome sequencing to identify thrombosis modifier genes” by Kärt Tomberg, Ran-
dal J. Westrick, Emilee N. Kotnik, David Siemieniak, Guojing Zhu, Thomas L. Saunders, 
and David Ginsburg. 
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 CHAPTER V: Conclusions and future perspectives 
 
Limitations of traditional mapping strategies 
 
Suppression of the perinatal lethality of the F5L/L Tfpi+/- genotype with haploinsuf-
ficiency or complete loss of F8 (Chapter II) demonstrated the feasibility of our proposed 
sensitized ENU screen, and indeed a total of 168 viable F5L/L Tfpi+/- mice (henceforth 
‘rescues’) were obtained from the ENU screens described in Chapter II and Chapter IV. 
A subset of these rescues could represent the previously described low background 
survival rate (3.75% of the expected F5L/L Tfpi+/- conceptuses) [47]. However, the ob-
served number of rescues was higher in both screens (4.43% and 8.32% of the ex-
pected F5L/L Tfpi+/- conceptuses, p=0.22 and p=4x10-10), suggesting that at least a sub-
set of the rescues reflect the effect of authentic ENU-induced suppressor mutations. 
Before the introduction of NGS, traditional mapping of the loci responsible for 
specific phenotype(s) relied on genetic markers based on differences between two in-
bred mouse strains. Our initial ENU mutagenesis was performed on the C57BL/6J ge-
netic background, with the surviving G1 rescues outcrossed to 129S1/SvImJ strain to 
introduce genetic markers for mapping (Chapter II). 16 of the 98 rescues produced 
progeny with the F5L/L Tfpi+/- genotype, with 8/16 generating large pedigrees with >45 
rescue progeny (Table 2-4). The size of these pedigrees should have provided sufficient 
power to map an ENU-induced variant co-segregating with the rescue phenotype to a 
specific genetic locus. With the exception of the F3 locus for pedigree MF5L6 (Chapter 
II), no significant linkage peaks were identified for any of the remaining pedigrees by 
this approach. We suspect that complex strain modifiers introduced by outcrossing to 
129S1/SvImJ resulted in a high number of phenocopies obscuring mapping of the origi-
nal ENU-induced suppressor mutations within these pedigrees. Consistent with this hy-
pothesis, we observed suppression of the F5L/L Tfpi+/- phenotype by outcrossing to other 
strains (DBA/2J, A/J, BALB/cJ) in the absence of ENU. Our failure to identify one or 
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more significant linkage peaks within our mixed C57BL/6Jx129S1/SvImJ pedigrees (an-
alyzed individually and jointly) suggests complex interactions among multiple strain-
specific modifiers rather than a single modifier locus. Genetic background is known to 
influence multiple traits in mice, including engineered phenotypes such as ENU mutants 
[193, 194]. Such heterogeneous genetic background has previously confounded efforts 
to both map [175] and phenotype ENU-induced mutations [195]. However, the mixed 
strain background likely increased the mating efficiency in the ENU rescue pedigrees as 
pedigrees maintained on the pure C57BL/6J background exhibited significantly reduced 
fertility in comparison (p=0.02; Figure 5-1). This latter effect markedly limited our power 
to map the causal loci using ENU-induced variants in crosses maintained in C57BL/6J. 
To exclude possible effects from linked variants and demonstrate causality for a 
mapped ENU-induced mutation that co-segregates with the lethal phenotype, a valida-
tion using an independent allele is desirable. In Chapter II we identified an ENU-induced 
variant in the Actr2 gene (Actr2R258G) that co-segregated with the rescue phenotype in 
one of the pedigrees. However, an independent loss-of-function allele failed to validate 
the rescue phenotype. Possible explanations include a linked unidentified variant (ENU, 
de novo or mixed strain variant) as the causal mutation or a unique gain-of-function re-
sulting from the ENU-induced R258G variant in Actr2. We are currently exploring the 
latter possibility by generating an independent knock-in allele of Actr2R258G using the 
CRISPR-Cas9 system [196]. A similar validation approach is also being applied to the 
Plcb4R335Q variant identified in pedigree 13 (Chapter IV) with independent knock-in and 
knock-out alleles for the Plcb4 gene. 
 
Mutation burden approach in a dominant ENU screen 
 
Recent advances in high throughput sequencing and genome editing, in addition 
to the limitations of pedigree-based mapping strategies discussed above, led us to test 
the mutation burden in 107 rescue mice by WES, as described in Chapter IV. The 
strengths of this approach include the potential to uncover all or most genes for which 
haploinsufficiency will rescue the sensitized phenotype. This approach does not require 
the phenotyped mice to survive past genotyping, be fertile, or produce pedigrees and 
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therefore can expand dominant ENU screening strategies to multiple phenotypes such 
as developmental abnormalities and sterility that could not be addressed with the 
traditional approach. Also, it substantially reduces the number of required mouse cages 
and experimental time. 
However, the mutation burden analysis introduces certain limitations. Currently, 
this approach is restricted to protein coding variants, as our knowledge of the functional 
significance of non-coding/regulator variants is still limited. It is particularly difficult to 
assess the “harmfulness” of a non-coding variant as well as to assign that effect to a 
specific target gene or genes. Also, the majority of phenotype causing ENU variants 
have been mapped to coding regions [197]. In addition, only genes acting through a 
loss-of-function mechanism will be readily detected, as gain-of-function mutations are 
generally restricted to a single or small number of specific substitutions. To increase 
screening resolution from gene level to a single amino acid/nucleotide level would 
require much higher and currently unrealistic numbers of mice. 
The power of the mutation burden analysis is directly associated with the number 
of mice screened. The more mice screened, the better the distinction between 
mutations accumulating within functionally important genes and the background 
mutations in all other genes. The estimated number of screened mice required for 
obtaining an ENU mutation in a particular gene is approximately proportional to the size 
of the coding region of that gene. Assuming the published ENU mutation rate of ~1.5 
mutations per megabase (Mb, see Introduction for details), the largest gene in the 
mouse genome (Ttn, ~0.1 Mb coding region) should require screening of less than 10 
mice on average to obtain one ENU-induced mutation. A medium size gene (~1200 bp 
coding region) requires screening ~500 mice, whereas Sln (93 bp coding region) would 
require analysis of more than 7,000 mice on average to be hit once by ENU. With 
analysis of approximately 20,000 mice, the entire coding genome should be saturated 
by multiple mutations, with an average of ~3 independent mutations in the smallest 
genes, and ~3000 mutations in Ttn. 
Here, we screened approximately ~2,500 conceptuses carrying the lethal F5L/L 
Tfpi+/- genotype (total from screens in Chapter II and Chapter IV) and identified 3481 
potentially harmful variants in 107 WES mice (~32.5 variants per mouse), which 
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corresponds to a mutation rate of 0.96 per Mb. Assuming this mutation rate, we on 
average targeted genes with a coding region of 1250 bp or larger (~10,000 genes) with 
at least three independent potentially harmful mutations, giving us power to theoretically 
test enrichment in ~48% of the genes in the mouse genome. However, this estimate is 
further limited by the fact that we did not have access to WES data from all 186 
identified rescues. In addition, even if the mutation had suppressor potential in the 
screen, it could only act if the context of other mutations would facilitate it. For example, 
if the suppressor variant was co-induced with another harmful variant in an essential 
developmental gene, the latter would define the phenotypic outcome. The lack of 
coverage for smaller genes might explain why we did not achieve significant enrichment 
for mutations in the F3 gene (882 bp coding region) identified as a modifier gene in 
Chapter II. The enrichment for mutations in F8, shown in Chapter II to suppress the 
lethality of F5L/L Tfpi+/-, was further limited by its location on the X chromosome, and thus 
only female offspring will inherit ENU-induced mutations from the mutagenized G0 male. 
Of note, the number of exomes examined in the current screen does not provide 
sufficient power to exclude any genes as modifiers based on significant 
underrepresentation within the data set. 
Identification of 12 potential candidate genes from a screen with ~25% genome 
coverage (rough estimation taking into account the above mentioned limitations), 
suggest the presence of ~30-40 additional modifier genes that could be captured with 
genome wide coverage. The number of modifier genes could be much larger when also 
considering genes with moderate penetrance, requiring even higher coverage for 
identification. While still preliminary, the CRISPR-Cas9 validation experiments suggests 
that this sensitized forward screen coupled with the burden analysis approach has 
enabled us to identify previously unknown modifiers of thrombosis. 
Variation in these genes in humans could explain a significant portion of the 
incomplete penetrance and variable expressivity among patients with FVL, offer new 
insights into the overall regulation of hemostasis, and facilitate the development of 
future novel therapeutic interventions.  
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Future perspectives for current screen 
 
Independent alleles for 6 candidate genes 
Out of 39 progeny from the CRISPR-Cas9 targeting experiment (Chapter IV), 36 
mice carried one or more targeted alleles in Itgb6, Cpn1, Sntg1, Ces3b, C6, and Arl6ip5 
(Figure 5-2). Two different alleles per each gene were maintained for further analysis 
(Figure 5-3; Table 4-1). Currently, most of these alleles co-exist with other CRISPR-
Cas9 induced mutations in these mice and one or more outcrosses will be required to 
isolate each of the alleles. Once isolated, each allele will be tested for rescue of F5L/L 
Tfpi+/- lethality to validate the corresponding gene as an authentic suppressor. 
All validated genes will be further subjected to functional studies. While the 
particular experiments will vary depending on existing information about each candidate 
protein’s function and expression pattern, initial characterization of these CRISPR-
Cas9-edited alleles will be similar to experiments described for the Nbeal2 allele in 
Chapter III. We will assess the predicted effect of the deletion at both mRNA and protein 
levels in relevant tissues for mice heterozygous and homozygous for the deletion. 
Additionally, mice will be observed for deviations from Mendelian segregation and gross 
phenotype changes. Complete blood counts and other assays (e.g. blood clotting times) 
will be applied to evaluate the thrombotic state of these mice. The ultimate goal will be 
to understand how the candidate gene interacts with the coagulation system and affects 
thrombosis. 
 
Investigating overlap with human VTE studies 
The coagulation cascade is well conserved between humans and mice and the 
latter have served as a useful model to study VTE [198]. None of the candidate genes 
identified in Chapter IV have been previously reported to associate with significant 
signals in previous human VTE GWAS. Similar to other complex traits, the underlying 
genetic variants contributing to VTE range from rare alleles with large effects such as 
loss-of-function alleles in antithrombin III [15] to common variants with only moderate 
associated risk like non-O bloodtype (OR≈1.5) [199]. Common risk alleles for VTE have 
been identified by multiple GWAS efforts combined in a recent meta-analysis [26]. While 
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overlap in genes harboring rare and common variants is theoretically possible, no 
common risk alleles have been identified for a number of known genes that segregate 
with familial VTE such as SERPINC1, PROS and PROC (encoding antithrombin III, 
protein S, and protein C, respectively; see Introduction for details). Although ENU-
induced rescue variants in our screen have a large effect on the sensitized mouse 
phenotype, we explored potential overlap between the candidate genes and common 
risk alleles identified by GWAS. We obtained the p-values for all available variants 
within the candidate genes’ human orthologous loci ±1Mb from the INVENT consortium 
that published the largest VTE meta-analysis [26]. As expected none of the single 
nucleotide polymorphisms (SNP) in those regions reached genome-wide significance. 
However, the lead SNP (rs72812220) at the Fabp6 gene locus had a suggestive p-value 
of 1.28x10-6 (Figure 5-4). 
Overlap of the identified candidates and rare alleles with large effects in VTE 
patient populations would be theoretically more interesting and relevant given the lack 
of an obvious signal in GWAS. Unfortunately, WES/WGS has not been applied to a 
large VTE patient cohort to date but targeted sequencing of a few candidate genes has 
shown an enrichment of rare alleles in VTE patients [200]. Our lab is currently analyzing 
WES from ~400 VTE patients and ~7,000 controls, which should provide a powerful 
data set to compare with our mouse data. 
The six candidate genes identified in Chapter IV (Arl6ip5, Itgb6, C6, Cpn1, Sntg1, 
and Ces3b) have been reported to exhibit a wide range of functions in diverse tissues 
and may identify multiple biological pathways that influence overall hemostatic balance. 
C6 is a component of the complement system and has been linked to endothelial cell 
activation and thrombosis. Mice deficient in C3, C5, or C6 were reported to be resistant 
to thrombosis induced by antiphospholipid antibodies [201]. Cpn1 encodes the active 
subunit of Carboxypeptidase N (CPN), which has been shown to reduce fibrinolysis by 
decreasing cellular plasminogen binding [202, 203]. Haploinsufficiency for CPN could 
increase fibrinolysis leading to enhanced dissolution of F5L/L Tfpi+/- associated thrombi. 
Itgb6 encodes the beta subunit of integrin αVβ6. While a number of other integrins (e.g. 
α1β1, α2β6, αIIbβ3) have been shown to play important roles in platelet adhesion and 
aggregation, αVβ6 has been primarily associated with enhanced fibrosis [204]. Arl6ip5 
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is a negative regulator of intracellular protein trafficking from the endoplasmic reticulum 
(ER) [205]. Although, not yet associated with known hemostatic proteins, Arl6ip5 could 
influence the transport of key coagulation proteins, since the majority are either 
secreted or cell surface bound. For example, combined deficiencies of coagulation 
factors V and VIII result from a defect in an ER-Golgi transport system [206]. Less is 
known about Ces3b, Sntg1, and Plcb4 and their potential role in thrombosis. Ces3b is a 
member of a large family of carboxylesterases but its function has not been investigated 
while Sntg1 is only known to encode a brain specific protein [207]. Plcb4 encodes 
phospholipase C, beta 4 and has been recently associated with auriculocondylar 
syndrome [208]. 
 
Opportunities beyond the current screen 
 
Alternative thrombosis mutagenesis screening strategies 
There are many other possible ways to set up a mutagenesis screen for a throm-
botic phenotype in mice. While a non-sensitized dominant ENU mutagenesis screen 
(reviewed in Introduction) for thrombosis would be more direct, with all G1 progeny be-
ing informative, there are two major challenges with this approach. First, an effective 
screen requires an assay that would serve as a proxy for the phenotype of interest while 
feasible to be tested in hundreds to thousands of animals. Directly screening of mice for 
a rare thrombotic event somewhere in their vasculature is unfeasible. An alternative 
would be measurement of various thrombosis biomarkers in plasma, such as D-dimer. 
In addition, there is a possibility of not identifying any dominant ENU-induced mutations 
that cause thrombosis without provocation. An early ENU screen by Bode et al for hy-
perphenylalaninemia [78] failed to identify a causative dominant mutation in 7000 
screened mice, illustrating this potential risk (reviewed in Introduction). In line with this 
concern, mice haploinsufficient for known autosomal dominant VTE risk factors such as 
antithrombin III and protein C are phenotypically normal without a thrombogenic stimu-
lus [209, 210]. 
A non-sensitized recessive screen (reviewed in Introduction) is more likely to re-
veal a phenotype based on the observation that most Mendelian disorders have a re-
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cessive rather than a dominant mode of inheritance. Recessive screens require a more 
elaborate mating scheme and much larger number of animals and have therefore been 
mainly executed by large centers where mouse mutants are screened for hundreds of 
phenotypes in parallel [83]. Phenotypes related to thrombosis, including the above-
mentioned D-dimer test and others, were measured as part of a recessive screen by the 
Jackson Laboratory Center for Mouse Heart, Lung, Blood, and Sleep Disorders [211]. 
However, the MGI database (informatixs.jax.org), lists only one mouse (hlb258) from 
that screen with a coagulation abnormality (in fibrinogen levels). While there are multiple 
explanations for why only one mouse was identified, the assay and the age of pheno-
typing play an important role. For example, complete depletion of antithrombin III [209] 
results in embryonic or perinatal lethality. Of course, hypomorphic alleles often present 
with a milder phenotype and therefore might be detected. 
A screen sensitized for lethal thrombosis addresses a number of the above chal-
lenges. First, survival is a straightforward phenotype that only required genotyping of 
the G1 mice. Second, a sensitized background may be necessary to unmask the effect 
of haploinsufficient protein levels that without the background would not display a phe-
notype. There are many alternative lethal thrombosis models that could be used for a 
sensitized screen. For example, Tfpi-/- mice die around embryonic day 10.5 [92], which 
theoretically makes the screening for survival already possible at birth and also might 
screen for genes influencing a different aspect of the coagulation system. Genetic sup-
pression of TFPI lethality has been previously described and demonstrates the feasibil-
ity of such a screen. For example, Tfpi-/- Par4-/- mice survive to adulthood [212], while 
partial rescue (until birth) is observed for mice additionally haploinsufficient or complete-
ly deficient for factor VII [213]. Mice exhibiting very low levels of tissue factor also par-
tially rescue Tfpi-/- lethality [214]. In addition, low tissue factor levels also prolong em-
bryonic survival by ~2 days for antithrombin III null mice [209] while factor XI deficiency 
has been shown to rescue protein C deficiency [215]. 
 
Alternative mutagenesis strategies 
While ENU has proven to be a valuable mutagen in mouse screens, it has a 
number of limitations. First, the requirement for three generations of mice to test for 
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complete deficiency of a screened gene limits the utility of recessive screens. Also, 
while ENU-induced point mutations may occasionally reveal interesting gain-of-function 
variants and hypomorphic phenotypes, typically ~30% of coding ENU variants result in 
loss-of-function alleles and the majority of the coding ENU-variants (>60%) will have no 
functional consequence (Introduction). 
The emergence of CRISPR-Cas9 may enable new screening approaches. 
CRISPR-Cas9 can efficiently generate null (homozygotes and compound 
heterozygotes) and heterozygote, as well as mosaic animals. The diversity in events 
induced by CRISPR-Cas9 is potentially larger. In our CRISPR-Cas9 data, we have 
observed INDELs, SNVs, large deletions as well as inversions, with a higher proportion 
of coding mutations predicted to be harmful compared to ENU. CRISPRs could be 
designed to target the complete genome or just a subregion/subset of genes. 
While genome-wide CRISPR screens have already proven successful in cell 
culture [216, 217], there are a number of technical limitations that need to be addressed 
before such screens become feasible for mice. First, the delivery of the CRISPR 
reagents into the mouse is currently limited to either zygote injections or embryonic 
stem (ES) cells. Zygote injections require highly skilled personnel and are time 
consuming, while the injection efficiency is usually very high. Targeting ES cells on the 
other hand produce chimeric animals and requires additional matings. Delivering 
CRISPR reagents to male spermatogonial stem cells is a potential alternative but has 
not yet been reported. A knock-in mouse expressing low levels of guide sequences 
targeting all >20,000 genes (or all random target combinations like hexamers) with a 
temporally controlled Cas9 gene (e.g. under a germ cell specific promoter) could serve 
as another potential strategy. 
Simultaneous targeting of multiple genes located on different chromosomes by 
CRISPR-Cas9 has been successful for us and others [218] but when two targeting 
sgRNAs are located on the same chromosome and in close proximity, large deletions 
(>1 Mb) rather than two independent targeting events are typically observed [219]. Such 
deletions could be used to generate a systematic deletion series to cover the entire 
genome. 20 gRNA pairs targeting 20 different chromosomes could be co-injected 
simultaneously. 300 different gRNA cocktails would be enough to cover the entire 
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genome with overlapping deletions and is a feasible number for zygote injections. This 
approach might be further complicated by the byproduct of homozygous deletions that 
will result in lethality if the deletion overlaps an essential gene. 
Recent advances in high throughput sequencing and gene editing technologies 
have tremendously expanded opportunities to apply forward genetic screen approaches 
for identification of underlying genetic risk factors for VTE and numerous other human 
diseases. This thesis provides examples of how to utilize these new technical advances 
for discovering novel genes involved in thrombosis. 
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Figure 5-1: Size distribution of ENU pedigrees from performed screens  
The ENU rescue pedigrees from the screen in Chapter II (old screen, n=16; Table 2-4) 
are significantly larger than the ENU rescue pedigrees from the screen in Chapter IV 
(new screen, n=13; Table 4-2).   
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Figure 5-2: Distribution of CRISPR-Cas9 induced events by targeted genes 
A) Distribution of CRISPR-Cas9 induced events in total of 39 mice. B) Complementary 
Venn diagram depicting which combinations of the five targeted genes were present in 
mice (excluding the one mouse with targeting events in all six genes including C6).  
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Figure 5-3: CRISPR-Cas9 induced alleles 
The overview of CRISPR-Cas9 induced deletion alleles maintained for validation for A) 
Arl6ip5 B) Itgb6 C) C6 D) Cpn1 E) Sntg1 and F) Ces3b. Details of the alleles are pro-
vided in Table 4-1.  
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Figure 5-4: VTE GWAS results at the Fabp6 gene locus 
Regional association results were plotted using LocusZoom software [220]. The plot 
shows all SNPs tested for association with VTE within the Fabp6 gene ± 1Mb. The lead 
SNP in this region (rs72812220) is located in the 3rd intron of Fabp6 gene and has a p-
value of 1.28x10-6. 
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 APPENDICES
 
Appendix 2-1: All used primer sequences 
PRIMER NAME PRIMER SEQ 5'->3' 
F3_GENOTYPING_F CTCCCATTTCTTTTCCTCCTC 
F3_GENOTYPING_R GGGGCGTTTGTAAATGGCGG 
F3-NEO CCTGACTAGGGGAGGAGTAG 
UPSTREAMF3_1F GACACGCCATCTGTCCAGTA 
UPSTREAMF3_1R CAAAAAGGTGGGCAGCTAAG 
UPSTREAMF3_2F AGCAGCTCCTGCAACTCACT 
UPSTREAMF3_2R GCACAGAGGAAGAGCAAAGG 
UPSTREAMF3_3F CACAGGGGCCTTTATTTTGA 
UPSTREAMF3_3R AAAGTAGGGCAGGGGAAAAA 
UPSTREAMF3_4F ACCATCTTTGAAGCCCAGAA 
UPSTREAMF3_4R AGGATGGAGCAGAACTGAGG 
UPSTREAMF3_5F CTGTCCTGGGAAACCTGTGT 
UPSTREAMF3_5R CATGCACCACTGCACCTATC 
UPSTREAMF3_6F CCAGGACAGCCTCGAACTTA 
UPSTREAMF3_6R AGAAAATGGCTGCTGTGCTT 
UPSTREAMF3_7F TGGCCTAGCAACTGTATTTTGA 
UPSTREAMF3_7R CAGAAGCTGCTCAGTCATGG 
UPSTREAMF3_8F GTCCTTTTCCTGGGAAGACA 
UPSTREAMF3_8R CAGTTTACAAGCACCCAGGAG 
UPSTREAMF3_9F GCTTCAGCGACAAGAGTTCA 
UPSTREAMF3_9R ACTCCCAACTGAGCAAAGGA 
UPSTREAMF3_10F TCTTCACGCATGTCTGCTTT 
UPSTREAMF3_10R TGCTTTGTACAATCTTCCTTCC 
UPSTREAMF3_11F TGAGTGGGACGACAGCTTAG 
UPSTREAMF3_11R CACTTGCAAGCTTTGGGTTT 
UPSTREAMF3_12F TGTCGAGCAAATGCTACCAG 
UPSTREAMF3_12R GCAGTGGCTAGCAGATCATTC 
UPSTREAMF3_13F TCTCAGGCTTCATGTTGCAG 
UPSTREAMF3_13R CCCCTCCTGTAGGAAACTCC 
F3GENE_1F GGTCTCCGCAGTACCTGGAT 
F3GENE_1R TTCTCAGGACCAATGCCACT 
F3GENE_2F GCTCCTGTAGCGTAGCCAAC 
F3GENE_2R CTTCAAGGGCCCAACATCTA 
F3GENE_3F GCCCTGAGGATTTGAATGAA 
F3GENE_3R TGTCACATGGTGGGATGCTA 
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F3GENE_4F TCAGGCAAGACAGAGTGCAT 
F3GENE_4R CATACTGCAATCCGTGGAAA 
F3GENE_5F ACGTGTGTGGGGGACTAGC 
F3GENE_5R CGCTTTCTCTGGAATGCCTA 
F3GENE_6F CACACCCTCTGCTCTTGACA 
F3GENE_6R TGTAGGATGGCCTGGAACTC 
F3GENE_7F GCCAGGTTAAAACCAAAGCA 
F3GENE_7R CACTGCTTCAGGGCAGTGTA 
F3GENE_8F CACTGTGGTCACTGTGTTGCT 
F3GENE_8R GAAACCAAAAGCTTGCCAAA 
F3GENE_9F CCAATGCCCTTTTCTGGTTA 
F3GENE_9R GCATGCATGAACACACACAC 
F3GENE_10F GACAGCTCTCGGGAACAAGT 
F3GENE_10R CAAGCTGTGCAGGGATTACA 
F3GENE_11F TGGTGATGCAGGTCAGTTGT 
F3GENE_11R TGCCTTGACTAATGGCAATG 
F3GENE_12F AAGGTGGTCACCATTGAGGT 
F3GENE_12R TATGGACTGGATGGACAGCA 
F3GENE_13F TCACACTGACTGCTGGTGGT 
F3GENE_13R GGGCTCTGGGTGAAGTCATA 
F3GENE_14F TGCTGTCCATCCAGTCCATA 
F3GENE_14R ACATTCAGCAGGGGAGTCAC 
F3GENE_15F TGGGTCAAACAAAACACTGC 
F3GENE_15R AAAGAACCCAGCACCTCCTT 
F3GENE_16F TTTGTGCCTCTTCTGTGTGG 
F3GENE_16R TCTGCTTAGCGCTCTTCTCC 
F3GENE_17F ATTCTGCTGGGCTCTTTGAA 
F3GENE_17R GAGCTGGGTTTGTTTGCTTC 
F3GENE_18F GGAGATCTGGAACTCGCTTG 
F3GENE_18R TGTCTGTGGTCGAGAAGCAC 
F3GENE_19F TCGGAGGCTCAGACTTTGTT 
F3GENE_19R TAAAAACTTTGGGGCGTTTG 
F3GENE_20F TCCCGTTTCTTTTCCTCCTT 
F3GENE_20R CCCCTGGTCTGATGAAAGAA 
F3GENE_21F CACACACACCAAGGAGATGC 
F3GENE_21R AGGGGACAGATGGGGATTAC 
F3GENE_22F GTGTGTGAGCCTGCCATCTA 
F3GENE_22R ACACATCCCACACCCAATCT 
F3GENE_23F GGATGAAGGGCAATTGAGAA 
F3GENE_23R ATGCATTAGAGGCTGGGAAG 
F3GENE_24F AGATTGGGTGTGGGATGTGT 
F3GENE_24R TGGTGACGGTCTTGTAGCTG 
F3GENE_25F CCTGGTAGCCATCACTCACA 
F3GENE_25R GCATGCTGTGGAGAATCAAA 
F3GENE_26F CATCTGCAAGGAAGGGTCTC 
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F3GENE_26R GGGGTCCCCAATATGAAGAT 
F3GENE_27F CAAGCACGGGAAAGGTAAGA 
F3GENE_27R ATTGACGCACGAGGGATTAG 
F3GENE_28F GTATGTGCTTGCGTGTGTGA 
F3GENE_28R GGAAGTGACCAAGGGAACAA 
F3GENE_29F CAAAATAGCCCAGGAAGCAG 
F3GENE_29R GCTACTGCCCCCTTAGTCGT 
F3GENE_30F TTGTTCCCTTGGTCACTTCC 
F3GENE_30R ATGCCCCTTGGTCTCTTTCT 
F3GENE_31F TAGCTATGGCCTGGCTCTGT 
F3GENE_31R TGATGGTGGAGACGAAGAGA 
F3GENE_32F TTCTGCCTTCTTGCCTCTGT 
F3GENE_32R ACCACTGCTCCCACAATGAT 
F3GENE_33F CCCCAGCCAACTACTGTCTC 
F3GENE_33R ATGTTGCACAGTTCCCATCA 
F3GENE_34F CGAGCCTCCATGTTGACTTT 
F3GENE_34R AATCACAAAGATGCCCCAAG 
F3GENE_35F CCAGCTAACGCTTTGATTCC 
F3GENE_35R TTGTCTCAATTCCCAATCACC 
MFF_OF CACTCATTGCTGGGTCCTTT 
MFF_OR ATTTCCAAGTGCAACCAAGC 
MFF_IF CCCTCTGCTCGGATTGATAC 
MFF_IR TATGCAACAAAGTGGCAAGG 
DGKQ_OF TGTCCAAAACTGTGCCAGAC 
DGKQ_OR CCACACAGGTTCCACCTTTT 
DGKQ_IF CCACAGGCTTCAGTCAACAA 
DGKQ_IR ACAGGTGGGCTTAGTCATCG 
ANPEP_OF TAGCTTCAGAGCTGGGCTTC 
ANPEP_OR GGGCTGTGGTTTCACAACTT 
ANPEP_IF CTCCAGAGGCTGGAGACTTC 
ANPEP_IR GGTGAGCACTTAACCCCAAA 
NUMA1_OF TCCCAAACATTTTGCCATTT 
NUMA1_OR TTTTCTTGCAAGGGAAAGGA 
NUMA1_IF CTTACCCGCCACACATTTTC 
NUMA1_IR CTGGACCTGACACGGACTCT 
BAG2_OF CTGTGTCTGCCAACACTGGA 
BAG2_OR GTTGCTGACGTGGGAAGTTT 
BAG2_IF CCGGTGAATTTGAAGGCTAA 
BAG2_IR GACTGCCAACCGTCTGATG 
UGGT1_OF TCCCTAGCACTGCTTCCTGT 
UGGT1_OR GCAGAAGGCTTGGCTTATTG 
UGGT1_IF CGGGAAGGCATCTGAATAAA 
UGGT1_IR GACGCTGAGACTGCATCAAG 
IL1R2_OF CCACCTAACCCAAGCCTCTA 
IL1R2_OR GGCTGCTATGGCTTGTTCTC 
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IL1R2_IF GTCAACCTATGGTGCCCTGT 
IL1R2_IR CCTCCACATTTTCTCCCAGA 
LZTFL1_OF TGAGTGCTCCTCAAGGAAGG 
LZTFL1_OR CAGAAAGTGGGGGAGTTAAGTG 
LZTFL1_IF AGTGACTGTGCCTTGCTGTT 
LZTFL1_IR TGTCATGATGTCGGTCTCTTG 
STAT2_OF TGTCCCATTGTCTGTCCTTG 
STAT2_OR GCCCTTGCATTTCCTATCAA 
STAT2_IF GACCAGGAGTTGCCATTGAT 
STAT2_IR AGGTCCTCAGGCAAATCTGA 
OLFR1373_OF CAGGGTGCATAATGGTTGTG 
OLFR1373_OR ACACCAGGGCCAAGAAGT 
OLFR1373_IF CACCTTCCAAAGCTGATGGT 
OLFR1373_IR GGGGGAGGGTATAGGGAACT 
ALOXE3_OF AATCGGTGCTGGGATCTATG 
ALOXE3_OR AAGTCTCAACCCTGCCCTTT 
ALOXE3_IF TGAGGCTTAGGGATGGCTTA 
ALOXE3_IR CATCTCAACACACGGTGGTC 
PDHB_OF ACTGGTCTTGAATGGGCAAC 
PDHB_OR GGGGCATCTAGTGAGGCTTA 
PDHB_IF GGCAGCTATGGCCTGTCTTA 
PDHB_IR CTGCATACCTGCACATTTGG 
MAPK8IP2_OF GCAGCCACACCCTATTTGTT 
MAPK8IP2_OR TACTTCATGGCGCTCCTCTT 
MAPK8IP2_IF ACAGGCACTTGCTGGAGACT 
MAPK8IP2_IR CAGAGCAGGGAGTTGGGTTA 
CRYBG3_OF TGAGTCCTGGAAGTCTGCAA 
CRYBG3_OR GTCTCTCCTGTTTCCCGACA 
CRYBG3_IF ACTGGAGGTCGTTGGTTCAC 
CRYBG3_IR TGAGGCATTTGATGGAGACA 
MAP3K4_OF CTTCAGTGCTTTGTCCACGA 
MAP3K4_OR CCTCAGGAGACAAACCGTGT 
MAP3K4_IF TCCTCTGACTCGAGCCTCTC 
MAP3K4_IR AGCAGGTGAAGCGGATAATG 
CDC5L_OF CAAGAACTGCCACCACTTGA 
CDC5L_OR GCCTCCATTTATCTTTTTCTGC 
CDC5L_IF ACCGTGTTTAGTGCCCTCAT 
CDC5L_IR TGCCTGTGTGTAATCTTTTTCTG 
CYP2C39_OF GACAACAGGGCAGATGGAGT 
CYP2C39_OR CTGCCCTCTGGACCATAAAG 
CYP2C39_IF AACACTAGTGACCTTAACCAAGGA 
CYP2C39_IR CACGGGGTATGTTGTTAGGG 
PPRC1_OF GACCCAGGAGAACAGACCAA 
PPRC1_OR CCCTGCATCCTCTCTTCATC 
PPRC1_IF TGTTGCAAAGCTACCTGCTG 
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PPRC1_IR AAAGGAGGCACAGACGAGAA 
MEX3B_OF CCTGGCTTCCAGGTTGTAAA 
MEX3B_OR GTTGCGATAGCTGGAGAAGG 
MEX3B_IF GGAGGAGCCTGTCTTTGTTG 
MEX3B_IR AGATCAAAGCCCACGTCTGT 
SMARCA4_OF TGGTGAGTGCCTCAGAGCTA 
SMARCA4_OR TGAACCCCAGGACCTAGTGA 
SMARCA4_IF TCTGTGTGGTCCCCTTTCTC 
SMARCA4_IR TTGCTAGCCTCCAGGCTCTA 
EGR2_OF GGAGGGCAAAAGGAGATACC 
EGR2_OR CTAGCCCAGTAGCGCAGAGT 
EGR2_IF AGTTGGGTCTCCAGGTTGTG 
EGR2_IR GCTTCAAGGACCAGGAGATG 
DCC_OF GAAGGAAGGCAACAGGATGA 
DCC_OR CTGGGGATTCATCTCAGCAT 
DCC_IF CTTTTCTCACCCCAAAGCAA 
DCC_IR GGAAAGACAGCCAGGACAAG 
A630007B06RIK_OF AGTGCCAAAGTGTCCCAAAG 
A630007B06RIK_OR TCGTCTGCTTGCTTCTCTTG 
A630007B06RIK_IF TTTGGGCAGAAAATGTGCTA 
A630007B06RIK_IR CAGTCACTCGATGGTGAGGA 
FBLIM1_OF TGGTCCAGTTTGCCACCTAT 
FBLIM1_OR GCACAATGGGTAGCTGGATT 
FBLIM1_IF GGCTCGCCACCTATGTTTT 
FBLIM1_IR ACCCCTGTCGGGAAGAGTAG 
KNTC1_OF GCCATTGAGAACACGGACTT 
KNTC1_OR TGATTTATGGGAGGGTGCAT 
KNTC1_IF TCAGCCAAGAAGGTAAGCAAA 
KNTC1_IR TCATCGAGCCTCTAGCCTTT 
CUX1_OF GACCCTTTGATCAGGAGCTG 
CUX1_OR GGCTTGCCTAGAATTCACCA 
CUX1_IF GGCGACACATCAGTCTTTGA 
CUX1_IR GTGCAGCGTCTACACGACAT 
CCR1_OF GGAATGCCCCATTTTGTTTA 
CCR1_OR TGCTATGCAGGGATCATCAG 
CCR1_IF GACCTTCCTTGGTTGACACC 
CCR1_IR CTGCTCAGAAGACCCAGTGA 
RIC8B_OF GAACAGAAGAACCGGGACTG 
RIC8B_OR GCCTGGGAGCTACTCTCAAA 
RIC8B_IF CCCTGAATGGAATGGAGAGA 
RIC8B_IR ACAAATGCCCAAGTCTGACC 
GRIA1_OF GAAGGCCAACTGATTTTCCA 
GRIA1_OR TGGCATCACATTTTCATGGT 
GRIA1_IF AGCTGATTTGCTGGACTGGT 
GRIA1_IR GTCCCACGTTTGACTTGGAT 
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DHX8_OF CAGTGCTCTCGTTGTGCTTT 
DHX8_OR CTTCCCTTGCCACCACAG 
DHX8_IF ACCCAGACAGACCCACTCAC 
DHX8_IR CCATGGAACACTGTCTCTGC 
ANKRD55_OF CCACCTTTGACAGTGTCGTG 
ANKRD55_OR CAGCCCATTCAGGGTAGAAA 
ANKRD55_IF CCACCAATCAGAACCCAGAG 
ANKRD55_IR TGGCTGTAGTTCCCGTTTTT 
WDFY4_OF CACACACACACATGCTTGCT 
WDFY4_OR CCCCACACACACACCTGTTA 
WDFY4_IF GGCTTGCTCACCCAATAACT 
WDFY4_IR GGGCACTTTGGTGTACCACT 
RUNX1_OF AGTTTCCCTCCGGGATTCTT 
RUNX1_OR GGCAGTCTAGGAAGCCTGTG 
RUNX1_IF GATGGCGCTCAGCTCAGTAG 
RUNX1_IR CTACTCTGCCGTCCATCTCC 
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Appendix 4-1: Overview of WES mice 
SeqID 
Mouse 
ID 
Sex Days Gen 
Sibling 
sets 
Sample 
origin 
Seq Capture 
Mean 
Coverage 
82305* 82305 M 300 G2   S2 CGT A 31.79 
105065 33586 M 884 G2  S1 NGC R 60.54 
105066 39748 M 585 G3  S1 NGC R 67.99 
105068 53882 F 626 G1  S1 NGC R 61.91 
105069 55922 M 750 G4  S1 NGC R 64.52 
105070 57258 M >100 G1  S1 NGC R 60.54 
105071 57372 F 263 G1  S1 NGC R 61.03 
105072 82086 F 227 G1 11 S2 NGC R 65.52 
105073 82458 M 358 G1  S2 NGC R 62.92 
105074 82620 F 337 G1  S2 NGC R 65.03 
105075 82723 M 416 G1 4 S2 NGC R 59.27 
105076 82841 F 404 G1  S2 NGC R 46.35 
105077 83071 F 232 G1  S2 NGC R 56.26 
105078 83188 F 365 G1 5 S2 NGC R 59.5 
105079 83217 M 258 G1 7 S2 NGC R 61.05 
105080 83230 F 362 G1  S2 NGC R 63.49 
105081*
* 
83457 M 437 G1 4 S2 NGC R 62.24 
105082 83737 M 663 G1  S2 NGC R 60.65 
105083 83796 M 561 G1 8 S2 NGC R 67.12 
105084 83875 M 396 G1  S2 NGC R 60.78 
105085 83882 M 255 G1  S2 NGC R 58.38 
105086 88129 M 493 G1  S2 NGC R 61.07 
105087 96868 M 659 G1  S1 NGC R 57.75 
105088 98420 F 681 G1  S1 NGC R 55.54 
118761 60654 M 416 G1 10 S2 NGC R 81.36 
118762 60693 F 22 G1 11 S2 NGC R 78.75 
118763 60712 M 28 G1 10 S2 NGC R 80.03 
118764 60716 F 50 G1  S2 NGC R 80.04 
118765 82147 M 346 G1 10 S2 NGC R 81.18 
118766 82194 M 31 G1 1 S2 NGC R 78.53 
118767 82395 F 17 G1 1 S2 NGC R 80.62 
118769 82744 F 57 G1 5 S2 NGC R 82.19 
118770 83010 F 65 G1 2 S2 NGC R 79.06 
118771 83140 F 22 G1  S2 NGC R 80.46 
118772 83164 M 36 G1 6 S2 NGC R 141.92 
118773 83411 F 23 G1 2 S2 NGC R 81.77 
118774 83520 M 17 G1 3 S2 NGC R 78.04 
118775 83619 M 46 G1 12 S2 NGC R 79.34 
118776 83685 F 35 G1 7 S2 NGC R 79.45 
118777 83689 M 35 G1 7 S2 NGC R 82.98 
118778 83794 F 27 G1 8 S2 NGC R 80.53 
118779 83929 M 35 G1  S2 NGC R 88.99 
118780 83971 F 65 G1 3 S2 NGC R 102.62 
118781 88025 M 56 G1  S2 NGC R 79.16 
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118782 88041 F 43 G1 6 S2 NGC R 78.85 
118784 88262 M 252 G1 9 S2 NGC R 78.14 
118785 88503 M 25 G1 9 S2 NGC R 82.96 
118786 88547 F 26 G1 4 S2 NGC R 83.89 
118787 88955 F 26 G1 12 S2 NGC R 104.35 
118789 10177 F 363 G1 13 S2 NGC R 67.88 
118790 10178 M 39 G1 13 S2 NGC R 70.28 
118791 10382 M 469 G1 14 S2 NGC R 102.03 
118792 10451 M 47 G1  S2 NGC R 82.23 
118793 10562 M 22 G1  S2 NGC R 74.15 
118794 10653 M 30 G1 14 S2 NGC R 93.52 
118796 11082 M 76 G1  S2 NGC R 86.69 
118798 11241 M 337 G1 16 S2 NGC R 76.98 
118799 11468 M 20 G1  S2 NGC R 78.23 
118800 11477 F 23 G1 15 S2 NGC R 74.31 
118801 11478 F 23 G1 15 S2 NGC R 78.35 
118802 11600 M 31 G1 16 S2 NGC R 76.63 
118803 42885 F NA G1  S1 NGC R 82.93 
118804 45755 M 136 G1  S1 NGC R 85.15 
118805 42058 F 306 G1  S1 NGC R 78.88 
118806 51255 F >100 G1  S1 NGC R 72.66 
118807 51283 F NA G1  S1 NGC R 85.73 
118808 57931 M 34 G1  S1 NGC R 87.82 
118810 22721 M NA G1  S1 NGC R 83.76 
118812 76278 F 147 G1  S1 NGC R 76.84 
118813 76387 F NA G1  S1 NGC R 80.86 
118814 76526 F 24 G1  S1 NGC R 95.4 
118815 76824 M NA G1  S1 NGC R 79.79 
118816 76582 F NA G1  S1 NGC R 78.66 
118818 76989 M >100 G1  S1 NGC R 88.59 
118819 80493 M >100 G1  S1 NGC R 71.19 
118820 80821 F >100 G1  S1 NGC R 77.77 
118821 80840 F >100 G1  S1 NGC R 82.13 
118823 89285 F NA G1  S1 NGC R 83.55 
118824 89957 M NA G1  S1 NGC R 87.92 
118825 89965 M NA G1  S1 NGC R 79.96 
118826 90152 M NA G1  S1 NGC R 75.21 
118829 91310 M <100 G1  S1 NGC R 96.11 
118830 91570 M NA G1  S1 NGC R 95.28 
118831 96245 F 539 G1 17 S1 NGC R 80.34 
118832 96247 F NA G1 17 S1 NGC R 77.35 
118833 96440 M NA G1  S1 NGC R 87.01 
118836 96839 F NA G1  S1 NGC R 95.44 
118838 98172 F 860 G1  S1 NGC R 101.62 
118839 98313 M NA G1  S1 NGC R 103.59 
118841 98491 M >100 G1  S1 NGC R 77.99 
118844 2164 M 770 G1  S1 NGC R 82.43 
118845 2216 F NA G1  S1 NGC R 80.36 
118846 2383 M NA G1  S1 NGC R 87.26 
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118847 2730 M NA G1  S1 NGC R 77.88 
118848 3000 M NA G1  S1 NGC R 86.7 
118851 5401 F NA G1  S1 NGC R 94.12 
118852 6654 M NA G1  S1 NGC R 78.29 
118853 6927 M 24 G1  S1 NGC R 82.06 
118855 13019 F 66 G1  S1 NGC R 91.97 
118858 14418 F 42 G1  S1 NGC R 85.67 
118868 24744 F 294 G1  S1 NGC R 78 
118872 29035 F 56 G1  S1 NGC R 82.41 
118875 33095 M 46 G1  S1 NGC R 86.25 
119157 82522 M 346 G1  S2 NGC R 73.89 
119158 10020 F 387 G1  S2 NGC R 85.87 
119159 10722 M 442 G1  S2 NGC R 86.95 
119160 11187 M 298 G1  S2 NGC R 77.46 
FCH*** 11954 M 158 G1 16 S2 BGI A 22.25 
Gen=Generation; Seq=Sequencing platform; F=Female; M=Male; S1=screen 1; 
S2=screen 2; CGT=Centrillion Genomics Technologies; NGC=Northwest Genomics 
Center; BGI=Beijing Genomics Institute; A=Agilent SureSelect Mouse All Exon Kit; 
R=Roche/NimbleGen SeqCap EZ System 
*Used for Pedigree 1 analysis; excluded from burden analysis as G1 mouse (60654) 
was included instead 
**Used for Pedigree 6 analysis 
***Used for Pedigree 13 analysis 
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Appendix 4-2: All used primer sequences 
Primer Name Primer sequence (5'->3') Experient 
4931408C20RIK_OF AAGGCAAATCATAGGCTGCT PEDIGREE 1 
4931409C20RIK_OR ATTGTGGGGATCAAGCAGAG PEDIGREE 1 
4931410C20RIK_IF TTCACACCTGTCCTTCTAGGG PEDIGREE 1 
4931411C20RIK_IR TATGGAAAGCCAGGAAGTGG PEDIGREE 1 
PFDN2_OF GCCTTTGTAACTTGCCATCC PEDIGREE 1 
PFDN2_OR TTCTGACTCAGGGATCCACA PEDIGREE 1 
PFDN2_IF GCTGGCTTTAATCGCCTTC PEDIGREE 1 
PFDN2_IR CACAGCCAACAACTCCTCAC PEDIGREE 1 
SEC16A_OF AAGAGGCTGCTGAGAAGCTG PEDIGREE 1 
SEC16A_OR CCCTCCCAAGGTAGGAGAAG PEDIGREE 1 
SEC16A_IF ATTGCCAGCAGGGCTACTAA PEDIGREE 1 
SEC16A_IR AGTGCAGGCAAGTTCTGGTT PEDIGREE 1 
PLD1_OF CCCCACACAGTTCAAGGTCT PEDIGREE 1 
PLD1_OR GGTACGCTCCCCATACAAAA PEDIGREE 1 
PLD1_IF AGTGAGGAGCCTGCTGAGTC PEDIGREE 1 
PLD1_IR TTCAAAGCTGATCCCAGGTC PEDIGREE 1 
KPRP_OF GGCCACAGTTGGTGTAGGAA PEDIGREE 1 
KPRP_OR GACCATGTGTGACCAGCAAC PEDIGREE 1 
KPRP_IF ATTGAGGAGTGCAGCTACCG PEDIGREE 1 
KPRP_IR GGAAGCTCCATGTGAGATGA PEDIGREE 1 
NDST4_OF GCAGTTGGAGAATTGGCTCT PEDIGREE 1 
NDST4_OR TTAAAAATGCTGCCCAATGA PEDIGREE 1 
NDST4_IF TCATGCACACACACTGTGAAA PEDIGREE 1 
NDST4_IR CCGTGATGATGGTTCCTCTT PEDIGREE 1 
GSTCD_OF TCTTGAGGGCTCAGCTTCAT PEDIGREE 1 
GSTCD_OR CAGGAACCGGGTGTAAAAGA PEDIGREE 1 
GSTCD_IF GCAAACAGCAATTCTGGACA PEDIGREE 1 
GSTCD_IR CATGCAGAGTGGGGAAAGTT PEDIGREE 1 
MMEL1_OF TCTGAAAAACCGTCCTCACC PEDIGREE 1 
MMEL1_OR CCGAGTGCCAGCCATATTAG PEDIGREE 1 
MMEL1_IF ATGTTCCCTTCTGTGCTGGA PEDIGREE 1 
MMEL1_IR GGGTCTCACCTTCAGACCAA PEDIGREE 1 
KCNH2_OF ATGCCGAGAATGAGGAAAGA PEDIGREE 1 
KCNH2_OR GCAGATGTGCTGCCTGAGTA PEDIGREE 1 
KCNH2_IF AATGCCTCTTCCAGCTCCTT PEDIGREE 1 
KCNH2_IR CCTGCTGCTGGTCATCTACA PEDIGREE 1 
TMCC1_OF AGCTTGAGCTTCGCGTTAAA PEDIGREE 1 
TMCC1_OR GTCGTCTCCAAACCCAGAGA PEDIGREE 1 
TMCC1_IF ACTGCTTTGCTGACTGACGA PEDIGREE 1 
TMCC1_IR GGAAAGGCTTTAGGGGTGAT PEDIGREE 1 
D6WSU163E_OF CTACCCTCGACAGCTCTGAA PEDIGREE 1 
D6WSU163E_OR CGGAAGTGCAACGAAATACA PEDIGREE 1 
D6WSU163E_IF TGAATCCCTCAGGAAAGACAA PEDIGREE 1 
D6WSU163E_IR CACCATCATTCCCTGATAGGA PEDIGREE 1 
TAS2R131_OF AATTTGCCAGTGACCTTCCA PEDIGREE 1 
TAS2R131_OR ACATTTCCCATCCCCTTTTC PEDIGREE 1 
137 
TAS2R131_IF TTAATTGGCCTGCTCATTGG PEDIGREE 1 
TAS2R131_IR GGAGATTGAGAGGTGTGCTTG PEDIGREE 1 
ZFP939_OF GTTCACAGTGCAGGAAAGCA PEDIGREE 1 
ZFP939_OR GGTATGCGTGAGGGAGAAAA PEDIGREE 1 
ZFP939_IF AGCAAGTCTGGGCTTACTGC PEDIGREE 1 
ZFP939_IR CAGGGATTCTCCCTTGTTTG PEDIGREE 1 
VPS33B_OF GTCGGAAACCAGAGATTGGA PEDIGREE 1 
VPS33B_OR GCAGCGGTCCTGAGTAAATC PEDIGREE 1 
VPS33B_IF CTGGTGAAGTTGGGGTCCTA PEDIGREE 1 
VPS33B_IR AGCACCTTCAGGCTCTTGTC PEDIGREE 1 
VMN2R78_OF TCACTCATTCACTCACTCATGTTT PEDIGREE 1 
VMN2R78_OR CAATTGAAAATGAAAACTGTCAAA PEDIGREE 1 
VMN2R78_IF GAGATCGTTCGGTGGCTTT PEDIGREE 1 
VMN2R78_IR AAGTTTGAAACATGCAACCAT PEDIGREE 1 
SOBP_OF GAATCGTTCACATGGGGAAT PEDIGREE 1 
SOBP_OR TCTGACACTGCCAACTGCTC PEDIGREE 1 
SOBP_IF GGCACTATCACTGGGTACGG PEDIGREE 1 
SOBP_IR CATCTTCATGGAGCAGCAAA PEDIGREE 1 
VMN2R81_OF CCCCCAAAGACACAGCTCTA PEDIGREE 1 
VMN2R81_OR CTGCCAGGGGAATAACAGAG PEDIGREE 1 
VMN2R81_IF TCTGGGGGAAACCCTACTTC PEDIGREE 1 
VMN2R81_IR GCCACTGCATACACAGCATT PEDIGREE 1 
ADAMTS2_OF TCAGAGTCTCCGAGGTCTCC PEDIGREE 1 
ADAMTS2_OR AAATCGTCCCCCTTTCTCTG PEDIGREE 1 
ADAMTS2_IF GTGTCCCACGTGGTGTCTTT PEDIGREE 1 
ADAMTS2_IR CCCTAAGCACTGTGGAGGAG PEDIGREE 1 
UBE2O_OF GCAGCAGAAGGCTCCAATTA PEDIGREE 1 
UBE2O_OR CATTAATCCGTGTGGTGCAG PEDIGREE 1 
UBE2O_IF GGGCAGCTACTTGTCCTCTG PEDIGREE 1 
UBE2O_IR GAATTGAGTCCTGGCTGGAA PEDIGREE 1 
MFSD2B_OF CCAGGTTACCAGGGAGGAGT PEDIGREE 1 
MFSD2B_OR CTCTCCTGCTGTCCTGTTCC PEDIGREE 1 
MFSD2B_IF CGGAGGCTCTGACCTTCTCT PEDIGREE 1 
MFSD2B_IR AGGGCCACCAGTTACTTCCT PEDIGREE 1 
LRRC9_OF TCATGGGAGCATTAGATGGA PEDIGREE 1 
LRRC9_OR TGGTAGTTTCTGGGGATGGA PEDIGREE 1 
LRRC9_IF TGGGGAACAAGCCTTCTTAG PEDIGREE 1 
LRRC9_IR ATGAGTGCTGAGGGGCTAGA PEDIGREE 1 
FOS_OF GGATTTGACTGGAGGTCTGC PEDIGREE 1 
FOS_OR CTGGAAGAGGTGAGGACTGG PEDIGREE 1 
FOS_IF GAAGGCAGAACCCTTTGATG PEDIGREE 1 
FOS_IR CACAGCCTGGTGTGTTTCAC PEDIGREE 1 
VMN1R214_OF TCAACCAGTTACCAAACACCTG PEDIGREE 1 
VMN1R214_OR GGAAGAATGGAAGGATGTGC PEDIGREE 1 
VMN1R214_IF CTCATCTGCAACATGCGTCT PEDIGREE 1 
VMN1R214_IR CCTCCTCCATCCAGATGCT PEDIGREE 1 
CADPS_OF GCAATTCGAAGGCACAAGAG PEDIGREE 1 
CADPS_OR GGACAGAGCCTCAAGTCACA PEDIGREE 1 
CADPS_IF AGGGGTTTGTGTGATCTGGA PEDIGREE 1 
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CADPS_IR AAGAGTCCCAGGTTCCATCC PEDIGREE 1 
AKAP11_OF CCAAACTTTTCCCCACAAGA PEDIGREE 1 
AKAP11_OR TTGAGCTGCCTGAAATTCCT PEDIGREE 1 
AKAP11_IF CGTATGATTTCTTCCCCTTTTAAT PEDIGREE 1 
AKAP11_IR TGGAGACTTACTTGCTCATGGA PEDIGREE 1 
E430025E21RIK_OF GGCTCATAACCACCGAGTGT PEDIGREE 1 
E430025E21RIK_OR CAGTGCTATTCCCCTGCAAT PEDIGREE 1 
E430025E21RIK_IF CAAAAGCTGGGGTTCAAGAC PEDIGREE 1 
E430025E21RIK_IR TGCTCTGGGCTCCTAACCTA PEDIGREE 1 
MB21D2_OF AAACAGCAAAATCAGGCAGAA PEDIGREE 1 
MB21D2_OR GACTCCCTGCCAGCTACTTG PEDIGREE 1 
MB21D2_IF CCAAGTCCAATGTTAGCTGGA PEDIGREE 1 
MB21D2_IR TTTCATCCCTCAGTGCAACA PEDIGREE 1 
ITGB5_OF GGTAGGGGCTGTAAGGATGG PEDIGREE 1 
ITGB5_OR GGATTCCCCAGTAAGGCAAT PEDIGREE 1 
ITGB5_IF CCTGAGTTGAATTCTCTGCACTT PEDIGREE 1 
ITGB5_IR CACACCCAACACAAGCTCAA PEDIGREE 1 
NR1I2_OF CAGCAGAAGAAGAGGCCTTG PEDIGREE 1 
NR1I2_OR AATGCCGTGGTCACATTTTT PEDIGREE 1 
NR1I2_IF AGTTAGGAGGGGAGGCTTTG PEDIGREE 1 
NR1I2_IR CCCGAATGAGAGTCTTGCTC PEDIGREE 1 
CD47_OF GAAAGGCACAGCTCTTGTCC PEDIGREE 1 
CD47_OR GGGAAGCTATGTGGCTATGG PEDIGREE 1 
CD47_IF GAGGTTAGGTTTGGGTGCTG PEDIGREE 1 
CD47_IR GTGTGACTCACCCATGATGC PEDIGREE 1 
PTK7_OF GTGCATCCTGTCGTGAGAGA PEDIGREE 1 
PTK7_OR GCTTGTTTGGGGTAGAGACG PEDIGREE 1 
PTK7_IF CTAGCATCCGAGGAAAGGTG PEDIGREE 1 
PTK7_IR CGAGATGATGCTGGCAACTA PEDIGREE 1 
TTC39D_OF CGCCATCAACCTTATTCACC PEDIGREE 1 
TTC39D_OR TGTTAAAACGTGCACGGAAA PEDIGREE 1 
TTC39D_IF AGTTCATACCACGCCCTGAT PEDIGREE 1 
TTC39D_IR TGGCAGCAGTAGAAGCCTTT PEDIGREE 1 
SUV420H1_OF GTCTGCATCCCCATTGTCTT PEDIGREE 1 
SUV420H1_OR TTTCCAGATTCTGCCTGCTT PEDIGREE 1 
SUV420H1_IF GTCAGCTGCCTACGTTCTCC PEDIGREE 1 
SUV420H1_IR CTCTTGCCTCACAGAAAATTG PEDIGREE 1 
SGOL2_OF TCGGTTGTTCTCCTGAAACC PEDIGREE 6 
SGOL2_OR TGTCCAAACACATGAAAAGAGG PEDIGREE 6 
SGOL2_IF CGGTGGAGATAACACCCAAC PEDIGREE 6 
SGOL2_IR TGTTTCAACTGAAAACACACCA PEDIGREE 6 
DNAJB2_OF TTGGAACCTTTGCGTGTGTA PEDIGREE 6 
DNAJB2_OR GTGGAGGGACAGAGTTTGGA PEDIGREE 6 
DNAJB2_IF CTCTTGCAGGTGTCCCAGAT PEDIGREE 6 
DNAJB2_IR GGGCCACACTATTCTGCACT PEDIGREE 6 
SPTAN1_OF CTTTGAGAGGGACCTTGCAG PEDIGREE 6 
SPTAN1_OR TCCCCTGCCTTTAACTTGTG PEDIGREE 6 
SPTAN1_IF AAGCTGAGGCCTGAACTCTG PEDIGREE 6 
SPTAN1_IR TTCAGTGCTATGCCTGCTGT PEDIGREE 6 
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PKN3_OF CCCACTTTCTGTCAGTGCAA PEDIGREE 6 
PKN3_OR AGGACTCCAGGAACTGCTCA PEDIGREE 6 
PKN3_IF TGGGTGTACCCTGCCTCTAC PEDIGREE 6 
PKN3_IR CTGGTGAACTCTCCCTCGAA PEDIGREE 6 
N28178_OF CAGGCTCCAGACACATTTGA PEDIGREE 6 
N28178_OR AAGGAGTTTGAAGGCATGGA PEDIGREE 6 
N28178_IF TTTAGCAGAGCCGACCCTAA PEDIGREE 6 
N28178_IR TCTTGGGGCCTCTCACTATG PEDIGREE 6 
CCDC17_OF AGCATTACCTCCAGCCCTTT PEDIGREE 6 
CCDC17_OR AGCCTACAGGCTGACCAGAA PEDIGREE 6 
CCDC17_IF GCCTGTGCCCAGGTTAGTAG PEDIGREE 6 
CCDC17_IR GGGTTGATCTCTGCCAATGT PEDIGREE 6 
GM13083_OF AGGAGGTTCTGCAACCTTGA PEDIGREE 6 
GM13083_OR ACCTGCCTTCCATTTGTCAG PEDIGREE 6 
GM13083_IF ACCAGCTCAAACACCTGGAT PEDIGREE 6 
GM13083_IR GCCTAGCAATGACCTCACCT PEDIGREE 6 
D630045J12RIK_OF GAGAGTCAGAGGGGGAGCTT PEDIGREE 6 
D630045J12RIK_OR AGGTGGATGTGAGTGGCATT PEDIGREE 6 
D630045J12RIK_IF CAGCCATGGTGGAAAAAGTT PEDIGREE 6 
D630045J12RIK_IR TCTCCACACCAAGCTCACTG PEDIGREE 6 
FAM13A_OF TGGTGTGTCTAATCGCTGCT PEDIGREE 6 
FAM13A_OR TTTACTGGCCCTCAAGTTGC PEDIGREE 6 
FAM13A_IF GGATTGCCTGCTTTGTGAGT PEDIGREE 6 
FAM13A_IR GGAACCTCCAGAAAAGAACCA PEDIGREE 6 
ANTXR1_OF CTGACTGGGCTTGGCTTACT PEDIGREE 6 
ANTXR1_OR CCGCAGATATTTGTGCAAGA PEDIGREE 6 
ANTXR1_IF TGGAGGATAGAGTTGGCACA PEDIGREE 6 
ANTXR1_IR GGTTGGCTCCTTACTGCTGA PEDIGREE 6 
FANCD2_OF AGGCACTAGAGGTGTTGATGG PEDIGREE 6 
FANCD2_OR GAACTGTAGCTCCAGCCTCCT PEDIGREE 6 
FANCD2_IF TCTCTTCAGATTCGCCAGGA PEDIGREE 6 
FANCD2_IR CCAATTTTGTGACAGCTTTGC PEDIGREE 6 
MUG1_OF TGGTGTGTCTAATCGCTGCT PEDIGREE 6 
MUG1_OR TTTACTGGCCCTCAAGTTGC PEDIGREE 6 
MUG1_IF GGATTGCCTGCTTTGTGAGT PEDIGREE 6 
MUG1_IR GGAACCTCCAGAAAAGAACCA PEDIGREE 6 
LENG9_OF GGAAGCGGAAGTAGCGTATG PEDIGREE 6 
LENG9_OR AAGACGTGACTCCCTGGATG PEDIGREE 6 
LENG9_IF GAATGGCTCTTCCTGCACTC PEDIGREE 6 
LENG9_IR GGTTCCCAGTGGCTTACAAA PEDIGREE 6 
RYR1_OF AAAAGGCCAGATCCCAGACT PEDIGREE 6 
RYR1_OR AAACCCTTGCTTGGTCCTCT PEDIGREE 6 
RYR1_IF AAATGTTCACAGGGCTCCAC PEDIGREE 6 
RYR1_IR GCCAAGGCCTTTCTATTTCC PEDIGREE 6 
HS3ST4_OF GAGCGCTTCACGACTCCT PEDIGREE 6 
HS3ST4_OR TCCTCCGCTTGTTCTCAACT PEDIGREE 6 
HS3ST4_IF ACCCCTGATTATGGGGAGAA PEDIGREE 6 
HS3ST4_IR CCCTGTATTGGCCTGGATT PEDIGREE 6 
LONP2_OF CAGTGTGATTAAAGTGCTCTGGA PEDIGREE 6 
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LONP2_OR AAAGGGGGAAAAAGAAAGGA PEDIGREE 6 
LONP2_IF AGTCAACCTGGAGTGGCAAT PEDIGREE 6 
LONP2_IR TGAGTGAGGTCTGGACGGTA PEDIGREE 6 
KARS_OF CCCAACCATGTCTCACTCCT PEDIGREE 6 
KARS_OR CCATCGTCCAAGAATCCACT PEDIGREE 6 
KARS_IF CAACTGCCTGTCTGTTACGC PEDIGREE 6 
KARS_IR ATTGTTGTGATCCGTGTTGC PEDIGREE 6 
BC021891_OF CGTTTCAGTGGTGGTGTTTG PEDIGREE 6 
BC021891_OR GAGCCAGGATCTGGAGTGAG PEDIGREE 6 
BC021891_IF TGCAAAGACAGCCAGAGAGA PEDIGREE 6 
BC021891_IR GAGCATTCCCCAAAGATGAC PEDIGREE 6 
HTR1B_OF GAAACCAGCAGGCATCCTTA PEDIGREE 6 
HTR1B_OR GCTGTCGTCGGATATCACCT PEDIGREE 6 
HTR1B_IF TGATCCCTAGGGTCTTGGTG PEDIGREE 6 
HTR1B_IR CTGGTGTGGGTCTTCTCCAT PEDIGREE 6 
NHSL1_OF AAGCGCTTTTTGAAGCAGTC PEDIGREE 6 
NHSL1_OR CTCAAGGTCCCTGGAAATGA PEDIGREE 6 
NHSL1_IF CCATGTGACCTGGCTAACCT PEDIGREE 6 
NHSL1_IR TCCACTGCACAGAGCGTAAC PEDIGREE 6 
FZR1_OF AGCCCTGGCTTACCTTTTGT PEDIGREE 6 
FZR1_OR AGGGCATAGCCTCATGTGAT PEDIGREE 6 
FZR1_IF GCTTGCTGCTGAGGGAATAC PEDIGREE 6 
FZR1_IR GACAATGGCAAAGGTGAGG PEDIGREE 6 
SUPT6_OF GCTGGTATCCCAGGAGGAAC PEDIGREE 6 
SUPT6_OR GCTCCCCGGTGTTCATAAAT PEDIGREE 6 
SUPT6_IF GAAGGTGGGCTTCTCCTTCT PEDIGREE 6 
SUPT6_IR CTTTGCAGTGGGGTGAGATT PEDIGREE 6 
DDX46_OF AAACTGGCCTTTGTCCTCCT PEDIGREE 6 
DDX46_OR GCACTTCTTTTCCCGTGTTC PEDIGREE 6 
DDX46_IF TTCCCACAAGACAAGTGCAG PEDIGREE 6 
DDX46_IR GGGCCAATAAAGAGGAGGAG PEDIGREE 6 
AGTPBP1_OF AGGTGACTGACTTGGCTGCT PEDIGREE 6 
AGTPBP1_OR GGTGAACGTGTGTTTGTTGC PEDIGREE 6 
AGTPBP1_IF CCTCCTAAAGGGCCAAAAAC PEDIGREE 6 
AGTPBP1_IR CGGTCTGTGTGAGCAACATT PEDIGREE 6 
GSDMC2_OF TTGGAAGGGGTGGATTAAAA PEDIGREE 6 
GSDMC2_OR CACACACCGGCAGATGATAC PEDIGREE 6 
GSDMC2_IF ATTCCCACTGGCCTAAAACA PEDIGREE 6 
GSDMC2_IR TCAGGCCTTGCTCATTAGGT PEDIGREE 6 
PCDHGB4_OF TCAGCCTTTACACCGCTTCT PEDIGREE 6 
PCDHGB4_OR TTGTCCCTGGTTTTGAGGAC PEDIGREE 6 
PCDHGB4_IF ATATCCACACCACGCAGCTT PEDIGREE 6 
PCDHGB4_IR AATGTCCTCCAGCTCCACAC PEDIGREE 6 
PREX2_OF GCTGATGAGGAAATGGAAGG PEDIGREE 13 
PREX2_OR CCCTATGCACCTTCCAAAAA PEDIGREE 13 
PREX2_IF CTGGGCAGTGATTAGCACAA PEDIGREE 13 
PREX2_IR TGGGACAATACTGGGGACAC PEDIGREE 13 
PLA2G4A_OF TCAGGGAAGCTGAGAAGGAA PEDIGREE 13 
PLA2G4A_OR AGAGGAACGTGACCCATCTG PEDIGREE 13 
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PLA2G4A_IF TAAGGCACCATGTTTTGCAT PEDIGREE 13 
PLA2G4A_IR GTGGCTGACTAGGGAATGGA PEDIGREE 13 
ABCA2_OF ATGTGCCTGGAGTCCTTCAC PEDIGREE 13 
ABCA2_OR AATCTTCCGCACCATAGGAG PEDIGREE 13 
ABCA2_IF AACATGTCCCTGCCACCTAC PEDIGREE 13 
ABCA2_IR CCAAAGGATGCTGGGATAGA PEDIGREE 13 
IGSF10_OF CTGCGAGGCAGTTTCTATCC PEDIGREE 13 
IGSF10_OR GCGCTGCCTCTAATCCACTA PEDIGREE 13 
IGSF10_IF AGTGCCCCTGACTGAAGAAA PEDIGREE 13 
IGSF10_IR TTCCTGGATACTCGCAAACC PEDIGREE 13 
CPA1_OF TGAGCATCAGAACTGGGTCA PEDIGREE 13 
CPA1_OR GACCTACTTGCCCCTTCCTC PEDIGREE 13 
CPA1_IF ACCATTTCCCTGCCTCTTTT PEDIGREE 13 
CPA1_IR ACTTGTGGGGCTCAAAGGTA PEDIGREE 13 
MITF_OF ACCTGAAAGCCCCGAATAAC PEDIGREE 13 
MITF_OR GCTTTCCCTTTCCACTTTCC PEDIGREE 13 
MITF_IF AGCTCAGAGGCACCAGGTAA PEDIGREE 13 
MITF_IR GTGATGGGAGTTACGGAAGC PEDIGREE 13 
CHD4_OF CTGTGGTTGAGAGCATGGTG PEDIGREE 13 
CHD4_OR CTTACGGCTCCGACTACTGC PEDIGREE 13 
CHD4_IF GCAAAGGTGCAGTGGAATTT PEDIGREE 13 
CHD4_IR AATCGTCGTCCTCACTCTGG PEDIGREE 13 
SETD1A_OF CGAGAGAAGGAAGCTGGAGA PEDIGREE 13 
SETD1A_OR CCTCTAGGACCTGGGGAGAG PEDIGREE 13 
SETD1A_IF CAAGGCAAACACCGAAAATC PEDIGREE 13 
SETD1A_IR GGGCATTGGCTAACACAACT PEDIGREE 13 
1700029H14RIK_OF TAAGAAAAGCCCCAAGCAAA PEDIGREE 13 
1700029H14RIK_OR CCTAGAGCCAGCATGACCTC PEDIGREE 13 
1700029H14RIK_IF AGAAAGGCAGGGTTTCCATT PEDIGREE 13 
1700029H14RIK_IR GAGATGCCTTTGGTCTGAGG PEDIGREE 13 
OLFR904_OF TCGCTATGTGGCCATCTGTA PEDIGREE 13 
OLFR904_OR AGCATGCCTCTAACCACAGG PEDIGREE 13 
OLFR904_IF TGCCATGTCCCCTAAATTGT PEDIGREE 13 
OLFR904_IR GGATTCATCATGGGAACCAC PEDIGREE 13 
NUP43_OF CACAGGTTTCCAAAGCCAAT PEDIGREE 13 
NUP43_OR GGACCCTCTGATGCTCTCAA PEDIGREE 13 
NUP43_IF GTCATGCTCCCTCATGGACT PEDIGREE 13 
NUP43_IR CAAATGCCACTTTCTGGTGA PEDIGREE 13 
KCNMB1_OF GTTACCAGAGGCCAGAGCAG PEDIGREE 13 
KCNMB1_OR TCAGAGGCATTTGTGCAGAC PEDIGREE 13 
KCNMB1_IF GCTCCATGTAAGTTGCAAAGC PEDIGREE 13 
KCNMB1_IR ATGCCTCGTCTGTCCTGACT PEDIGREE 13 
2700049A03RIK_OF TGAGCCATCTCTCTAGCCCTAA PEDIGREE 13 
2700049A03RIK_OR GCCTTGCTGGAAAAAGTGAG PEDIGREE 13 
2700049A03RIK_IF GTGTGTGTGTGTGGTGCTCA PEDIGREE 13 
2700049A03RIK_IR CTAAGCAGCCTCCTGCAATC PEDIGREE 13 
TEX21_OF GCTGTTGCTGGTGTATGAGG PEDIGREE 13 
TEX21_OR GGTTCCCGTGTTTTGTTTTG PEDIGREE 13 
TEX21_IF GACCTCTTGCTCTCGTCCTG PEDIGREE 13 
142 
TEX21_IR CAGAGGGCTGAGGAGCTCTA PEDIGREE 13 
TTLL5_OF GCATGAAATGGTGACCAAAA PEDIGREE 13 
TTLL5_OR GAACAAATCTGGCCTCGGTA PEDIGREE 13 
TTLL5_IF GGTGGTGGAAGTTCAGGAAG PEDIGREE 13 
TTLL5_IR AACTGGCTGAGAAACGGAGA PEDIGREE 13 
VRK1_OF CAGTGCGTCCGCATACTAAA PEDIGREE 13 
VRK1_OR ACACACACACGTCGGCTAAG PEDIGREE 13 
VRK1_IF AGAGGGTTCAAGGGCCTAAG PEDIGREE 13 
VRK1_IR ACCACACCTGCCTAAGGTGA PEDIGREE 13 
VMN1R-PS103_OF CACACGAACACACATGCAAA PEDIGREE 13 
VMN1R-PS103_OR CCAGATGCTCTGGGACTGAT PEDIGREE 13 
VMN1R-PS103_IF TCCCACAGACCACAGGATAA PEDIGREE 13 
VMN1R-PS103_IR CCACTCTCCCCAGGTAAACA PEDIGREE 13 
RREB1_OF CATCGAGAGCTACGTGCTTG PEDIGREE 13 
RREB1_OR ATTGCCCAAGAGGGGAGTAT PEDIGREE 13 
RREB1_IF AGAGGGCAGCTGTGTCACTT PEDIGREE 13 
RREB1_IR TGAGTGTGGGGCTCTAGCTT PEDIGREE 13 
PHACTR1_OF CCTAATGGGCACAAAGAGGA PEDIGREE 13 
PHACTR1_OR GCATCCCGTGAAAATAGCAT PEDIGREE 13 
PHACTR1_IF CTCATAGGACACACCCATGC PEDIGREE 13 
PHACTR1_IR AATGAGCATCCCAAGTCCTG PEDIGREE 13 
GM3558_OF CTCAAGAAGGGCTCCAACAC PEDIGREE 13 
GM3558_OR TCCTGTGGAATATGGCTGGT PEDIGREE 13 
GM3558_IF TTGAACCAGGCTACCTCCAC PEDIGREE 13 
GM3558_IR ATGACCTGCCTCTGTTTGGT PEDIGREE 13 
PNP2_OF GGCTGCAAGATGGACTCATT PEDIGREE 13 
PNP2_OR CTCCCGAGTCACACCAAGTT PEDIGREE 13 
PNP2_IF CAGCGAGTGCTCTGCACTAA PEDIGREE 13 
PNP2_IR CAGGTGAAGGCAGTGTCAAA PEDIGREE 13 
GGA1_OF CATCGAGGAGGTCAACAACA PEDIGREE 13 
GGA1_OR CCAGGCAGGGAGTAGAGACA PEDIGREE 13 
GGA1_IF CACCCCAACCCACTCATAAC PEDIGREE 13 
GGA1_IR GATACACTGGGGCTGTGACC PEDIGREE 13 
OLFR175-PS1_OF GGTACTGCAGAGGGTTGCAT PEDIGREE 13 
OLFR175-PS1_OR CCTGGGAATTTCAACGATGT PEDIGREE 13 
OLFR175-PS1_IF AGCAGTCTGCAGTTTCAGCA PEDIGREE 13 
OLFR175-PS1_IR AGGCAGTGGGTGGTGTTTAC PEDIGREE 13 
GANAB_OF TGGGGTTTTGATTGGGATAA PEDIGREE 13 
GANAB_OR CCCATTTCATTTGCCTGTTT PEDIGREE 13 
GANAB_IF CCTGGGCATGAACAAAGAAT PEDIGREE 13 
GANAB_IR CTTACAAACAAGGCCCTGGA PEDIGREE 13 
1700028P14RIK_OF CCTCCAGAACTCTTGCTCCA PEDIGREE 13 
1700028P14RIK_OR TGGTGTTTCTGCGACAGTCT PEDIGREE 13 
1700028P14RIK_IF ACAGCATGCTAAGCACTCCA PEDIGREE 13 
1700028P14RIK_IR TCAGCATTCCTTGAAAAGAGG PEDIGREE 13 
ARL6IP5_OF AACCACTTCCAGCCAATCAC BURDEN ANALYSIS TOP HIT 
ARL6IP5_OR TCAGCGTTTTCCTCACCTCT BURDEN ANALYSIS TOP HIT 
ARL6IP5_IF TTTAACCGCAGAACCAATCC BURDEN ANALYSIS TOP HIT 
ARL6IP5_IR GAAAGGGGACCTCAGAGAGC BURDEN ANALYSIS TOP HIT 
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ITGB6_1_OF GGAGGTGATACCTGGTCCAA BURDEN ANALYSIS TOP HIT 
ITGB6_1_OR CAGCCCCCTCATTACCATAA BURDEN ANALYSIS TOP HIT 
ITGB6_1_IF ACATTGGCAGTGGAACACAA BURDEN ANALYSIS TOP HIT 
ITGB6_1_IR GGCACCTGCTTTGAGCTACT BURDEN ANALYSIS TOP HIT 
ITGB6_2_OF GTCGCAGTCACATTCTGCAC BURDEN ANALYSIS TOP HIT 
ITGB6_2_OR GCAGCACATCATAGGTTGGA BURDEN ANALYSIS TOP HIT 
ITGB6_2_IF CACATTGAAGGATGCCTGGT BURDEN ANALYSIS TOP HIT 
ITGB6_2_IR CCTCCTTCCACAGCAAGAGT BURDEN ANALYSIS TOP HIT 
ITGB6_3_OF AGATCCAATCTCGAGGCAGA BURDEN ANALYSIS TOP HIT 
ITGB6_3_OR AAAGGGCAGCTTATCATCCA BURDEN ANALYSIS TOP HIT 
ITGB6_3_IF TACCTGCAAGGGTTGGTGAT BURDEN ANALYSIS TOP HIT 
ITGB6_3_IR TCCTCACTGCTGAGGGATTT BURDEN ANALYSIS TOP HIT 
ITGB6_4_OF GGACAGGCAAAGCAGAAAAG BURDEN ANALYSIS TOP HIT 
ITGB6_4_OR CACCAAATGCTCTCCTTGGT BURDEN ANALYSIS TOP HIT 
ITGB6_4_IF GGGAAGGTGGGGAGACTTAG BURDEN ANALYSIS TOP HIT 
ITGB6_4_IR CCGGTGTTTCTATTGTGCTG BURDEN ANALYSIS TOP HIT 
C6_1_OF ATGGCAGGCTAGGAGAGACA BURDEN ANALYSIS TOP HIT 
C6_1_OR TCATTGAATTGAACAGCGAAA BURDEN ANALYSIS TOP HIT 
C6_1_IF CCTATGGGATGCGCTACAGT BURDEN ANALYSIS TOP HIT 
C6_1_IR TTAAATGACAGGCAGCCTCA BURDEN ANALYSIS TOP HIT 
C6_2_OF TCACATTTTCCTCCGAGCTT BURDEN ANALYSIS TOP HIT 
C6_2_OR CTGTTCCGCAGTGAGATGAA BURDEN ANALYSIS TOP HIT 
C6_2_IF GTTCCTTTTTGCAGGGATCA BURDEN ANALYSIS TOP HIT 
C6_2_IR CGGCAAGTGTGAACAATTTTA BURDEN ANALYSIS TOP HIT 
C6_3_OF GCTCCAATTTTATCCCACGTT BURDEN ANALYSIS TOP HIT 
C6_3_OR TGCTGGGTAAATGACTCATCC BURDEN ANALYSIS TOP HIT 
C6_3_IF TGAGCCTTCCTCTGGAGTCA BURDEN ANALYSIS TOP HIT 
C6_3_IR TGACCTCATTGGGTTTTGGT BURDEN ANALYSIS TOP HIT 
C6_4_OF GGTAGCCCTCGCTGCTTATT BURDEN ANALYSIS TOP HIT 
C6_4_OR CAACTCCATGCAGCACATCT BURDEN ANALYSIS TOP HIT 
C6_4_IF CCCATGAGTACTGCATCCAC BURDEN ANALYSIS TOP HIT 
C6_4_IR GCTTCTTGTTGCTTGATTGC BURDEN ANALYSIS TOP HIT 
CPN1_1_OF CGGGAGACTTTCTTCACAGC BURDEN ANALYSIS TOP HIT 
CPN1_1_OR TAGCCTAGGCAGACCTGGAA BURDEN ANALYSIS TOP HIT 
CPN1_1_IF CCAGAGTCCCCAGCTTACAG BURDEN ANALYSIS TOP HIT 
CPN1_1_IR CTCAGGAACAGCTCTGTGGA BURDEN ANALYSIS TOP HIT 
CPN1_2_OF TCATTGAGGACTTGCTGCTG BURDEN ANALYSIS TOP HIT 
CPN1_2_OR TCAGCTAGCCTCCTGCATCT BURDEN ANALYSIS TOP HIT 
CPN1_2_IF TGCGTGCTTAATTCTTGACG BURDEN ANALYSIS TOP HIT 
CPN1_2_IR TGTCCATTTGTCTGTCCTTCC BURDEN ANALYSIS TOP HIT 
SNTG1_1_OF AATATGGCCCCTTCAGCTTT BURDEN ANALYSIS TOP HIT 
SNTG1_1_OR AGAAATGTTGGTGGCACCTG BURDEN ANALYSIS TOP HIT 
SNTG1_1_IF TCTGGAGTAATGCCTTTCAATG BURDEN ANALYSIS TOP HIT 
SNTG1_1_IR TGGTGTTGGGGCACATTATT BURDEN ANALYSIS TOP HIT 
SNTG1_2_OF ACGCACACACTCACACACAC BURDEN ANALYSIS TOP HIT 
SNTG1_2_OR CGAAGGGAAATGTCTGCCTA BURDEN ANALYSIS TOP HIT 
SNTG1_2_IF TGCATTTCTATTTGCCCCTAA BURDEN ANALYSIS TOP HIT 
SNTG1_2_IR GGGCTGCTTTTTATTGGAGA BURDEN ANALYSIS TOP HIT 
SNTG1_3_OF TGTGATCCCAGTCTTTTCCTG BURDEN ANALYSIS TOP HIT 
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SNTG1_3_OR GTGCCTGTGTACATGGGAGT BURDEN ANALYSIS TOP HIT 
SNTG1_3_IF CATCCCAGATTACAACCCACT BURDEN ANALYSIS TOP HIT 
SNTG1_3_IR CTTTGTGGTCCAGATTGTGGT BURDEN ANALYSIS TOP HIT 
PLAC8_OF CAAGCCCAGCTTCAACTTGT BURDEN ANALYSIS TOP HIT 
PLAC8_OR GAGGGTGGAGGGAGAGAACT BURDEN ANALYSIS TOP HIT 
PLAC8_IF GAGATGGCACGGGAGACTTA BURDEN ANALYSIS TOP HIT 
PLAC8_IR CGCACTCGAACACACACAC BURDEN ANALYSIS TOP HIT 
ITPRIP_1_OF AGGGCCATCTGAAACCACTT BURDEN ANALYSIS TOP HIT 
ITPRIP_1_OR ACCTCTGGACCACACTCTGC BURDEN ANALYSIS TOP HIT 
ITPRIP_1_IF ACCAGAACTCTGGGTGGAAG BURDEN ANALYSIS TOP HIT 
ITPRIP_1_IR GGTCCTCTTCCTGATCATCG BURDEN ANALYSIS TOP HIT 
ITPRIP_2_OF AGCAGATCATCCACGAAACC BURDEN ANALYSIS TOP HIT 
ITPRIP_2_OR GGAGACAGCTATCGGCTGAG BURDEN ANALYSIS TOP HIT 
ITPRIP_2_IF CCTCGATGATCAGGAAGAGG BURDEN ANALYSIS TOP HIT 
ITPRIP_2_IR AGAGCCAGAACCATCACCAG BURDEN ANALYSIS TOP HIT 
CES3B_1_OF ACTGCCTGACCCTCAACATC BURDEN ANALYSIS TOP HIT 
CES3B_1_OR TTTTGCCTCTTGGTTTTTGG BURDEN ANALYSIS TOP HIT 
CES3B_1_IF GACCCCATCCAACTCGACTA BURDEN ANALYSIS TOP HIT 
CES3B_1_IR GCCACACCCAGCTTTTACAT BURDEN ANALYSIS TOP HIT 
CES3B_2_OF AGCTGAGCTGGTCCAGTGTT BURDEN ANALYSIS TOP HIT 
CES3B_2_OR ATTTCCAGGGGCTTAATGCT BURDEN ANALYSIS TOP HIT 
CES3B_2_IF TGGTGACAGTGGCTCAGAAC BURDEN ANALYSIS TOP HIT 
CES3B_2_IR AACCATTCACCACCACGAAT BURDEN ANALYSIS TOP HIT 
CES3B_3_OF TGCTGCTCTCTGGAATTGTG BURDEN ANALYSIS TOP HIT 
CES3B_3_OR GTATCCTGCCCGAAGTACCA BURDEN ANALYSIS TOP HIT 
CES3B_3_IF GGGCTACACTGCACTTCTCC BURDEN ANALYSIS TOP HIT 
CES3B_3_IR GGGCTTGAAGGTTGCTGTAG BURDEN ANALYSIS TOP HIT 
FABP6_1_OF TTCAAGATCCTCCTGGCTTG BURDEN ANALYSIS TOP HIT 
FABP6_1_OR GACCAGCCCCCACTTTTTAT BURDEN ANALYSIS TOP HIT 
FABP6_1_IF TGTTGAGATTGCAGGCATTT BURDEN ANALYSIS TOP HIT 
FABP6_1_IR GTCCACCAAGCCAGCTCTAC BURDEN ANALYSIS TOP HIT 
FABP6_2_OF CCCAAGAGTTTGGGTTCCTA BURDEN ANALYSIS TOP HIT 
FABP6_2_OR AGGCTGAGGAGAGCTTAGGG BURDEN ANALYSIS TOP HIT 
FABP6_2_IF CAGGGAAGGGACACAAAGAA BURDEN ANALYSIS TOP HIT 
FABP6_2_IR GGCTGAGCAGAGAGGTGAAT BURDEN ANALYSIS TOP HIT 
STXBP3A_1_OF GTGCCAAAGGCAAAACAAAT BURDEN ANALYSIS TOP HIT 
STXBP3A_1_OR CCTCACCTGCCTCATGTCTT BURDEN ANALYSIS TOP HIT 
STXBP3A_1_IF CAACACAGGCTTTGGTGCTA BURDEN ANALYSIS TOP HIT 
STXBP3A_1_IR TGCATGTTGGGATGACTGTT BURDEN ANALYSIS TOP HIT 
STXBP3A_2_OF CACGCCTGGTGACCTAAGTT BURDEN ANALYSIS TOP HIT 
STXBP3A_2_OR TGCTAAGCGTTTGCACAGAG BURDEN ANALYSIS TOP HIT 
STXBP3A_2_IF CGCATGCGTTCTCTCTCTAA BURDEN ANALYSIS TOP HIT 
STXBP3A_2_IR TGAGAAAGGACTCCCACCAG BURDEN ANALYSIS TOP HIT 
STXBP3A_3_OF TGAAGCAGAGCTTGTTCATTG BURDEN ANALYSIS TOP HIT 
STXBP3A_3_OR AGCCATGAGCCAGTTAAGGA BURDEN ANALYSIS TOP HIT 
STXBP3A_3_IF GAAGCAAGGGACTGCTATGC BURDEN ANALYSIS TOP HIT 
STXBP3A_3_IR CCTTCCTGAGAATTGTTTGTTTC BURDEN ANALYSIS TOP HIT 
SCAPER_1_OF GAGTGATCTGAGCCGAGAGG BURDEN ANALYSIS TOP HIT 
SCAPER_1_OR TTTCCCTAGGCTGGGAGTTT BURDEN ANALYSIS TOP HIT 
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SCAPER_1_IF GGGAAAAGACGATTCTGTGC BURDEN ANALYSIS TOP HIT 
SCAPER_1_IR GTCTGTTGTAGGGGCAGAGG BURDEN ANALYSIS TOP HIT 
SCAPER_2_OF ACTATGGGCTCACCCCTTTC BURDEN ANALYSIS TOP HIT 
SCAPER_2_OR ATAGCCTTTGCCTTCCCTTC BURDEN ANALYSIS TOP HIT 
SCAPER_2_IF CTTCTTGGTTTGGGAATGGA BURDEN ANALYSIS TOP HIT 
SCAPER_2_IR TTCCCTGCAGTGAGAGATCA BURDEN ANALYSIS TOP HIT 
SCAPER_3_OF TGGCCTCAGACTCACAGAGA BURDEN ANALYSIS TOP HIT 
SCAPER_3_OR AGTGCATGGACAGATTTGGA BURDEN ANALYSIS TOP HIT 
SCAPER_3_IF CAGCAGGGCCAAGTTTTAAG BURDEN ANALYSIS TOP HIT 
SCAPER_3_IR TCTTCAGACCTGAGGGGTCTA BURDEN ANALYSIS TOP HIT 
ZFP386_1_OF TTGTGGATTGCCTGCTACTG BURDEN ANALYSIS TOP HIT 
ZFP386_1_OR TGGTGCTGACCAAGAATTGA BURDEN ANALYSIS TOP HIT 
ZFP386_1_IF TCTGGTCAGCGTGACAAAGT BURDEN ANALYSIS TOP HIT 
ZFP386_1_IR TCTGCCACATTCTTCACACC BURDEN ANALYSIS TOP HIT 
ZFP386_2_OF CAAGCCTTCAGAAACACCAAG BURDEN ANALYSIS TOP HIT 
ZFP386_2_OR TGTAGGGTTTCTCCCAAGGA BURDEN ANALYSIS TOP HIT 
ZFP386_2_IF TGTGCAGAATGTGGCAAATC BURDEN ANALYSIS TOP HIT 
ZFP386_2_IR CCCCCAGTTTGAATTAGAGGA BURDEN ANALYSIS TOP HIT 
PYHIN1_OF ATGGCCCATTTCACAATCTC SHARED VARIANT 
PYHIN1_OR TCAGAATGCCCCCAAAGATA SHARED VARIANT 
PYHIN1_IF ATGGCATGGGTCTTTCACTC SHARED VARIANT 
PYHIN1_IR CACCAAAATAGGCCATGTCA SHARED VARIANT 
PLCB4_OF TCTTGGGAAGGACCATGAAG SHARED VARIANT 
PLCB4_OR TCATAATAGCAGCCCCAAGG SHARED VARIANT 
PLCB4_IF TGAAAATGCCCCTGTCTTCT SHARED VARIANT 
PLCB4_IR GCAGTGAAGCTGCCGATATT SHARED VARIANT 
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Appendix 4-3: gRNA sequences, primers, and templates 
 
Gene Active Guide 
Sequence 
PCR Genotyping 
Primers 
Amplic
on Size 
Synthetic template 
Arl6ip5 GTTTCGCCC
GGCCGGAC
TTC 
Primer1: 5’ 
GGATAAAGCCC
ACTGCTCTG 3’ 
Primer2: 5’ 
TGGGAGGGGG
TAGTTCTCAT 3’ 
663 bp 5’ 
tcgatttcttggctttatatatcttGATCACTAATA
CGACTCACTATAGGGTTTCGCCCGG
CCGGACTTCgttttagagctaGAAAtagcaa
gttaaaataaggctagtccgttatcaacttgaaaaag
tggcaccgagtcggtgctttt 3’ 
C6 gCGATAAGC
TTTGTATCA
AGC 
Primer1: 5’ 
GAAGGGATTCC
TGTGTGGCTT 3’ 
Primer2: 5’ 
TGGTATGACCA
GAGGTGGAC 3’ 
679 bp 5’ 
tcgatttcttggctttatatatcttGATCACTAATA
CGACTCACTATAGGCGATAAGCTTT
GTATCAAGCgttttagagctaGAAAtagcaa
gttaaaataaggctagtccgttatcaacttgaaaaag
tggcaccgagtcggtgctttt 3’ 
Ces3b GAGAACCG
AAGAGGTC
CCAC 
Primer1: 5’ 
ACAAATAGACG
CTGGAGGAGC 
3’  
Primer2: 5’ 
CCCTTGTAGCC
CAGGGTATT 3’ 
673 bp 
 
5’ 
tcgatttcttggctttatatatcttGATCACTAATA
CGACTCACTATAGGGAGAACCGAAG
AGGTCCCACgttttagagctaGAAAtagcaa
gttaaaataaggctagtccgttatcaacttgaaaaag
tggcaccgagtcggtgctttt 3’ 
 
Cpn1* g1: 
gACAGCTGC
AGAAGCAG
CTCG* 
g2: 
GCTGTCGG
AATTCCTCT
GCG* 
Primer1: 5’ 
CAGGGATGGTT
GGACACAGG 3’ 
Primer2: 5’ 
TGAGGTTAGCT
GGACTGGTG 3’ 
815 bp NA 
Itgb6 GCAGCTTTC
TGCACCACC
CC 
Primer 1: 5’ 
CAGGTGTTGAA
CAGGAGGCT 3’ 
Primer2: 5’ 
TGGCCACCAAT
TATCCAGACA 3’ 
810 bp 5’ 
tcgatttcttggctttatatatcttGATCACTAATA
CGACTCACTATAGGGCAGCTTTCTG
CACCACCCCgttttagagctaGAAAtagcaa
gttaaaataaggctagtccgttatcaacttgaaaaag
tggcaccgagtcggtgctttt 3’ 
Sntg1 AGGTGTAAC
CGGACTTTA
AA 
Primer 1: 5’ 
CACTGTTATACG
ACAGCCAGGA 
3’ 
Primer2: 5’ 
CAGCCTGAGTC
TCACTTTGG 3’ 
607 bp 5’ t 
tcgatttcttggctttatatatcttGATCACTAATA
CGACTCACTATAGGAGGTGTAACCG
GACTTTAAAgttttagagctaGAAAtagcaag
ttaaaataaggctagtccgttatcaacttgaaaaagt
ggcaccgagtcggtgctttt 3’ 
*Neither sgRNA Cpn1-g1 nor Cpn1-g2 were active when tested with in vitro assays. 
Zygote microinjection with the guide sequences in pX330-U6-Chimeric_BB-CBh-
hSpCas9 nevertheless resulted in gene-editing in mice. 
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Appendix 4-4: Potentially deleterious ENU-induced variants from WES in genes 
with >1 mutation 
C Position R A Type 
Mouse 
ID 
Gene E AA # P-val 
2 76708957 T C NS 45755 Ttn 186 p.T26235A 15 4.0E-02 
2 76718079 T A NS 83071 Ttn 180 p.T23633S 15 4.0E-02 
2 76742907 T 
T
C 
FSI 10562 Ttn 154 p.K17554fs 15 4.0E-02 
2 76742918 T C NS 83411 Ttn 154 p.N17550S 15 4.0E-02 
2 76747394 T C NS 96440 Ttn 154 p.D16058G 15 4.0E-02 
2 76757126 C T NS 90152 Ttn 145 p.R13214H 15 4.0E-02 
2 76758848 T C NS 10382 Ttn 143 p.T12997A 15 4.0E-02 
2 76759160 C T NS 11187 Ttn 142 p.R12923H 15 4.0E-02 
2 76764765 A G NS 82147 Ttn 133 p.I12020T 15 4.0E-02 
2 76768436 C T NS 11477 Ttn 132 p.A11051T 15 4.0E-02 
2 76769813 C T NS 2383 Ttn 129 p.E10679K 15 4.0E-02 
2 76781067 A G NS 10653 Ttn 110 p.C9047R 15 4.0E-02 
2 76856801 A G SP 96868 Ttn na na 15 4.0E-02 
2 76877986 T A NS 29035 Ttn 93 p.D8018V 15 4.0E-02 
2 76889411 G T NS 3000 Ttn 74 p.A6224E 15 4.0E-02 
4 32669030 A G NS 83520 Mdn1 6 p.T363A 5 2.3E-02 
4 32686337 T C NS 98313 Mdn1 19 p.V868A 5 2.3E-02 
4 32726897 A C NS 11600 Mdn1 52 p.K2652T 5 2.3E-02 
4 32746482 A G NS 83164 Mdn1 76 p.S4143G 5 2.3E-02 
4 32760731 A G NS 11478 Mdn1 89 p.E4927G 5 2.3E-02 
7 56100169 T A NS 51255 Herc2 13 p.S564R 5 1.4E-02 
7 56138950 A G NS 82086 Herc2 35 p.Q1816R 5 1.4E-02 
7 56157762 T C NS 91570 Herc2 47 p.V2533A 5 1.4E-02 
7 56163760 T A NS 10451 Herc2 49 p.C2580S 5 1.4E-02 
7 56206639 T C SP 45755 Herc2 na na 5 1.4E-02 
14 31265420 T C NS 57931 Dnah1 67 p.T3541A 5 8.7E-03 
14 31269461 T C NS 82458 Dnah1 59 p.E3120G 5 8.7E-03 
14 31269841 T C NS 22721 Dnah1 58 p.E3068G 5 8.7E-03 
14 31292482 C T NS 83071 Dnah1 34 p.A1769T 5 8.7E-03 
14 31307925 G T SG 11187 Dnah1 10 p.Y474X 5 8.7E-03 
15 44479643 T C NS 60716 Pkhd1l1 6 p.V172A 5 8.7E-03 
15 44491110 A T NS 80493 Pkhd1l1 11 p.D299V 5 8.7E-03 
15 44529638 A T NS 98491 Pkhd1l1 38 p.I1790L 5 8.7E-03 
15 44545499 G T SP 98172 Pkhd1l1 na na 5 8.7E-03 
15 44564366 A G NS 76582 Pkhd1l1 59 p.D3273G 5 8.7E-03 
1 20310555 T A NS 83929 Pkhd1 50 p.N2687Y 4 2.9E-02 
1 20350445 A T NS 13019 Pkhd1 47 p.I2479N 4 2.9E-02 
1 20350524 C A NS 83619 Pkhd1 47 p.G2453W 4 2.9E-02 
1 20364141 T C NS 88503 Pkhd1 44 p.N2358D 4 2.9E-02 
2 40876669 A T SG 88129 Lrp1b 54 p.C2845X 4 4.1E-02 
2 40882215 C T NS 89957 Lrp1b 52 p.V2775M 4 4.1E-02 
2 41122947 T A NS 83875 Lrp1b 37 p.D1996V 4 4.1E-02 
2 41295549 T G NS 83010 Lrp1b 27 p.T1499P 4 4.1E-02 
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2 60611441 T A NS 13019 Itgb6 13 p.N675I 4 1.1E-04 
2 60628375 G T NS 10562 Itgb6 9 p.P401Q 4 1.1E-04 
2 60668525 T G NS 45755 Itgb6 4 p.Q119P 4 1.1E-04 
2 60674011 C T SP 11468 Itgb6 na na 4 1.1E-04 
6 125566323 T C NS 10020 Vwf 5 p.F173L 4 9.8E-03 
6 125665197 T A SG 88129 Vwf 41 p.C2360X 4 9.8E-03 
6 125666677 T C NS 83140 Vwf 42 p.C2394R 4 9.8E-03 
6 125683632 G A NS 6927 Vwf 49 p.C2701Y 4 9.8E-03 
9 55580247 A C NS 83971 Scaper 30 p.V1270G 4 9.4E-04 
9 55685898 A T NS 82522 Scaper 25 p.V978D 4 9.4E-04 
9 55883916 C T NS 29035 Scaper 9 p.A233T 4 9.4E-04 
9 55883919 A G NS 83882 Scaper 9 p.S232P 4 9.4E-04 
13 81433679 A G NS 13019 Gpr98 70 p.S4749P 4 8.5E-02 
13 81522247 T C NS 88547 Gpr98 32 p.T2327A 4 8.5E-02 
13 81543527 T C NS 29035 Gpr98 23 p.D1647G 4 8.5E-02 
13 81592638 C A NS 82522 Gpr98 4 p.V124L 4 8.5E-02 
15 4755321 C A NS 29035 C6 6 p.T223N 4 1.1E-04 
15 4759850 T G NS 83010 C6 7 p.I259S 4 1.1E-04 
15 4781860 C T SG 83737 C6 9 p.Q397X 4 1.1E-04 
15 4789620 A T NS 83796 C6 10 p.E478V 4 1.1E-04 
1 8414292 A T NS 14418 Sntg1 20 p.F436I 3 5.7E-04 
1 8677834 A T NS 13019 Sntg1 10 p.N112K 3 5.7E-04 
1 8681990 A G NS 24744 Sntg1 7 p.F68L 3 5.7E-04 
1 34192554 T C NS 11600 Dst 39 p.L3254P 3 2.1E-01 
1 34266912 T A NS 11187 Dst 77 p.I6405N 3 2.1E-01 
1 34268807 A G NS 83685 Dst 79 p.T6503A 3 2.1E-01 
1 53413767 C A NS 83217 Dnah7a 63 p.V3851L 3 9.2E-02 
1 53565718 A T NS 76824 Dnah7a 25 p.Y1294N 3 9.2E-02 
1 53605839 C A NS 80821 Dnah7a 20 p.V1013L 3 9.2E-02 
1 150573553 C T NS 80821 Hmcn1 105 p.C5445Y 3 1.5E-01 
1 150619087 G A SG 98491 Hmcn1 81 p.Q4084X 3 1.5E-01 
1 150723332 T A NS 89965 Hmcn1 31 p.D1611V 3 1.5E-01 
2 6427781 A G NS 80840 Usp6nl 13 p.M299V 3 2.2E-03 
2 6440935 C A NS 89957 Usp6nl 15 p.N551K 3 2.2E-03 
2 6441137 C A NS 88129 Usp6nl 15 p.P619T 3 2.2E-03 
2 14271327 C T SG 13019 Mrc1 9 p.Q491X 3 9.6E-03 
2 14315239 G A NS 83929 Mrc1 22 p.V995I 3 9.6E-03 
2 14325245 C T NS 83882 Mrc1 26 p.P1222S 3 9.6E-03 
2 21399337 G A NS 11082 Gpr158 2 p.D307N 3 5.8E-03 
2 21810680 A T NS 6927 Gpr158 8 p.H628L 3 5.8E-03 
2 21826776 A C NS 10653 Gpr158 11 p.T896P 3 5.8E-03 
2 59900770 A G NS 29035 Baz2b 36 p.V2084A 3 2.4E-02 
2 59962147 T C NS 80840 Baz2b 9 p.R546G 3 2.4E-02 
2 59978601 G T NS 82147 Baz2b 5 p.H101Q 3 2.4E-02 
2 112728922 T C NS 91570 Ryr3 64 p.D3039G 3 1.3E-01 
2 112756284 A C NS 33095 Ryr3 55 p.D2740E 3 1.3E-01 
2 112756516 T A NS 89285 Ryr3 54 p.T2728S 3 1.3E-01 
3 30936887 A G NS 91570 Phc3 8 p.S394P 3 3.5E-03 
3 30958021 C T NS 83875 Phc3 4 p.M133I 3 3.5E-03 
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3 30965808 A G NS 60712 Phc3 2 p.S48P 3 3.5E-03 
3 97699199 A G NS 82744 Pde4dip 37 p.C1983R 3 3.4E-02 
3 97754545 C T NS 51255 Pde4dip 11 p.E452K 3 3.4E-02 
3 97793564 C A NS 11187 Pde4dip 3 p.R88L 3 3.4E-02 
3 108821795 T C NS 88547 Stxbp3a 6 p.E144G 3 8.3E-04 
3 108827107 T A NS 83737 Stxbp3a 3 p.I34L 3 8.3E-04 
3 108827586 T A NS 10177 Stxbp3a 2 p.E29V 3 8.3E-04 
4 128395066 A C NS 80821 Csmd2 21 p.S1133R 3 7.6E-02 
4 128483386 A T NS 82086 Csmd2 40 p.M2020L 3 7.6E-02 
4 128546684 T C NS 60716 Csmd2 60 p.S3181P 3 7.6E-02 
5 3960225 A T NS 11468 Akap9 7 p.L309F 3 8.2E-02 
5 4029850 T A NS 76387 Akap9 23 p.D1867E 3 8.2E-02 
5 4044016 A T NS 83929 Akap9 28 p.R2179S 3 8.2E-02 
5 96657145 G A SP 98491 Fras1 na na 3 9.1E-02 
5 96691359 C T NS 82086 Fras1 36 p.T1579M 3 9.1E-02 
5 96700523 A G NS 96245 Fras1 40 p.D1799G 3 9.1E-02 
5 124750855 C T NS 98313 Dnah10 14 p.P755L 3 1.2E-01 
5 124754254 T C NS 22721 Dnah10 16 p.I839T 3 1.2E-01 
5 124803391 A G NS 88025 Dnah10 49 p.D2821G 3 1.2E-01 
6 38158085 A C NS 96868 
D630045J12
Rik 
11 p.S1387A 3 2.0E-02 
6 38195359 A G NS 83457 
D630045J12
Rik 
2 p.S625P 3 2.0E-02 
6 38196361 C T NS 96440 
D630045J12
Rik 
2 p.V291I 3 2.0E-02 
6 97210822 T C NS 53882 Arl6ip5 1 p.M1T 3 3.3E-05 
6 97210913 A T NS 83217 Arl6ip5 1 p.K31N 3 3.3E-05 
6 97210957 A C NS 83071 Arl6ip5 1 p.N46T 3 3.3E-05 
6 108381201 A T NS 83875 Itpr1 18 p.K576M 3 4.3E-02 
6 108386813 A G NS 6927 Itpr1 21 p.T799A 3 4.3E-02 
6 108405515 A G NS 82194 Itpr1 34 p.D1456G 3 4.3E-02 
7 75611077 A T NS 80821 Akap13 7 p.T1150S 3 4.5E-02 
7 75723901 T C NS 10562 Akap13 20 p.S1869P 3 4.5E-02 
7 75735725 T A NS 11241 Akap13 27 p.V2216D 3 4.5E-02 
7 105758172 G A NS 10722 Dchs1 15 p.P2112S 3 6.3E-02 
7 105762230 C A NS 76278 Dchs1 10 p.V1560L 3 6.3E-02 
7 105772940 T C NS 88955 Dchs1 2 p.H91R 3 6.3E-02 
7 112059064 T C NS 33095 Usp47 6 p.Y217H 3 8.3E-03 
7 112082440 T C NS 76582 Usp47 13 p.M486T 3 8.3E-03 
7 112086024 C A NS 60654 Usp47 16 p.H581N 3 8.3E-03 
8 14928847 T C NS 83140 Arhgef10 3 p.V38A 3 7.9E-03 
8 14930203 T C NS 5401 Arhgef10 4 p.S148P 3 7.9E-03 
8 14961286 G A SP 83685 Arhgef10 16 na 3 7.9E-03 
8 105085650 T A NS 98420 Ces3b 4 p.V177D 3 7.5E-04 
8 105088716 C T NS 24744 Ces3b 8 p.T344I 3 7.5E-04 
8 105091569 A T NS 98313 Ces3b 10 p.D401V 3 7.5E-04 
11 69421734 T C NS 82086 Dnah2 83 p.N4335S 3 1.1E-01 
11 69463628 A G NS 76582 Dnah2 43 p.Y2261H 3 1.1E-01 
11 69464975 T C NS 76278 Dnah2 42 p.D2218G 3 1.1E-01 
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11 117721060 A G NS 10382 Tnrc6c 5 p.T175A 3 1.9E-02 
11 117721327 G A NS 88025 Tnrc6c 5 p.V264I 3 1.9E-02 
11 117749719 T A NS 88041 Tnrc6c 15 p.M1445K 3 1.9E-02 
11 118040981 C T SP 98172 Dnah17 na na 3 1.1E-01 
11 118041504 C T NS 33095 Dnah17 68 p.R3632Q 3 1.1E-01 
11 118082870 T C NS 98420 Dnah17 38 p.Y1937C 3 1.1E-01 
12 8001795 T C NS 3000 Apob 22 p.I1120T 3 1.1E-01 
12 8002221 G A NS 82723 Apob 23 p.V1221M 3 1.1E-01 
12 8010844 A T NS 13019 Apob 26 p.I3109L 3 1.1E-01 
12 116059795 T C NS 96839 Zfp386 3 p.S378P 3 9.8E-04 
12 116060481 T A NS 88129 Zfp386 3 p.N606K 3 9.8E-04 
12 116060483 A C NS 6654 Zfp386 3 p.E607A 3 9.8E-04 
12 117880550 A G NS 11241 Dnah11 80 p.L4327P 3 1.1E-01 
12 118007969 A G NS 29035 Dnah11 54 p.L2951P 3 1.1E-01 
12 118111061 T G NS 89965 Dnah11 23 p.D1352A 3 1.1E-01 
13 93083378 A G NS 88955 Cmya5 4 p.C3188R 3 7.8E-02 
13 93090556 T G NS 11468 Cmya5 2 p.I2675L 3 7.8E-02 
13 93098044 T A NS 5401 Cmya5 2 p.I179F 3 7.8E-02 
14 31145819 T A NS 83875 Stab1 48 p.I1665F 3 3.8E-02 
14 31150668 T A NS 88262 Stab1 32 p.Q1135L 3 3.8E-02 
14 31154471 G A NS 2383 Stab1 25 p.T887I 3 3.8E-02 
14 47016301 A G NS 83217 Samd4 3 p.E74G 3 1.4E-03 
14 47016462 T C NS 51283 Samd4 3 p.Y128H 3 1.4E-03 
14 47089105 T C NS 76278 Samd4 10 p.V565A 3 1.4E-03 
15 4899191 A T NS 80821 Mroh2b 1 p.E2V 3 1.2E-02 
15 4904241 T C NS 51283 Mroh2b 4 p.V91A 3 1.2E-02 
15 4915225 A C NS 83971 Mroh2b 13 p.D436A 3 1.2E-02 
15 47650098 C T SP 83164 Csmd3 na na 3 8.0E-02 
15 47659192 A T NS 83689 Csmd3 52 p.C2694S 3 8.0E-02 
15 47838435 A T NS 2383 Csmd3 31 p.W1751R 3 8.0E-02 
15 58052644 A T NS 96868 Zhx1 3 p.N735K 3 2.5E-03 
15 58052719 A T NS 2383 Zhx1 3 p.D710E 3 2.5E-03 
15 58054047 A G NS 13019 Zhx1 3 p.S268P 3 2.5E-03 
15 66705348 A G NS 89285 Tg 21 p.T1507A 3 4.4E-02 
15 66735223 A G NS 22721 Tg 29 p.D1822G 3 4.4E-02 
15 66764268 T C NS 83217 Tg 38 p.I2187T 3 4.4E-02 
16 32751034 C G SG 83140 Muc4 2 p.S304X 3 7.0E-02 
16 32752353 A C NS 98420 Muc4 2 p.T744P 3 7.0E-02 
16 32753289 T C NS 96440 Muc4 2 p.S1056P 3 7.0E-02 
18 49852300 A G NS 90152 Dmxl1 7 p.T205A 3 5.3E-02 
18 49864168 T G NS 29035 Dmxl1 11 p.D510E 3 5.3E-02 
18 49893679 T A NS 11468 Dmxl1 24 p.S1951R 3 5.3E-02 
19 43966248 T C NS 2383 Cpn1 6 p.K313R 3 4.1E-04 
19 43966305 T C NS 60716 Cpn1 6 p.D294G 3 4.1E-04 
19 43973982 T C NS 76278 Cpn1 3 p.N176S 3 4.1E-04 
19 47897442 T C NS 89957 Itprip 2 p.T245A 3 7.1E-04 
19 47897591 A T NS 96868 Itprip 2 p.M195K 3 7.1E-04 
19 47898054 T A NS 82841 Itprip 2 p.M41L 3 7.1E-04 
1 11140236 A T NS 11954 Prex2 17 p.I588F 2 7.4E-02 
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1 11170704 T C NS 91570 Prex2 25 p.L1012S 2 7.4E-02 
1 22475705 T A NS 82620 Rims1 13 p.H539L 2 6.5E-02 
1 22726976 A T NS 90152 Rims1 2 p.C67S 2 6.5E-02 
1 36185863 A T NS 88041 Uggt1 16 p.D563E 2 7.1E-02 
1 36221324 T A NS 82620 Uggt1 5 p.I137L 2 7.1E-02 
1 43051769 T A NS 83971 Tgfbrap1 12 p.D732V 2 2.7E-02 
1 43071541 A G NS 2383 Tgfbrap1 4 p.I268T 2 2.7E-02 
1 45376160 A C NS 76989 Col5a2 54 p.I1473R 2 6.7E-02 
1 45422387 A T NS 83875 Col5a2 10 p.M246K 2 6.7E-02 
1 58056280 C A NS 10382 Aox1 8 p.P218T 2 5.6E-02 
1 58082019 A T NS 98491 Aox1 25 p.E883V 2 5.6E-02 
1 58121005 C A NS 11468 Aox3 5 p.Q116K 2 5.6E-02 
1 58152686 A G NS 42058 Aox3 14 p.I466V 2 5.6E-02 
1 63737880 T A NS 10451 Fastkd2 6 p.Y392N 2 1.8E-02 
1 63748048 T C NS 91570 Fastkd2 9 p.L547S 2 1.8E-02 
1 71599302 A G NS 24744 Fn1 36 p.Y1842H 2 1.4E-01 
1 71600419 T A NS 83737 Fn1 34 p.T1738S 2 1.4E-01 
1 74910539 C T NS 29035 Ccdc108 22 p.V1220M 2 9.2E-02 
1 74931987 C A NS 96868 Ccdc108 3 p.R57S 2 9.2E-02 
1 84370841 C T NS 91570 Dner 13 p.V713M 2 2.1E-02 
1 84534898 T G NS 82522 Dner 5 p.D316A 2 2.1E-02 
1 93320773 A G SP 14418 Pask na na 2 6.0E-02 
1 93327376 T C NS 83188 Pask 7 p.D324G 2 6.0E-02 
1 116428850 A G NS 82458 Cntnap5a 16 p.E810G 2 5.4E-02 
1 116455155 C T NS 83929 Cntnap5a 19 p.T1051I 2 5.4E-02 
1 127366425 C T NS 6927 Mgat5 6 p.S168L 2 2.1E-02 
1 127390838 C T SG 89957 Mgat5 10 p.Q357X 2 2.1E-02 
1 128589159 A C NS 83882 Cxcr4 2 p.F255C 2 5.5E-03 
1 128589627 T C NS 11468 Cxcr4 2 p.D99G 2 5.5E-03 
1 130449415 A T SP 57258 Cd55 na na 2 6.4E-03 
1 130452511 A T SG 3000 Cd55 6 p.Y243X 2 6.4E-03 
1 134987027 A T NS 83685 Lgr6 18 p.L938Q 2 3.3E-02 
1 135072889 T A NS 10451 Lgr6 3 p.I118F 2 3.3E-02 
1 135877676 T C NS 83794 Pkp1 11 p.N674S 2 2.0E-02 
1 135877815 T C NS 83971 Pkp1 11 p.T628A 2 2.0E-02 
1 136281454 T C NS 57372 Camsap2 13 p.M773V 2 6.6E-02 
1 136285962 A T NS 96440 Camsap2 10 p.N371K 2 6.6E-02 
1 138080196 A G NS 82723 Ptprc 22 p.V729A 2 5.3E-02 
1 138082755 A G NS 51283 Ptprc 20 p.C612R 2 5.3E-02 
1 153471745 A G NS 11468 Dhx9 12 p.S405P 2 5.9E-02 
1 153472536 T C NS 98491 Dhx9 10 p.I311M 2 5.9E-02 
1 171216511 A T NS 89965 Nr1i3 4 p.H134L 2 5.5E-03 
1 171217077 T C NS 5401 Nr1i3 6 p.S194P 2 5.5E-03 
1 172210373 T A NS 45755 Casq1 11 p.D397V 2 6.9E-03 
1 172216837 T G NS 88041 Casq1 3 p.D141A 2 6.9E-03 
2 20806213 G T NS 82620 Etl4 18 p.V1318F 2 1.0E-01 
2 20806666 A T NS 5401 Etl4 18 p.M1469L 2 1.0E-01 
2 25083688 A G NS 91310 Entpd8 6 p.D249G 2 1.0E-02 
2 25085084 T A NS 13019 Entpd8 10 p.F476I 2 1.0E-02 
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2 25888768 T G NS 76989 Kcnt1 4 p.I76S 2 5.0E-02 
2 25907569 T A NS 60654 Kcnt1 23 p.V844E 2 5.0E-02 
2 31898235 G A NS 6654 Lamc3 2 p.A136T 2 7.3E-02 
2 31920676 G A NS 80493 Lamc3 14 p.A853T 2 7.3E-02 
2 49272874 A G NS 60712 Mbd5 12 p.T1123A 2 8.3E-02 
2 49274741 T A NS 89285 Mbd5 13 p.N1243K 2 8.3E-02 
2 52226552 A G NS 24744 Neb 82 p.L4137P 2 2.7E-01 
2 52325788 T A NS 88955 Neb 8 p.Q169L 2 2.7E-01 
2 54857839 C T NS 82458 Galnt13 7 p.T244M 2 1.2E-02 
2 55112905 T C NS 83875 Galnt13 13 p.C539R 2 1.2E-02 
2 62264042 G T NS 6927 Slc4a10 11 p.Q446H 2 4.3E-02 
2 62304731 A G NS 91310 Slc4a10 22 p.M1008V 2 4.3E-02 
2 66501669 G A NS 11477 Scn9a 22 p.R1279W 2 NA 
2 66533091 T C NS 42885 Scn9a 17 p.M939V 2 NA 
2 66697618 A T NS 82522 Scn7a 15 p.S843T 2 8.0E-02 
2 66703908 T C NS 88041 Scn7a 12 p.I474M 2 8.0E-02 
2 69938252 A T NS 5401 Ubr3 8 p.I468F 2 9.5E-02 
2 70020625 T C NS 96868 Ubr3 37 p.C1796R 2 9.5E-02 
2 72398379 G A NS 80493 Zak 11 p.R314H 2 2.4E-02 
2 72416587 T C NS 2164 Zak 15 p.F417S 2 2.4E-02 
2 73381969 G T NS 76526 Gpr155 3 p.S103R 2 2.7E-02 
2 73382172 A G NS 11468 Gpr155 3 p.S36P 2 2.7E-02 
2 77011612 A T NS 11187 Ccdc141 24 p.S1492T 2 7.0E-02 
2 77014433 T C NS 82194 Ccdc141 23 p.E1430G 2 7.0E-02 
2 86041490 C A SG 29035 Olfr1033 3 p.Y58X 2 4.2E-03 
2 86041852 A T NS 82522 Olfr1033 3 p.D179V 2 4.2E-03 
2 91557676 G A SP 96868 Ckap5 6 na 2 1.0E-01 
2 91576022 T A NS 83929 Ckap5 18 p.N752K 2 1.0E-01 
2 104429946 A G NS 88129 Hipk3 16 p.I1162T 2 4.7E-02 
2 104434435 T C NS 53882 Hipk3 11 p.I736V 2 4.7E-02 
2 119071812 T A NS 13019 Casc5 8 p.S1331R 2 1.1E-01 
2 119086628 T A NS 88041 Casc5 13 p.V1764E 2 1.1E-01 
2 125581775 A T NS 42058 Cep152 20 p.M902K 2 8.4E-02 
2 125594919 G T NS 5401 Cep152 13 p.T567K 2 8.4E-02 
2 126826936 C A NS 80493 Trpm7 17 p.G687C 2 9.3E-02 
2 126851501 T C NS 96440 Trpm7 4 p.T55A 2 9.3E-02 
2 129199827 T A NS 76278 Slc20a1 2 p.F37I 2 1.8E-02 
2 129207616 T G NS 11477 Slc20a1 7 p.V266G 2 1.8E-02 
2 129463543 T C NS 88262 
F830045P16
Rik 
4 p.T304A 2 9.7E-03 
2 129472641 T A NS 88503 
F830045P16
Rik 
3 p.I239F 2 9.7E-03 
2 130026791 T C NS 82522 Tgm3 5 p.V216A 2 1.9E-02 
2 130042003 A C NS 76526 Tgm3 10 p.N527T 2 1.9E-02 
2 130671460 T A SP 45755 Itpa na na 2 1.7E-03 
2 130671577 C T NS 83140 Itpa 3 p.P49L 2 1.7E-03 
2 132934993 C T NS 2164 Fermt1 5 p.D192N 2 1.8E-02 
2 132936051 T A NS 82522 Fermt1 4 p.N166I 2 1.8E-02 
2 135930006 G A NS 11600 Plcb4 7 p.V141I 2 4.6E-02 
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2 135950232 T A NS 10382 Plcb4 13 p.F292I 2 4.6E-02 
2 154227156 A C NS 82841 Bpifb5 3 p.Q131P 2 9.8E-03 
2 154228116 A T NS 91310 Bpifb5 4 p.Q162L 2 9.8E-03 
2 155621351 A T NS 96245 Myh7b 16 p.Q501L 2 9.9E-02 
2 155623228 A G NS 83737 Myh7b 20 p.N668S 2 9.9E-02 
2 156506483 A T NS 96868 Epb4.1l1 9 p.I336F 2 2.8E-02 
2 156533791 T G NS 11187 Epb4.1l1 18 p.L758R 2 2.8E-02 
2 157995409 T C NS 82522 Tti1 4 p.D917G 2 4.0E-02 
2 158008170 G A NS 33095 Tti1 1 p.T383M 2 4.0E-02 
2 158036117 T A NS 83010 Rprd1b 2 p.H91Q 2 4.6E-03 
2 158075012 T A NS 82395 Rprd1b 7 p.L304Q 2 4.6E-03 
2 165420006 C G NS 83071 Slc13a3 10 p.A436P 2 1.4E-02 
2 165445620 A T NS 76582 Slc13a3 3 p.L138Q 2 1.4E-02 
2 168182274 A T NS 89957 Adnp 4 p.W1034R 2 4.1E-02 
2 168184598 T A NS 11477 Adnp 4 p.N259I 2 4.1E-02 
2 178363431 T C NS 11468 Sycp2 28 p.D881G 2 6.7E-02 
2 178401911 A T NS 60716 Sycp2 5 p.M134K 2 6.7E-02 
2 181007874 G A SP 83685 Col20a1 na na 2 5.5E-02 
2 181015604 T C NS 2164 Col20a1 33 p.I1239T 2 5.5E-02 
2 181351091 A G NS 76526 Rtel1 23 p.Y648C 2 4.8E-02 
2 181355986 A T NS 10382 Rtel1 34 p.R1176W 2 4.8E-02 
3 28048031 T A SG 60654 Pld1 11 p.C310X 2 3.7E-02 
3 28076401 A T NS 3000 Pld1 15 p.H450L 2 3.7E-02 
3 31150319 T A NS 10177 Cldn11 1 p.V57D 2 1.9E-03 
3 31163219 T C NS 96440 Cldn11 3 p.S179P 2 1.9E-03 
3 38949600 T C NS 2216 Fat4 3 p.S1823P 2 2.5E-01 
3 38983056 T G NS 98420 Fat4 9 p.V3619G 2 2.5E-01 
3 53516794 C T NS 80821 Frem2 24 p.R3074H 2 1.8E-01 
3 53547681 C T NS 10020 Frem2 9 p.G2158E 2 1.8E-01 
3 59325883 T A NS 11954 Igsf10 6 p.T1810S 2 1.4E-01 
3 59330916 A T NS 88025 Igsf10 5 p.F615I 2 1.4E-01 
3 63697503 T C NS 10020 Plch1 23 p.D1660G 2 8.0E-02 
3 63784035 G A NS 83882 Plch1 2 p.T49I 2 8.0E-02 
3 72949750 G T NS 83140 Sis 10 p.Q403K 2 9.0E-02 
3 72965643 G A NS 91310 Sis 2 p.P54L 2 9.0E-02 
3 87974803 A G NS 76278 Nes 3 p.T305A 2 9.3E-02 
3 87977807 A T NS 83737 Nes 4 p.R1124S 2 9.3E-02 
3 89221030 A G NS 89957 Thbs3 11 p.T417A 2 3.2E-02 
3 89226419 T C NS 83140 Thbs3 22 p.S930P 2 3.2E-02 
3 92824294 C A NS 60693 Kprp 2 p.R483L 2 1.7E-02 
3 92825401 A G NS 60654 Kprp 2 p.V114A 2 1.7E-02 
3 93470911 T A NS 3000 Tchhl1 3 p.D307E 2 1.6E-02 
3 93471635 C T NS 83164 Tchhl1 3 p.H549Y 2 1.6E-02 
3 99885519 G T NS 88262 Spag17 1 p.G10W 2 1.3E-01 
3 100004747 T C NS 2383 Spag17 7 p.L311P 2 1.3E-01 
3 101439500 T C NS 83685 Igsf3 7 p.F584L 2 4.7E-02 
3 101439746 T C NS 88547 Igsf3 7 p.S666P 2 4.7E-02 
3 108752110 A G NS 2216 Aknad1 2 p.T147A 2 1.8E-02 
3 108774984 T A NS 60716 Aknad1 8 p.D487E 2 1.8E-02 
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3 125561508 C A NS 60654 Ndst4 3 p.T355K 2 2.8E-02 
3 125710057 A G NS 24744 Ndst4 10 p.D650G 2 2.8E-02 
4 3904355 A G NS 88041 Plag1 6 p.S279P 2 1.0E-02 
4 3904576 A T NS 98491 Plag1 6 p.V205E 2 1.0E-02 
4 8828316 A C NS 83875 Chd7 13 p.N1086H 2 1.7E-01 
4 8854190 C T SG 11082 Chd7 29 p.Q1921X 2 1.7E-01 
4 16129060 A T SG 10562 Ripk2 8 p.L330X 2 1.2E-02 
4 16155078 A G NS 11187 Ripk2 3 p.L147P 2 1.2E-02 
4 19611757 A G NS 11478 Wwp1 25 p.L905P 2 3.0E-02 
4 19618338 C A NS 96247 Wwp1 24 p.K868N 2 3.0E-02 
4 22487008 A G NS 60716 Pou3f2 1 p.F375S 2 8.2E-03 
4 22487038 A G NS 10562 Pou3f2 1 p.V365A 2 8.2E-03 
4 28938644 G A NS 42058 Epha7 7 p.A500T 2 3.5E-02 
4 28963944 A G NS 11187 Epha7 17 p.S980G 2 3.5E-02 
4 43540616 C T NS 83685 Tln1 34 p.V1462M 2 1.4E-01 
4 43548076 A G NS 10562 Tln1 18 p.V689A 2 1.4E-01 
4 49447771 T C NS 6654 Acnat1 3 p.Y270C 2 7.3E-03 
4 49450650 G T NS 13019 Acnat1 1 p.P154T 2 7.3E-03 
4 58946266 T A NS 24744 Zkscan16 2 p.F47Y 2 2.0E-02 
4 58957625 T C NS 82086 Zkscan16 6 p.S636P 2 2.0E-02 
4 65176264 C T NS 11082 Pappa 3 p.H509Y 2 7.6E-02 
4 65204695 A T NS 98491 Pappa 7 p.T756S 2 7.6E-02 
4 75955248 C T NS 82522 Ptprd 36 p.V1337M 2 6.8E-02 
4 75998536 C T NS 88547 Ptprd 31 p.V1047I 2 6.8E-02 
4 82914754 A G NS 11468 Frem1 30 p.S1900P 2 1.2E-01 
4 82916711 T C NS 98420 Frem1 29 p.E1844G 2 1.2E-01 
4 86774361 C T NS 88955 Dennd4c 2 p.S36L 2 9.6E-02 
4 86786082 A G NS 83010 Dennd4c 6 p.Y278C 2 9.6E-02 
4 88178290 T C SP 39748 Focad na na 2 8.8E-02 
4 88403376 T C NS 96247 Focad 41 p.S1655P 2 8.8E-02 
4 108513278 A T NS 80821 Zcchc11 14 p.Q830H 2 7.7E-02 
4 108549321 A G NS 33095 Zcchc11 27 p.D1357G 2 7.7E-02 
4 115601108 T C NS 83140 Cyp4a32 1 p.L45P 2 1.1E-02 
4 115611338 A T NS 88955 Cyp4a32 8 p.H339L 2 1.1E-02 
4 116877793 T C NS 6654 Zswim5 1 p.Y112H 2 4.7E-02 
4 116986873 A G NS 83520 Zswim5 14 p.Q1036R 2 4.7E-02 
4 123465902 C T NS 88041 Macf1 38 p.S3428N 2 2.7E-01 
4 123476142 T A NS 83230 Macf1 36 p.I1609F 2 2.7E-01 
4 138096761 A G NS 3000 Eif4g3 7 p.R21G 2 7.3E-02 
4 138206012 A G NS 83230 Eif4g3 35 p.E1521G 2 7.3E-02 
4 138304883 A C NS 83071 Ddost 1 p.K2T 2 8.0E-03 
4 138311958 T G NS 89965 Ddost 11 p.M434R 2 8.0E-03 
4 141474192 T C NS 83689 Spen 12 p.T2375A 2 2.1E-01 
4 141479234 T A NS 6654 Spen 12 p.Y694F 2 2.1E-01 
4 141796525 T C NS 5401 Casp9 2 p.S75P 2 8.5E-03 
4 141805504 T G NS 55922 Casp9 4 p.F237C 2 8.5E-03 
4 143851812 T C NS 22721 Gm13103 3 p.I214T 2 9.8E-03 
4 143851827 G A NS 11187 Gm13103 3 p.C219Y 2 9.8E-03 
4 148483594 A T NS 98491 Mtor 21 p.I1053F 2 1.4E-01 
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4 148549380 T A NS 83188 Mtor 51 p.N2343K 2 1.4E-01 
4 149650647 C T NS 76526 Pik3cd 24 p.R1045Q 2 3.8E-02 
4 149654297 T C NS 76278 Pik3cd 17 p.Q723R 2 3.8E-02 
4 152031440 T A NS 76278 Tas1r1 4 p.I453F 2 2.6E-02 
4 152034647 G A NS 55922 Tas1r1 2 p.T155I 2 2.6E-02 
4 156169312 T A SG 83882 Agrn 31 p.K1749X 2 1.1E-01 
4 156175098 A T SP 57258 Agrn na na 2 1.1E-01 
5 21760695 G A NS 83929 Dnajc2 14 p.H487Y 2 1.5E-02 
5 21768554 A T NS 91570 Dnajc2 9 p.N272K 2 1.5E-02 
5 23473531 T C NS 80840 Kmt2e 7 p.Y203H 2 9.3E-02 
5 23485514 T A NS 98172 Kmt2e 13 p.M509K 2 9.3E-02 
5 32316649 G A NS 42885 Plb1 26 p.V507I 2 6.6E-02 
5 32317492 C A NS 5401 Plb1 29 p.H591N 2 6.6E-02 
5 64264336 T C NS 11600 Tbc1d1 6 p.I357T 2 4.5E-02 
5 64279375 T A NS 11478 Tbc1d1 10 p.D523E 2 4.5E-02 
5 66276573 T C NS 80840 Nsun7 5 p.S189P 2 1.9E-02 
5 66289500 A T NS 11468 Nsun7 10 p.E461V 2 1.9E-02 
5 73101557 T C NS 83971 Fryl 20 p.D628G 2 1.7E-01 
5 73125551 A T NS 82086 Fryl 8 p.L152Q 2 1.7E-01 
5 89179786 C T NS 2216 Slc4a4 16 p.T703I 2 4.1E-02 
5 89179810 A G NS 91570 Slc4a4 16 p.K711R 2 4.1E-02 
5 100556535 G T NS 22721 Plac8 4 p.L99I 2 5.8E-04 
5 100556576 T C NS 82147 Plac8 4 p.Y85C 2 5.8E-04 
5 103784319 A G NS 83882 Aff1 3 p.K276E 2 4.9E-02 
5 103815060 C T NS 83010 Aff1 5 p.P382S 2 4.9E-02 
5 112307703 T A NS 10382 Tpst2 3 p.V36E 2 6.4E-03 
5 112308116 T C NS 2730 Tpst2 3 p.F174L 2 6.4E-03 
5 123951216 A G NS 10653 Ccdc62 7 p.K306E 2 1.9E-02 
5 123951228 C T NS 80821 Ccdc62 7 p.L310F 2 1.9E-02 
5 125622539 T C NS 57372 Tmem132b 2 p.V47A 2 4.0E-02 
5 125785991 T C NS 98313 Tmem132b 8 p.S687P 2 4.0E-02 
5 129109635 T C NS 80821 Gpr133 3 p.I54T 2 2.9E-02 
5 129109651 C A NS 88129 Gpr133 3 p.D59E 2 2.9E-02 
5 140635561 A G NS 83411 Ttyh3 3 p.Y120H 2 1.1E-02 
5 140648823 G A NS 11478 Ttyh3 1 p.A2V 2 1.1E-02 
5 147676422 A T NS 60712 Flt1 8 p.S336R 2 5.6E-02 
5 147699817 T A NS 60716 Flt1 3 p.K119M 2 5.6E-02 
5 150038233 T A NS 60716 Rxfp2 3 p.F73I 2 2.1E-02 
5 150051610 G A NS 76526 Rxfp2 8 p.G214E 2 2.1E-02 
5 150722313 A G NS 33095 Pds5b 4 p.T111A 2 6.4E-02 
5 150779226 A G NS 88547 Pds5b 22 p.T808A 2 6.4E-02 
6 3687603 A T NS 11468 Calcr 16 p.I465N 2 1.1E-02 
6 3707599 T C NS 6927 Calcr 10 p.M234V 2 1.1E-02 
6 12379405 A T NS 60693 Thsd7a 13 p.C1007S 2 7.8E-02 
6 12500995 T A NS 76989 Thsd7a 4 p.D471V 2 7.8E-02 
6 22961668 T A NS 42058 Ptprz1 4 p.I126K 2 1.2E-01 
6 23029281 A G NS 98172 Ptprz1 19 p.D1807G 2 1.2E-01 
6 24796067 T C NS 5401 Spam1 2 p.F6L 2 1.1E-02 
6 24796824 T C NS 6654 Spam1 2 p.L258P 2 1.1E-02 
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6 28545519 T A NS 45755 Snd1 10 p.V358E 2 3.0E-02 
6 28829804 A T NS 11478 Lrrc4 1 p.I604N 2 1.7E-02 
6 28831364 T C NS 83071 Lrrc4 1 p.N84S 2 1.7E-02 
6 28888083 C A NS 89965 Snd1 23 p.T876K 2 3.0E-02 
6 41032430 A G NS 82395 
2210010C04
Rik 
4 p.S157P 2 2.7E-03 
6 41033091 T C NS 83875 
2210010C04
Rik 
3 p.N103S 2 2.7E-03 
6 42673538 A G NS 11082 Fam115a 8 p.M869T 2 3.0E-02 
6 42679172 A G NS 76526 Fam115a 3 p.V290A 2 3.0E-02 
6 43274772 T C NS 98172 Arhgef5 2 p.I819T 2 7.3E-02 
6 43280669 T C NS 88025 Arhgef5 8 p.L1290P 2 7.3E-02 
6 63256935 A G NS 14418 Grid2 1 p.I27V 2 3.5E-02 
6 64094381 T C NS 11187 Grid2 8 p.V396A 2 3.5E-02 
6 71216853 T A NS 57931 Smyd1 9 p.M397L 2 9.8E-03 
6 71262182 T C NS 98172 Smyd1 1 p.N8S 2 9.8E-03 
6 85340715 T A NS 96868 Rab11fip5 4 p.E1064V 2 5.5E-02 
6 85348672 A G NS 96440 Rab11fip5 2 p.S251P 2 5.5E-02 
6 85622422 A G NS 88262 Alms1 8 p.E1410G 2 1.8E-01 
6 85696238 T A NS 90152 Alms1 18 p.F3031L 2 1.8E-01 
6 88586788 T A NS 76989 Kbtbd12 5 p.H559L 2 1.5E-02 
6 88618756 C T NS 29035 Kbtbd12 2 p.V31I 2 1.5E-02 
6 90409351 T C NS 91570 Ccdc37 13 p.Q428R 2 1.5E-02 
6 90413019 A G NS 11600 Ccdc37 9 p.S250P 2 1.5E-02 
6 97160331 A C NS 60654 Tmf1 13 p.L888R 2 4.0E-02 
6 97176228 A G NS 11600 Tmf1 2 p.S295P 2 4.0E-02 
6 115888829 C T NS 57931 Ift122 11 p.S360L 2 4.6E-02 
6 115920373 T C NS 10177 Ift122 23 p.L911P 2 4.6E-02 
6 116695289 C T NS 60716 Tmem72 5 p.R197H 2 3.3E-03 
6 116696858 A G NS 83971 Tmem72 4 p.S100P 2 3.3E-03 
6 118687100 A T NS 88025 Cacna1c 14 p.M700K 2 1.2E-01 
6 118741895 T C NS 76387 Cacna1c 8 p.N398S 2 1.2E-01 
6 119320781 A G NS 83875 Lrtm2 4 p.S100P 2 5.8E-03 
6 119320949 T C NS 98172 Lrtm2 4 p.T44A 2 5.8E-03 
6 120394245 T A NS 88955 Kdm5a 12 p.V550E 2 8.1E-02 
6 120404971 G A NS 82086 Kdm5a 15 p.V659M 2 8.1E-02 
6 122040671 A G NS 76582 Mug2 12 p.S456G 2 6.4E-02 
6 122075274 A G NS 76989 Mug2 24 p.Q997R 2 6.4E-02 
6 124438333 T A NS 29035 Clstn3 14 p.M728L 2 3.2E-02 
6 124457996 C T NS 96868 Clstn3 7 p.G357D 2 3.2E-02 
6 124904543 T C NS 60712 Lag3 8 p.R489G 2 1.1E-02 
6 124908427 T G NS 98313 Lag3 5 p.H330P 2 1.1E-02 
6 125101279 T C NS 83794 Chd4 5 p.F160S 2 9.7E-02 
6 125101969 T A NS 11954 Chd4 7 p.I289N 2 9.7E-02 
6 132957094 A G NS 3000 Tas2r131 1 p.F251L 2 4.1E-03 
6 132957264 A T SG 60654 Tas2r131 1 p.L194X 2 4.1E-03 
6 142658586 T C NS 88547 Abcc9 16 p.N641S 2 7.1E-02 
6 142672612 T A NS 96245 Abcc9 13 p.I546F 2 7.1E-02 
6 149000023 A T NS 83217 Dennd5b 19 p.C1122S 2 5.2E-02 
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6 149068427 T C NS 14418 Dennd5b 3 p.Y176C 2 5.2E-02 
7 27877871 T C NS 83971 Zfp607 5 p.L122P 2 1.8E-02 
7 27879333 T A NS 82522 Zfp607 5 p.N609K 2 1.8E-02 
7 29077046 C T NS 83929 Ryr1 40 p.V2215I 2 2.6E-01 
7 29109255 T C NS 83457 Ryr1 13 p.E464G 2 2.6E-01 
7 30775332 A T NS 60693 Dmkn 13 p.H413L 2 1.1E-02 
7 30776115 C A NS 82395 Dmkn 14 p.Q443K 2 1.1E-02 
7 42612599 G A NS 88547 
9830147E19
Rik 
4 p.P606S 2 1.6E-02 
7 42612837 A T NS 10020 
9830147E19
Rik 
4 p.N526K 2 1.6E-02 
7 45650928 C G NS 83217 Fut2 3 p.R140P 2 5.2E-03 
7 45651270 A G NS 91310 Fut2 3 p.I26T 2 5.2E-03 
7 65311085 T C NS 88025 Tjp1 23 p.H1373R 2 8.5E-02 
7 65313310 C A SG 22721 Tjp1 21 p.E1040X 2 8.5E-02 
7 66259951 C T NS 10562 Lrrk1 34 p.G2004S 2 1.0E-01 
7 66265494 G T NS 83619 Lrrk1 31 p.S1615R 2 1.0E-01 
7 79097853 T C NS 57931 Acan 12 p.S791P 2 1.1E-01 
7 79099764 T C NS 6927 Acan 12 p.S1428P 2 1.1E-01 
7 79691948 T A NS 6654 Ticrr 19 p.M1094K 2 9.5E-02 
7 79693713 A G NS 82620 Ticrr 20 p.S1109G 2 9.5E-02 
7 80713863 A G NS 76824 Iqgap1 38 p.F1648S 2 7.9E-02 
7 80760889 T C NS 51283 Iqgap1 7 p.Y192C 2 7.9E-02 
7 83973301 T C NS 11468 
9930013L23
Rik 
13 p.I557V 2 5.8E-02 
7 83973331 T C NS 83411 
9930013L23
Rik 
13 p.M547V 2 5.8E-02 
7 98067160 A C NS 83882 Myo7a 33 p.S1471A 2 1.2E-01 
7 98092483 T C NS 5401 Myo7a 13 p.Q493R 2 1.2E-01 
7 104893019 A G NS 82522 Olfr666 1 p.M203T 2 4.3E-03 
7 104893325 A G NS 83010 Olfr666 1 p.V101A 2 4.3E-03 
7 107181907 T A NS 98491 Nlrp14 3 p.W104R 2 3.5E-02 
7 107182192 G A NS 90152 Nlrp14 3 p.V199M 2 3.5E-02 
7 110369529 C A NS 60654 Sbf2 22 p.R888L 2 9.4E-02 
7 110447049 G C NS 88041 Sbf2 9 p.P314A 2 9.4E-02 
7 113299364 T A NS 82522 Arntl 13 p.I333K 2 1.5E-02 
7 113304395 T A NS 11477 Arntl 16 p.M466K 2 1.5E-02 
7 118184636 A T NS 83689 Smg1 22 p.V1009D 2 2.1E-01 
7 118212982 A T NS 6654 Smg1 2 p.S53T 2 2.1E-01 
7 127788499 T G NS 11954 Setd1a 12 p.D997E 2 8.2E-02 
7 127799173 T A NS 29035 Setd1a 18 p.I1641N 2 8.2E-02 
7 133930045 C T NS 11477 Adam12 14 p.C487Y 2 2.9E-02 
7 133967900 T C NS 2730 Adam12 9 p.H282R 2 2.9E-02 
7 139089523 T C NS 82744 Dpysl4 2 p.L18P 2 1.3E-02 
7 139096320 T C NS 82522 Dpysl4 9 p.S322P 2 1.3E-02 
7 141620815 T C NS 2383 Ap2a2 13 p.L525P 2 3.1E-02 
7 141627947 A G NS 60716 Ap2a2 17 p.T753A 2 3.1E-02 
8 15081294 A G NS 57372 Myom2 10 p.M331V 2 6.5E-02 
8 15111958 A T SP 88129 Myom2 na na 2 6.5E-02 
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8 15912420 A G NS 82086 Csmd1 63 p.L3258P 2 2.0E-01 
8 16092347 T A NS 11600 Csmd1 29 p.N1514I 2 2.0E-01 
8 41290775 T C NS 89285 Pcm1 21 p.V1153A 2 1.0E-01 
8 41293515 T A NS 6927 Pcm1 22 p.D1211E 2 1.0E-01 
8 44952851 A C NS 39748 Fat1 1 p.I880L 2 2.4E-01 
8 44952852 T C NS 60693 Fat1 1 p.I880T 2 2.4E-01 
8 48235439 C T NS 42058 Tenm3 25 p.R2355K 2 1.5E-01 
8 48276325 T C NS 82841 Tenm3 21 p.T1533A 2 1.5E-01 
8 55872906 G A NS 10177 Adam29 2 p.S171F 2 2.2E-02 
8 55873357 T C NS 96440 Adam29 2 p.I21V 2 2.2E-02 
8 68892757 T C NS 96868 Lpl 3 p.F138L 2 9.2E-03 
8 68896745 A C NS 88025 Lpl 6 p.N308H 2 9.2E-03 
8 84887044 T C NS 88503 Gcdh 12 p.D427G 2 8.3E-03 
8 84893077 C T NS 89957 Gcdh 4 p.R81H 2 8.3E-03 
8 85970927 A G NS 83929 Phkb 15 p.D455G 2 4.0E-02 
8 86016877 A C NS 13019 Phkb 18 p.I535L 2 4.0E-02 
8 87773612 C T NS 82147 Zfp423 5 p.E1186K 2 5.3E-02 
8 87782031 G A SG 60716 Zfp423 4 p.Q562X 2 5.3E-02 
8 90252717 T C NS 22721 Tox3 6 p.T307A 2 1.3E-02 
8 90270360 C T NS 82147 Tox3 3 p.D92N 2 1.3E-02 
8 91102246 G T NS 11187 Rbl2 14 p.G635C 2 4.3E-02 
8 91106796 T C NS 45755 Rbl2 16 p.L776P 2 4.3E-02 
8 105358408 C A NS 22721 Slc9a5 10 p.L514I 2 2.9E-02 
8 105359377 T A NS 76582 Slc9a5 12 p.V592E 2 2.9E-02 
8 105461068 A G NS 2164 Lrrc36 10 p.T539A 2 2.1E-02 
8 105463898 T A NS 80840 Lrrc36 11 p.V612E 2 2.1E-02 
8 106657868 A G NS 83971 Cdh1 7 p.R323G 2 2.8E-02 
8 106665445 A G NS 11478 Cdh1 14 p.E741G 2 2.8E-02 
8 107416245 G A NS 82194 Nob1 8 p.T268I 2 6.8E-03 
8 107424984 C A NS 83971 Nob1 1 p.L15F 2 6.8E-03 
8 110298180 T C NS 24744 Hydin 3 p.V74A 2 2.6E-01 
8 110595458 C T NS 10722 Hydin 80 p.R4581C 2 2.6E-01 
8 110835659 A T NS 88547 Sf3b3 9 p.S375T 2 4.8E-02 
8 110842840 C A NS 96868 Sf3b3 3 p.S82I 2 4.8E-02 
8 110883939 T C NS 60716 Fuk 22 p.D944G 2 4.0E-02 
8 110886577 G T NS 57931 Fuk 19 p.H829Q 2 4.0E-02 
8 120571004 C T NS 11600 Gse1 9 p.T639I 2 4.9E-02 
8 120575134 A G NS 98491 Gse1 13 p.S982G 2 4.9E-02 
8 123373994 C T NS 96868 Tcf25 1 p.P41L 2 1.8E-02 
8 123393197 G C NS 82522 Tcf25 11 p.R394P 2 1.8E-02 
8 128993081 T A SP 96440 Ccdc7 na na 2 5.9E-03 
8 129061812 A T NS 83230 Ccdc7 3 p.M12K 2 5.9E-03 
9 4330330 A G NS 83794 Kbtbd3 4 p.T235A 2 1.5E-02 
9 4331087 C T NS 76824 Kbtbd3 4 p.A487V 2 1.5E-02 
9 7023334 A G NS 82522 Dync2h1 70 p.Y3557H 2 2.3E-01 
9 7172898 A G NS 10562 Dync2h1 4 p.F176L 2 2.3E-01 
9 15998377 C T NS 3000 Fat3 9 p.A2110T 2 2.4E-01 
9 16006567 T C NS 88025 Fat3 7 p.D1520G 2 2.4E-01 
9 18330818 T A NS 11600 Naalad2 16 p.T559S 2 2.1E-02 
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9 18376560 T C NS 89957 Naalad2 6 p.D220G 2 2.1E-02 
9 20772193 C A NS 76526 Col5a3 64 p.G1561V 2 8.4E-02 
9 20801230 G A NS 10382 Col5a3 14 p.R488C 2 8.4E-02 
9 35457424 A T NS 88025 Cdon 6 p.H318L 2 5.1E-02 
9 35478658 T A NS 10382 Cdon 13 p.N869K 2 5.1E-02 
9 42338913 A G NS 13019 Tecta 18 p.V1861A 2 1.1E-01 
9 42373115 G T NS 11478 Tecta 10 p.D891E 2 1.1E-01 
9 52120286 A T NS 5401 Zc3h12c 4 p.V360E 2 2.9E-02 
9 52120378 T A NS 11477 Zc3h12c 4 p.L329F 2 2.9E-02 
9 62796708 G T NS 98491 Fem1b 2 p.N423K 2 1.5E-02 
9 62811164 T C NS 57931 Fem1b 1 p.T48A 2 1.5E-02 
9 64235805 G A SG 29035 Uchl4 1 p.W189X 2 2.4E-03 
9 64235900 A T NS 83230 Uchl4 1 p.D221V 2 2.4E-03 
9 64508751 T C NS 10722 Megf11 4 p.Y81H 2 4.1E-02 
9 64691921 A T NS 11082 Megf11 17 p.Q737L 2 4.1E-02 
9 64924555 T C NS 2383 Slc24a1 10 p.I1087V 2 4.3E-02 
9 64948266 T A NS 11477 Slc24a1 2 p.H453L 2 4.3E-02 
9 69759903 T C NS 76989 Foxb1 2 p.D115G 2 4.6E-03 
9 69759915 A G NS 83071 Foxb1 2 p.V111A 2 4.6E-03 
9 70579361 C A NS 11477 Sltm 10 p.T436K 2 3.7E-02 
9 70586948 C T SG 76824 Sltm 18 p.R894X 2 3.7E-02 
9 72362101 C T NS 80840 Zfp280d 22 p.T840I 2 3.3E-02 
9 72362320 G A NS 83737 Zfp280d 22 p.R913H 2 3.3E-02 
9 72731228 T A NS 60712 Nedd4 16 p.W466R 2 2.9E-02 
9 72739509 A G NS 11478 Nedd4 23 p.N715D 2 2.9E-02 
9 79626992 A T NS 83230 Col12a1 51 p.H2651Q 2 NA 
9 79631641 A G NS 96440 Col12a1 47 p.F2458L 2 NA 
9 95999437 T C NS 83164 Xrn1 21 p.I788T 2 8.3E-02 
9 96051698 A T NS 89957 Xrn1 41 p.M1607L 2 8.3E-02 
9 99576632 A T NS 90152 Dbr1 2 p.H85L 2 1.2E-02 
9 99579443 G T SP 89285 Dbr1 na na 2 1.2E-02 
9 111349345 A G NS 88025 Trank1 7 p.D367G 2 1.7E-01 
9 111389180 A T NS 76278 Trank1 19 p.Y1876F 2 1.7E-01 
10 5052828 C A NS 10020 Syne1 43 p.R2263L 2 1.7E-01 
10 5117085 A T NS 96440 Syne1 25 p.V1294E 2 1.7E-01 
10 10741602 T A NS 80493 Grm1 6 p.Y479F 2 4.7E-02 
10 11079875 A T NS 89285 Grm1 2 p.Y222N 2 4.7E-02 
10 11164414 T C NS 90152 Shprh 9 p.Y544H 2 8.0E-02 
10 11164592 T C NS 83929 Shprh 9 p.V603A 2 8.0E-02 
10 14128144 A G NS 45755 Hivep2 4 p.Y162C 2 1.3E-01 
10 14132531 T A NS 11187 Hivep2 4 p.S1624R 2 1.3E-01 
10 18498132 A G NS 2216 Nhsl1 3 p.D104G 2 7.3E-02 
10 18516089 T A NS 83457 Nhsl1 5 p.V197E 2 7.3E-02 
10 39805605 A G NS 96245 Rev3l 7 p.I255V 2 1.8E-01 
10 39874219 T A NS 10382 Rev3l 32 p.F3122I 2 1.8E-01 
10 53348693 T C NS 80493 Cep85l 3 p.T267A 2 2.4E-02 
10 53348752 A G NS 2164 Cep85l 3 p.L247P 2 2.4E-02 
10 61614103 T C NS 76387 Npffr1 2 p.L52P 2 7.8E-03 
10 61614178 T C NS 10382 Npffr1 2 p.V77A 2 7.8E-03 
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10 76357073 G A SG 10722 Pcnt 37 p.Q2681X 2 1.6E-01 
10 76429217 T C NS 22721 Pcnt 8 p.N353S 2 1.6E-01 
10 84374668 A G NS 83010 Nuak1 7 p.S519P 2 1.7E-02 
10 84380792 A T SG 13019 Nuak1 5 p.Y219X 2 1.7E-02 
10 88400664 T A NS 10178 Gnptab 2 p.W44R 2 5.0E-02 
10 88440309 T C NS 83929 Gnptab 19 p.S1153P 2 5.0E-02 
10 88978802 A C NS 82522 Ano4 22 p.W675G 2 3.2E-02 
10 88995266 T A NS 91570 Ano4 16 p.K498N 2 3.2E-02 
10 93845784 C T NS 98172 Usp44 3 p.T32I 2 1.9E-02 
10 93846545 G A NS 5401 Usp44 3 p.V286I 2 1.9E-02 
10 107771168 T A NS 91570 Otogl 53 p.D2118V 2 1.3E-01 
10 107806754 T A NS 83411 Otogl 33 p.N1272Y 2 1.3E-01 
10 109703351 G T NS 24744 Nav3 33 p.T2063K 2 1.3E-01 
10 109754958 A T NS 57372 Nav3 19 p.M1544K 2 1.3E-01 
10 123002865 T C NS 83230 Mon2 32 p.K1572E 2 8.3E-02 
10 123036045 A T NS 89957 Mon2 9 p.I358K 2 8.3E-02 
10 127331738 T C NS 83737 Gli1 13 p.S549G 2 4.2E-02 
10 127331767 A G NS 82086 Gli1 13 p.V539A 2 4.2E-02 
10 128942934 T A NS 83230 Itga7 6 p.I306K 2 4.3E-02 
10 128943836 A G NS 80493 Itga7 9 p.D456G 2 4.3E-02 
11 5962443 T C SP 88129 Ykt6 na na 2 1.7E-03 
11 5966040 T A NS 96245 Ykt6 7 p.M198K 2 1.7E-03 
11 12254663 G T NS 42885 Cobl 12 p.Q680K 2 5.6E-02 
11 12267081 T C NS 96245 Cobl 10 p.E469G 2 5.6E-02 
11 29205704 T A NS 11468 Smek2 11 p.C557S 2 2.5E-02 
11 29211624 G A NS 83071 Smek2 14 p.R666H 2 2.5E-02 
11 29553649 G C NS 80493 
1700034F02
Rik 
2 p.E22Q 2 1.4E-02 
11 29560845 C A SG 80840 
1700034F02
Rik 
6 p.Y282X 2 1.4E-02 
11 43597466 T C NS 83217 Fabp6 3 p.E111G 2 7.5E-04 
11 43601464 A T NS 11241 Fabp6 1 p.D16E 2 7.5E-04 
11 50873024 T A NS 83230 Zfp454 6 p.Q527L 2 1.2E-02 
11 50873839 C A NS 6654 Zfp454 6 p.E255D 2 1.2E-02 
11 58891502 C A SG 24744 Zfp39 5 p.E145X 2 2.0E-02 
11 58900671 A T NS 57372 Zfp39 3 p.D63E 2 2.0E-02 
11 59090640 T A NS 10562 Obscn 18 p.S1851C 2 2.6E-01 
11 59133029 A G NS 83230 Obscn 4 p.M605T 2 2.6E-01 
11 60779157 A G NS 2164 Smcr8 1 p.E377G 2 3.1E-02 
11 60779587 T A NS 6654 Smcr8 1 p.S520R 2 3.1E-02 
11 67297458 A G NS 5401 Myh8 24 p.T982A 2 9.8E-02 
11 67304394 A G NS 11187 Myh8 35 p.E1678G 2 9.8E-02 
11 68783262 A G NS 11600 Myh10 16 p.N674S 2 1.0E-01 
11 68783426 G T NS 90152 Myh10 17 p.C701F 2 1.0E-01 
11 70617342 C T NS 83071 Chrne 7 p.G203R 2 1.0E-02 
11 70618182 T C NS 88129 Chrne 5 p.D158G 2 1.0E-02 
11 75487163 T A SG 57258 Prpf8 1 p.Y24X 2 1.3E-01 
11 75506451 T C NS 88025 Prpf8 37 p.S2037P 2 1.3E-01 
11 76117805 T C NS 6927 Vps53 9 p.R230G 2 2.5E-02 
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11 76163853 T C NS 57931 Vps53 4 p.D77G 2 2.5E-02 
11 76210959 A G NS 82522 Gemin4 2 p.M992T 2 3.8E-02 
11 76211059 A G NS 2730 Gemin4 2 p.S959P 2 3.8E-02 
11 77454398 A G NS 14418 Ssh2 15 p.T1064A 2 6.2E-02 
11 77454405 A G NS 57372 Ssh2 15 p.E1066G 2 6.2E-02 
11 77550971 T A NS 82620 Taok1 15 p.K535N 2 3.5E-02 
11 77578815 T A NS 88025 Taok1 4 p.I73F 2 3.5E-02 
11 78212187 C T NS 83457 Supt6 31 p.D1407N 2 8.3E-02 
11 78229438 T A NS 29035 Supt6 9 p.I359F 2 8.3E-02 
11 78284148 T C NS 83882 
2610507B11
Rik 
28 p.I1703T 2 1.2E-01 
11 78289883 A T NS 80493 
2610507B11
Rik 
39 p.N2202I 2 1.2E-01 
11 80243477 T C NS 98172 Rhot1 11 p.Y299H 2 1.7E-02 
11 80253043 T C NS 88503 Rhot1 17 p.V511A 2 1.7E-02 
11 83422059 A G NS 83882 Gas2l2 6 p.V809A 2 2.7E-02 
11 83427400 A C NS 83971 Gas2l2 2 p.F161C 2 2.7E-02 
11 87868677 T C NS 2383 Epx 10 p.K529E 2 2.0E-02 
11 87871344 A T SG 83071 Epx 7 p.C360X 2 2.0E-02 
11 98155404 A T NS 10020 Med1 17 p.M1522K 2 7.3E-02 
11 98156625 T A NS 60716 Med1 17 p.K1115M 2 7.3E-02 
11 106511922 T 
T
G 
FSI 76824 Tex2 10 p.P1041fs 2 4.3E-02 
11 106567364 A T NS 29035 Tex2 2 p.D413E 2 4.3E-02 
11 113843082 G A NS 98491 Sdk2 19 p.T845I 2 1.1E-01 
11 113885288 T C NS 88503 Sdk2 5 p.D196G 2 1.1E-01 
11 120362479 T G NS 42885 Fscn2 1 p.S257R 2 9.9E-03 
11 120362508 A G NS 10562 Fscn2 1 p.N267S 2 9.9E-03 
12 4701343 C T NS 11477 Itsn2 31 p.T1284M 2 8.0E-02 
12 4712465 A T SP 10451 Itsn2 38 na 2 8.0E-02 
12 13335891 T C NS 96868 Nbas 20 p.F719L 2 1.3E-01 
12 13408196 C T NS 98313 Nbas 32 p.R1235C 2 1.3E-01 
12 38190115 G A NS 98420 Dgkb 16 p.G464R 2 2.4E-02 
12 38190120 T A NS 76278 Dgkb 16 p.N465K 2 2.4E-02 
12 50365637 C A NS 11241 Prkd1 16 p.A721S 2 3.0E-02 
12 50425590 A T NS 11478 Prkd1 4 p.L180Q 2 3.0E-02 
12 51888272 T C SP 83929 Heatr5a na na 2 1.1E-01 
12 51889645 C T NS 60712 Heatr5a 30 p.R1581H 2 1.1E-01 
12 53072496 A T NS 42058 Akap6 11 p.Q1115H 2 1.2E-01 
12 53141326 T C NS 83737 Akap6 13 p.I1841T 2 1.2E-01 
12 54916904 A T SG 88955 Baz1a 18 p.C798X 2 7.1E-02 
12 54929601 A T NS 83685 Baz1a 11 p.M430K 2 7.1E-02 
12 69318149 A G NS 33095 Nemf 26 p.S822P 2 3.9E-02 
12 69354717 T C NS 83188 Nemf 4 p.D96G 2 3.9E-02 
12 72481551 T A NS 60654 Lrrc9 20 p.W876R 2 6.4E-02 
12 72486378 T G NS 89285 Lrrc9 22 p.I1008S 2 6.4E-02 
12 73179237 A G NS 57372 Mnat1 4 p.N117D 2 4.1E-03 
12 73272465 T A SG 51255 Mnat1 8 p.Y287X 2 4.1E-03 
12 75391740 T C NS 96839 Rhoj 3 p.F100S 2 2.0E-03 
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12 75400177 C T NS 90152 Rhoj 5 p.A190V 2 2.0E-03 
12 78492072 A G NS 11477 Gphn 7 p.H164R 2 2.2E-02 
12 78664559 G T NS 83520 Gphn 19 p.K638N 2 2.2E-02 
12 80339621 C T NS 13019 Dcaf5 9 p.R577H 2 3.2E-02 
12 80339649 A C NS 11468 Dcaf5 9 p.S568A 2 3.2E-02 
12 81917689 T C NS 83929 Pcnx 6 p.F210S 2 1.3E-01 
12 81974410 C T NS 29035 Pcnx 22 p.T1397I 2 1.3E-01 
12 82357325 T C NS 10382 Sipa1l1 3 p.S531P 2 8.7E-02 
12 82450030 A T NS 82086 Sipa1l1 21 p.I1779L 2 8.7E-02 
12 89260402 T C NS 10178 Nrxn3 6 p.M269T 2 7.2E-02 
12 90332016 T C NS 5401 Nrxn3 20 p.V1441A 2 7.2E-02 
12 98222650 A G NS 82744 Galc 11 p.Y401H 2 1.8E-02 
12 98234339 A G NS 83619 Galc 8 p.W271R 2 1.8E-02 
12 104147387 C T NS 83737 Serpina3c 5 p.G367S 2 7.2E-03 
12 104151485 T G NS 91570 Serpina3c 2 p.D198A 2 7.2E-03 
12 110659137 A G NS 80821 Dync1h1 63 p.E3911G 2 2.4E-01 
12 110662923 G C NS 13019 Dync1h1 70 p.V4254L 2 2.4E-01 
12 113544063 G T NS 57372 Adam6a 1 p.V19F 2 2.1E-02 
12 113545101 T A NS 82086 Adam6a 1 p.C365S 2 2.1E-02 
13 9878327 A T NS 10178 Chrm3 5 p.F224L 2 1.4E-02 
13 9878963 C A NS 83619 Chrm3 5 p.L12F 2 1.4E-02 
13 11603732 T C NS 53882 Ryr2 86 p.T3866A 2 2.5E-01 
13 11761406 C T NS 76526 Ryr2 28 p.G1082R 2 2.5E-01 
13 23880453 A C NS 91570 Slc17a1 9 p.I331L 2 8.9E-03 
13 23892542 A T NS 2164 Slc17a1 12 p.E424V 2 8.9E-03 
13 24885627 A T SG 90152 
D130043K22
Rik 
17 p.R890X 2 4.0E-02 
13 24887916 A C NS 42885 
D130043K22
Rik 
18 p.N948H 2 4.0E-02 
13 33091347 G A NS 57372 Serpinb1b 5 p.V152M 2 6.2E-03 
13 33091656 A G NS 60712 Serpinb1b 6 p.D191G 2 6.2E-03 
13 49060759 T C NS 60716 Wnk2 20 p.D1547G 2 1.1E-01 
13 49146577 A G NS 57258 Wnk2 2 p.V219A 2 1.1E-01 
13 55639795 T C NS 11187 Ddx46 3 p.S71P 2 3.7E-02 
13 55652099 T A NS 83457 Ddx46 7 p.V274E 2 3.7E-02 
13 59477061 T C NS 60716 Agtpbp1 19 p.N826S 2 4.9E-02 
13 59536282 T C NS 83457 Agtpbp1 3 p.T42A 2 4.9E-02 
13 68620736 C T NS 29035 Adcy2 25 p.S1091N 2 4.1E-02 
13 68732076 A G SP 83164 Adcy2 na na 2 4.1E-02 
13 74157769 T A NS 83619 Slc9a3 5 p.S302T 2 2.5E-02 
13 74163769 C T NS 2164 Slc9a3 12 p.T612I 2 2.5E-02 
13 76066793 T C NS 76582 Arsk 6 p.D314G 2 1.2E-02 
13 76074863 A C NS 10178 Arsk 4 p.L205W 2 1.2E-02 
13 76140567 A G NS 60693 Ttc37 29 p.T940A 2 7.2E-02 
13 76175330 T C NS 11600 Ttc37 40 p.S1398P 2 7.2E-02 
13 89690534 T C NS 11477 Vcan 7 p.D1337G 2 1.9E-01 
13 89704094 T C NS 11187 Vcan 7 p.T916A 2 1.9E-01 
13 92752365 T C NS 98313 Thbs4 21 p.Y940C 2 3.3E-02 
13 92754437 C T NS 29035 Thbs4 20 p.V841M 2 3.3E-02 
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13 103824917 T C NS 83875 Erbb2ip 24 p.S1294G 2 6.4E-02 
13 103845502 A G SP 98420 Erbb2ip 17 na 2 6.4E-02 
13 104297263 T C NS 83971 Adamts6 3 p.S67P 2 4.2E-02 
13 104297477 A T NS 10451 Adamts6 3 p.Q138L 2 4.2E-02 
14 20300606 T C NS 6927 Nudt13 2 p.Y4H 2 5.3E-03 
14 20307741 T A NS 42885 Nudt13 5 p.I136N 2 5.3E-03 
14 21038057 G A NS 82744 Ap3m1 7 p.T311I 2 7.3E-03 
14 21038160 T C NS 13019 Ap3m1 7 p.K277E 2 7.3E-03 
14 24482412 T A SG 80821 Polr3a 5 p.K205X 2 6.0E-02 
14 24482532 T C NS 83875 Polr3a 5 p.T165A 2 6.0E-02 
14 30050249 T C NS 10382 Cacna1d 42 p.Y1812C 2 1.1E-01 
14 30124875 A G NS 76582 Cacna1d 12 p.F547L 2 1.1E-01 
14 32332493 T A SG 80840 Ogdhl 6 p.Y181X 2 3.7E-02 
14 32337845 A G NS 11241 Ogdhl 11 p.T439A 2 3.7E-02 
14 45595537 G C NS 83230 Ddhd1 15 p.F530L 2 3.0E-02 
14 45657675 C A NS 24744 Ddhd1 1 p.V113F 2 3.0E-02 
14 49178115 T C NS 88025 Naa30 3 p.F283L 2 5.7E-03 
14 49187642 T A SG 83140 Naa30 5 p.Y352X 2 5.7E-03 
14 54949892 T C NS 88955 Myh6 28 p.T1311A 2 9.8E-02 
14 54950514 A G NS 76989 Myh6 26 p.V1161A 2 9.8E-02 
14 54982214 A T NS 91310 Myh7 26 p.I1066N 2 9.8E-02 
14 54987349 T C NS 88129 Myh7 17 p.D587G 2 9.8E-02 
14 75316039 G A NS 91570 Zc3h13 8 p.R302Q 2 8.3E-02 
14 75323572 T C NS 88041 Zc3h13 10 p.V534A 2 8.3E-02 
14 79428300 A G NS 80821 Kbtbd7 1 p.D524G 2 1.8E-02 
14 79428513 T C NS 82522 Kbtbd7 1 p.V595A 2 1.8E-02 
14 86810401 T G NS 45755 Diap3 25 p.E1012A 2 4.6E-02 
14 87002913 T C NS 88955 Diap3 8 p.D245G 2 4.6E-02 
14 117435808 A G NS 2164 Gpc6 3 p.E159G 2 1.3E-02 
14 117974998 A G NS 90152 Gpc6 9 p.E527G 2 1.3E-02 
15 12834406 A G NS 2216 Drosha 4 p.T199A 2 5.9E-02 
15 12926209 T C NS 42885 Drosha 32 p.F1251L 2 5.9E-02 
15 30669505 A G NS 51255 Ctnnd2 8 p.Y420C 2 5.0E-02 
15 30806771 T A NS 83164 Ctnnd2 11 p.L612Q 2 5.0E-02 
15 50661091 A G NS 10451 Trps1 6 p.Y1144H 2 5.3E-02 
15 50822221 T C NS 83737 Trps1 4 p.T849A 2 5.3E-02 
15 54863742 C T NS 80493 Enpp2 17 p.M512I 2 3.0E-02 
15 54870264 A C NS 76582 Enpp2 13 p.D381E 2 3.0E-02 
15 63825049 A T SG 83457 Gsdmc2 12 p.Y424X 2 9.5E-03 
15 63835804 C T SG 96868 Gsdmc2 2 p.W47X 2 9.5E-03 
15 76106489 T C NS 83010 Eppk1 2 p.D2064G 2 2.7E-01 
15 76108226 T C NS 96440 Eppk1 2 p.Y1485C 2 2.7E-01 
15 78399732 T C SL 83188 Tst 2 p.X298W 2 3.9E-03 
15 78405731 A G NS 76278 Tst 1 p.S35P 2 3.9E-03 
15 79369690 A G NS 89965 Tmem184b 5 p.F169L 2 7.2E-03 
15 79378585 A G NS 82744 Tmem184b 2 p.V24A 2 7.2E-03 
15 82172845 C A NS 60654 Srebf2 4 p.N260K 2 4.3E-02 
15 82175265 A T NS 96245 Srebf2 5 p.I335F 2 4.3E-02 
15 85120625 T C NS 82744 Smc1b 7 p.D416G 2 5.0E-02 
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15 85131901 T A SG 2730 Smc1b 1 p.K13X 2 5.0E-02 
15 88730558 C T NS 83689 Brd1 2 p.E45K 2 4.7E-02 
15 88730597 T C NS 96440 Brd1 2 p.T32A 2 4.7E-02 
15 92677680 A T NS 76387 Pdzrn4 2 p.E83D 2 3.6E-02 
15 92743590 T C NS 11477 Pdzrn4 4 p.V150A 2 3.6E-02 
15 98863972 G T NS 82086 Kmt2d 11 p.T499K 2 2.7E-01 
15 98864972 G A NS 96247 Kmt2d 8 p.P306S 2 2.7E-01 
15 100798220 A G NS 90152 Slc4a8 14 p.D627G 2 4.0E-02 
15 100799733 G T NS 60654 Slc4a8 15 p.W662L 2 4.0E-02 
15 101676647 A G NS 33095 Krt6b 9 p.F516S 2 1.2E-02 
15 101676756 A G NS 11082 Krt6b 9 p.S480P 2 1.2E-02 
16 11104644 A T NS 82194 Txndc11 5 p.Y235N 2 3.2E-02 
16 11128485 A T SP 60693 Txndc11 na na 2 3.2E-02 
16 17626475 C T NS 83520 Smpd4 6 p.P131S 2 2.5E-02 
16 17629106 A G NS 2383 Smpd4 9 p.T233A 2 2.5E-02 
16 31050630 A G SP 82841 Xxylt1 na na 2 6.5E-03 
16 31081013 T C NS 60716 Xxylt1 1 p.E108G 2 6.5E-03 
16 31989204 A G NS 82620 Senp5 2 p.S411P 2 2.1E-02 
16 31989939 G A NS 83685 Senp5 2 p.P166S 2 2.1E-02 
16 32273165 C A NS 60716 Smco1 2 p.N20K 2 2.0E-03 
16 32273898 A G NS 11468 Smco1 3 p.Y129C 2 2.0E-03 
16 45581578 A T NS 88955 Slc9c1 18 p.E776V 2 4.6E-02 
16 45599541 G T NS 60716 Slc9c1 24 p.A1025S 2 4.6E-02 
16 64766378 G A NS 83010 
4930453N24
Rik 
3 p.H328Y 2 5.2E-03 
16 64770802 T A NS 83188 
4930453N24
Rik 
1 p.N21I 2 5.2E-03 
16 77055175 T A NS 76278 Usp25 6 p.F193I 2 3.8E-02 
16 77071768 T A NS 83188 Usp25 10 p.D352E 2 3.8E-02 
16 90245494 T A NS 83071 Scaf4 15 p.Q656L 2 4.8E-02 
16 90245506 G A NS 13019 Scaf4 15 p.A652V 2 4.8E-02 
17 4995810 A G NS 89957 Arid1b 1 p.Y239C 2 1.2E-01 
17 5040764 C T NS 83520 Arid1b 2 p.P528L 2 1.2E-01 
17 12918163 A G NS 29035 Tcp1 3 p.T91A 2 1.2E-02 
17 12919859 A G NS 42885 Tcp1 5 p.D141G 2 1.2E-02 
17 23580794 C A NS 88129 Zfp13 4 p.A107S 2 1.0E-02 
17 23585491 A G NS 83875 Zfp13 2 p.S2P 2 1.0E-02 
17 24224319 A G NS 10177 Ccnf 17 p.V638A 2 2.3E-02 
17 24249361 G A SG 60716 Ccnf 2 p.R21X 2 2.3E-02 
17 25104614 A G NS 88262 Telo2 15 p.I613T 2 2.6E-02 
17 25115144 T C NS 76278 Telo2 2 p.E43G 2 2.6E-02 
17 25840674 T C NS 83619 Rhot2 14 p.D392G 2 1.5E-02 
17 25842382 T C NS 60654 Rhot2 6 p.T105A 2 1.5E-02 
17 30635430 T A NS 2730 Dnah8 2 p.V22E 2 2.5E-01 
17 30758369 C T NS 89965 Dnah8 59 p.S2927L 2 2.5E-01 
17 33381337 A G NS 96440 Zfp101 4 p.S482P 2 1.5E-02 
17 33382053 A G NS 6927 Zfp101 4 p.V243A 2 1.5E-02 
17 34050434 C T SG 11468 Col11a2 10 p.R347X 2 7.8E-02 
17 34057249 A G SP 57258 Col11a2 na na 2 7.8E-02 
165 
17 34333356 A T NS 60716 H2-Eb2 2 p.R58S 2 3.6E-03 
17 34333486 G A NS 96868 H2-Eb2 2 p.A102T 2 3.6E-03 
17 34837892 
C
C
C
T
C
C
C
A
G
G
G
G
T
C
C
C
G
G
C
T
G
G 
C FSD 51255 Dxo 3 p.G119fs 2 6.6E-03 
17 34838043 A G NS 83929 Dxo 3 p.T167A 2 6.6E-03 
17 46399914 T G NS 83217 Zfp318 4 p.S854R 2 1.2E-01 
17 46412446 T C NS 60716 Zfp318 10 p.Y1792H 2 1.2E-01 
17 56375953 A G NS 10653 Kdm4b 8 p.T294A 2 4.0E-02 
17 56396507 C T NS 82086 Kdm4b 15 p.T696I 2 4.0E-02 
17 66817930 T C NS 11478 Ptprm 15 p.E783G 2 6.4E-02 
17 67095675 T A NS 11241 Ptprm 3 p.T73S 2 6.4E-02 
17 70657501 A T NS 83875 Dlgap1 3 p.Y113F 2 3.4E-02 
17 70787192 A G NS 88041 Dlgap1 7 p.N526S 2 3.4E-02 
17 71394847 G T NS 83794 Smchd1 25 p.A1050E 2 1.0E-01 
17 71426506 A G NS 10177 Smchd1 16 p.S694P 2 1.0E-01 
17 78400689 T C NS 96247 Fez2 5 p.K277E 2 6.0E-03 
17 78417939 T C NS 82522 Fez2 1 p.S49G 2 6.0E-03 
18 13844930 A G NS 42058 Zfp521 4 p.Y809H 2 5.5E-02 
18 13845614 T G NS 91570 Zfp521 4 p.I581L 2 5.5E-02 
18 20451866 C A NS 82194 Dsg4 6 p.N212K 2 3.7E-02 
18 20453066 A G NS 2730 Dsg4 7 p.K271R 2 3.7E-02 
18 20589979 A G NS 83140 Dsg2 9 p.D354G 2 4.2E-02 
18 20590093 A T NS 88025 Dsg2 9 p.H392L 2 4.2E-02 
18 22516409 G A NS 98313 Asxl3 12 p.C485Y 2 1.2E-01 
18 22524317 C T NS 11477 Asxl3 13 p.P1795S 2 1.2E-01 
18 31983320 A G NS 11241 Myo7b 24 p.V1029A 2 1.1E-01 
18 31998034 T G NS 60693 Myo7b 14 p.Y560S 2 1.1E-01 
18 34812382 A G NS 83689 Kdm3b 10 p.T949A 2 8.6E-02 
18 34827490 T C NS 76278 Kdm3b 16 p.V1376A 2 8.6E-02 
18 36968519 C A SG 60716 Pcdha6 1 p.S255X 2 3.2E-02 
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18 36969626 T A NS 88041 Pcdha6 1 p.V624E 2 3.2E-02 
18 37265734 T C NS 10722 Pcdhb1 1 p.V246A 2 2.5E-02 
18 37266517 T C NS 83164 Pcdhb1 1 p.I507T 2 2.5E-02 
18 37505896 C T NS 83071 Pcdhb20 1 p.P492S 2 2.4E-02 
18 37506535 T C NS 60693 Pcdhb20 1 p.S705P 2 2.4E-02 
18 74736188 T C NS 60654 Myo5b 32 p.L1423P 2 9.0E-02 
18 74742147 A C NS 11478 Myo5b 34 p.M1515L 2 9.0E-02 
18 77330976 A T NS 80493 Loxhd1 7 p.Y265F 2 1.1E-01 
18 77369158 G T NS 10020 Loxhd1 18 p.V825L 2 1.1E-01 
18 77643121 A T NS 83071 
8030462N17
Rik 
4 p.N319K 2 6.7E-03 
18 77674470 A G NS 11600 
8030462N17
Rik 
2 p.S49P 2 6.7E-03 
19 4739905 A T NS 83230 Sptbn2 19 p.D1307V 2 1.3E-01 
19 4748654 G A NS 98491 Sptbn2 29 p.E2004K 2 1.3E-01 
19 7274028 A G NS 11478 Rcor2 10 p.R302G 2 9.4E-03 
19 7274349 A G NS 88025 Rcor2 11 p.I378V 2 9.4E-03 
19 8910491 A G NS 3000 Ganab 11 p.Y363C 2 3.3E-02 
19 8912851 T C NS 11954 Ganab 18 p.Y715H 2 3.3E-02 
19 9017599 T C NS 83217 Ahnak 5 p.S5416P 2 2.7E-01 
19 9017824 A G NS 88503 Ahnak 5 p.I5491V 2 2.7E-01 
19 41877828 A T NS 90152 Rrp12 17 p.V662E 2 5.3E-02 
19 41895986 C T NS 10562 Rrp12 1 p.C31Y 2 5.3E-02 
19 43441968 T A SG 82522 Cnnm1 1 p.C508X 2 3.2E-02 
19 43491533 C T NS 60716 Cnnm1 8 p.T818I 2 3.2E-02 
19 47637718 A G NS 96245 Slk 16 p.D1100G 2 4.9E-02 
19 47637745 T A NS 10451 Slk 16 p.V1109D 2 4.9E-02 
20 20928450 T A NS 5401 Cfp 5 p.E211V 2 8.9E-03 
20 20931221 A G NS 83010 Cfp 2 p.V49A 2 8.9E-03 
20 36611767 T A SG 91310 Akap17b 7 p.K696X 2 3.3E-02 
20 36618661 G T NS 82744 Akap17b 4 p.Q276K 2 3.3E-02 
C=Chromosome; R=Reference allele; A=Alternative allele; E=Exon; AA= Amino Acid; 
#=Mutation count per gene; NS=Nonsynonymous SNV; SG=Stopgain; SP=Splicing; 
SL=Stoploss; FSI=Frameshift insertion; FSD=Frameshift deletion 
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